АКТИВИРОВАННАЯ ЛЕЙКОЦИТАРНАЯ КОМПОЗИЦИЯ

Группа изобретений относится к медицине и касается способа изготовления активированной лейкоцитарной композиции, включающего инкубацию лейкоцитов человека, подвергание лейкоцитов гипоосмотическому шоку и добавление к лейкоцитам физиологически приемлемого солевого раствора в количестве, достаточном для восстановления изотоничности. Группа изобретений также касается применения: активированной лейкоцитарной композиции в изготовлении лекарства для лечения ран; повязки для лечения ран, содержащей указанную композицию. Группа изобретений обеспечивает получение композиции, которая обладает в 90 раз большим количеством лейкоцитов по сравнению со способами, известными из уровня техники. 6 н. и 10 з.п. ф-лы, 3 ил., 6 табл., 3 пр.

Способ получения цитокинов из тромбоцитов пуповинной крови как субстрата для разработки лекарственных средств для человека и животных

Изобретение относится к медицине, и может быть использовано для получения цитокинов из тромбоцитов пуповинной крови. Способ включает три этапа: на первом этапе производят забор пуповинной крови у разных доноров, вводят в каждый пакет с донорской кровью раствор Стабизол в объеме 20% от объема крови пакета, центрифугируют каждый из пакетов с кровью в режиме плавного изменения программы, в результате чего кровь разделяется на обогащенную тромбоцитами плазму и эритроциты. Указанная программа состоит из следующих режимов: разгон до 540 RCF в течение 5 мин; разгон до 900 RCF в течение 2 мин; торможение до 300 RCF и вращение в течение 2 мин; торможение до 100 RCF и вращение в течение 1,3 мин с последующим отключением центрифуги, затем из пакетов удаляют эритроциты и утилизируют их. На втором этапе проводят объединение всех донорских пакетов ОТП и концентрирование всех тромбоцитов, для чего полученную обогащенную тромбоцитами плазму переносят в соответствующее количество пробирок типа фалькон объемом ...

Способ хирургического лечения первичного сквозного макулярного разрыва сетчатки

Изобретение относится к медицине, а именно, к офтальмологии. Выполняют витрэктомию, осуществляют окрашиваие внутренней пограничной мембраны (ВПМ), удаляют ВПМ, аппликацию обогащенной тромбоцитами плазмы крови (PRP), вводят в витреальную полость ПФОС. Для осуществления витрэктомии постановку инфузионной системы в витреальную полость, которая обеспечивает подачу солевого раствора BSS, выполняют под углом 45 градусов к касательной, проведенной к поверхности глазного яблока, в месте предполагаемой склеротомии. В ходе витрэктомии задние кортикальные слои стекловидного тела отделяют от сетчатки и диска зрительного нерва (ДЗН) аспирационным методом в направлении от центра к периферии. Далее формируют верхний инвертируемый однослойный лоскут ВПМ шириной 0,2 мм и длиной 1,5 мм на расстоянии 2,5 мм от края разрыва параллельно линии, проходящей через центр ДЗН и центр макулярного отверстия, сформированный верхний инвертируемый однослойный лоскут ВПМ переворачивают и внутренней стороной укладывают ...

СПОСОБ ВЫБОРА ХИРУРГИЧЕСКОЙ ОПЕРАЦИИ ПО ПОВОДУ МЕДИКАМЕНТОЗНОГО ОСТЕОНЕКРОЗА ЧЕЛЮСТЕЙ В ЗАВИСИМОСТИ ОТ ОБЪЕМА ОСТЕОДЕСТРУКЦИИ

Изобретение относится к медицине, а именно к хирургической стоматологии и челюстно-лицевой хирургии, и может быть использовано для выбора хирургической операции по поводу медикаментозного остеонекроза челюстей (МОНЧ) в зависимости от объема остеодеструкции. По данным стоматологического осмотра и результатам МСКТ определяют стадию МОНЧ в зависимости от локализации дефекта, его протяженности, глубины распространения и соответствующую этой стадии тактику лечения. Способ обеспечивает полное разобщение операционной раны с полостью рта, повышает эффективность лечения за счет обоснованного выбора адекватной хирургической операции по поводу МОНЧ в зависимости от объема остеодеструкции. 30 ил., 5 пр.

СПОСОБ КОМБИНИРОВАННОГО ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНОЙ ДИАБЕТИЧЕСКОЙ РЕТИНОПАТИИ, ОСЛОЖНЕННОЙ ЦЕНТРАЛЬНЫМ РЕТИНАЛЬНЫМ РАЗРЫВОМ С СОПУТСТВУЮЩИМ РЕТИНОШИЗИСОМ И ТРАКЦИОННО-РЕГМАТОГЕННОЙ ОТСЛОЙКОЙ СЕТЧАТКИ

Изобретение относится к медицине, а именно к офтальмологии. Осуществляют комбинированное лечение пролиферативной диабетической ретинопатии, осложненной центральным ретинальным разрывом с сопутствующим ретиношизисом и тракционно-регматогенной отслойкой сетчатки. Выполняют заднюю витрэктомию, дренирование субретинальной жидкости, вводят в витреальную полость перфторорганическое соединение (ПФОС), окрашивают и удаляют внутреннюю пограничную мембрану (ВПМ). Проводят замену ПФОС на воздушную смесь, аппликацию богатой тромбоцитами плазмы (БоТП) в зону разрыва. После выполнения задней витрэктомии удаляют фиброваскулярные пролиферации и ослабляют все витреоретинальные тракции, выполняют пассивное дренирование субретинальной жидкости в зоне ретинального разрыва. При этом из ретиношизиса у края разрыва частично дренируется интраретинальная жидкость. Далее полость стекловидного тела заполняют жидким ПФОС. После того как отек сетчатки и ретиношизис уменьшатся по высоте, выполняют вторую операцию, во ...

Способ хирургического лечения сквозного макулярного разрыва

Изобретение относится к медицине, а именно к офтальмологии, и может быть использовано для хирургического лечения сквозного макулярного разрыва. Для этого проводят субтотальную витрэктомию, мембранопилинг. Мобилизуют края разрыва с помощью пассивной аспирации радиальными движениями от периферии к центру в пределах макулы. Наносят на область разрыва перфторорганическое соединение (ПФОС) и вводят в область разрыва аутологичную кондиционированную плазму (АСР) или плазму, обогащенную тромбоцитами (PRP). Затем под контролем оптической когерентной томографии удаляют излишки АСР или PRP до полного сближения краев разрыва. Изобретение обеспечивает полное контролируемое закрытие макулярного разрыва без формирования сгустка и последующего нарушения архитектоники слоев сетчатки с минимально возможным дефектом слоя фоторецепторов, позволяет снизить риск развития послеоперационных осложнений и повторного хирургического вмешательства. 4 пр.

СПОСОБ ХИРУРГИЧЕСКОГО ЛЕЧЕНИЯ МАКУЛЯРНЫХ РАЗРЫВОВ С СОХРАНЕНИЕМ ВНУТРЕННЕЙ ПОГРАНИЧНОЙ МЕМБРАНЫ

Изобретение относится к медицине, а именно к офтальмологии. Проводят хирургическое лечение макулярных разрывов с сохранением внутренней пограничной мембраны. Выполняют установку троакаров, проводят трехпортовую витрэктомию, аппликацию богатой тромбоцитами плазмы крови (БоТП) в зону макулярного разрыва с последующим образованием пленки фибрина. После чего на пленку фибрина наносят ПФОС, далее удаляют ПФОС. При витрэктромии стекловидное тело удаляют только в задних и средних слоях до экваториальной зоны, сохраняя стекловидное тело на периферии, в переднем отделе и внутреннюю пограничную мембрану, после чего солевой раствор замещают на воздух. После однократного высушивания сетчатки в проекции диска зрительного нерва (ДЗН) наносят БоТП непосредственно в зону макулярного разрыва. Далее образования пленки фибрина удаляют остатки жидкой части БоТП в проекции ДЗН. Затем на пленку фибрина наносят жидкое ПФОС, далее удаляют ПФОС витреотомом с частотой резов 10000 в минуту, используя режим «моментальных ...

Способ лечения макулярного разрыва, осложненного друзеноидной отслойкой ретинального пигментного эпителия

Изобретение относится к медицине, а именно к офтальмологии. Первым этапом проводят лазерную коагуляцию сетчатки по краю макулярного разрыва со следующими энергетическими параметрами: длина волны 577 нм, мощность 50 мВт, длительность импульса 0,03-0,05 с, диаметр коагулята 100 мкм, расстояние между коагулятами 100 мкм, количество коагулятов составляет от 10 до 12. Затем не менее чем через 2 недели, но не более чем 2 месяца проводят оценку состояния макулярной зоны с использованием оптической когерентной томографии и при уменьшении высоты отслойки пигментного эпителия на 50% и более от исходных значений в макулярной зоне проводят второй этап лечения. А именно проводят трансконъюнктивальную трехпортовую 27G витрэктомию через плоскую часть цилиарного тела в присутствии ирригационного сбалансированного солевого раствора (BSS), с удалением задней гиалоидной мембраны, прилежащих задних слоев стекловидного тела, эпиретинальной мембраны и внутренней пограничной мембраны вокруг фовеолы в пределах ...

Способ лечения пузырно-влагалищных свищей

Изобретение относится к медицине, а именно к урологии, и может быть использовано для лечения пузырно-влагалищных свищей. Для этого получают из цельной крови аутологичную плазму. Активируют плазму путём замораживания её при t -80°С с последующим размораживанием на водяной бане и добавлением 10% раствора CaClв соотношении соответственно 10:1. Выполняют щипковую биопсию края наружного отверстия пузырно-влагалищного свища и гистологическое исследование проб тканей. После этого выполняют полифокальное обкалывание полученной плазмой парасвищевых тканей курсом 1 раз в неделю 4-5 раз. Повторяют гистологическое исследование края наружного отверстия пузырно-влагалищного свища. На втором этапе через неделю после курса лечения выполняют фистулопластику. Способ обеспечивает улучшение результатов оперативного лечения, снижение риска рецидивирования за счёт достижения распространенной васкуляризации тканей влагалища и стенки мочевого пузыря, усиления регенеративных процессов в области операционной раны ...

Способ лечения посттравматических анкилозов суставов кисти

Изобретение относится к медицине, а именно к травматологии и ортопедии, и может быть использовано для лечения посттравматических анкилозов суставов кисти. Переднюю капсулу поврежденного сустава рассекают под местной анестезией. Выполняют наложение динамического дистракционного аппарата внешней фиксации, для чего проводят поперечно две спицы диаметром 1,2 мм, вводя проксимальную спицу через центр головки проксимальной фаланги, дистальную - через центр головки дистальной фаланги. Обе спицы с обеих сторон сгибают на 90° с отступом от кожи на 5 мм. На каждом выступающем конце спицы формируют по крючку, которые соединяют между собой попарно резинкой. Затем интраоперационно в полость сустава и область коллатеральных связок вводят по 0,5 мл препарата низкомолекулярной гиалуроновой кислоты. На 7 на и 14 сутки в упомянутую область коллатеральных связок с медиальной и латеральной стороны проводят инъекции плазмы, обогащенной тромбоцитами, в объеме 0,5 мл, что составляет 1000000-1200000 клеток. Начиная ...

СПОСОБ И СОЕДИНЕНИЕ ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНЕЙ СУСТАВОВ ИЛИ БОЛИ В СУСТАВАХ, ИЛИ ДЛЯ ЛЕЧЕНИЯ КОЖИ ДЛЯ ЭСТЕТИЧЕСКОЙ ИЛИ ДРУГИХ ЦЕЛЕЙ И СПОСОБ ПОЛУЧЕНИЯ СОЕДИНЕНИЯ

... 1. Способ лечения сустава, пораженного болезнью сустава или болью в суставе, который включает инфильтрацию в сустав соединения, содержащего, по меньшей мере, одно соединение, полученное из крови. ! 2. Способ по п.1, в котором соединение, полученное из крови, инфильтрируют в сустав вслед за удалением синовиальной жидкости из данного сустава. ! 3. Способ по п.1, в котором соединение, полученное из крови, инфильтрируют в сустав после артроскопической операции, выполненной на данном суставе. ! 4. Способ по п.1, в котором соединение, полученное из крови, является аутологичным. ! 5. Способ по п.1, в котором соединение, полученное из крови, является гомологичным. ! 6. Способ по п.1, в котором соединение, полученное из крови, представляет собой плазму крови. ! 7. Способ по п.6, в котором соединение, полученное из крови, представляет собой плазму с высоким содержанием тромбоцитов (PRP). ! 8. Способ по п.7, в котором соединение, полученное из крови, представляет собой плазму с высоким содержанием ...

СПОСОБ ЛЕЧЕНИЯ ХРОНИЧЕСКОГО ВОСПАЛЕНИЯ ТКАНЕЙ ПАРОДОНТА И СЛИЗИСТОЙ ОБОЛОЧКИ С ЭЛЕМЕНТАМИ ГИПЕРКЕРАТОЗА У ЛИЦ МОЛОДОГО ВОЗРАСТА

Способ лечения хронического воспаления при воспалительных заболеваниях пародонта и слизистой оболочки рта с элементами гиперкератоза, включающий прооксидантную и антиоксидантную терапию, отличающийся тем, что в качестве терапии проводят инъекционное введение обогащенной тромбоцитами плазмы по 0,1-0,5 мл на мм- 1 раз в неделю, курсом 2-3 процедуры, и плацентарного препарата «Лаеннек» по 0,1-0,2 мл на ммпо 1 инъекции с интервалом в 2 дня, курсом 5-10 инъекций, причем при хроническом гингивите или пародонтите инъекции проводят в зубодесневой сосочек, маргинальную часть десны и в область переходной складки, а при лейкоплакии плоской формы, красном плоском лишае эрозивно-язвенной формы - под морфологические элементы, расположенные на слизистой оболочке рта, кроме того, дополнительно «Лаеннек» вводят внутривенно капельно в дозе 4 мл, которую растворяют в 250-500 мл 5%-ного физиологического раствора, на курс лечения 10 процедур с интервалом в 2 дня.

КОМПОЗИЦИЯ С ФАКТОРАМИ РОСТА ДЛЯ ПРИМЕНЕНИЯ В ИНТРАНАЗАЛЬНОМ ЛЕЧЕНИИ НЕЙРОДЕГЕНЕРАТИВНОГО ЗАБОЛЕВАНИЯ ИЛИ ДРУГИХ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ И СПОСОБ ЕЕ ПОЛУЧЕНИЯ

... 1. Композиция, полученная по меньшей мере из одного содержащего фактор роста компонента крови, для ее применение в качестве терапевтического средства, вводимого интраназальным путем, в лечении нейродегенеративного заболевания или другого заболевания центральной нервной системы, где содержащий фактор роста компонент крови является обогащенной факторами роста плазмой.2. Композиция по п. 1, отличающаяся тем, что композиция является надосадочной жидкостью.3. Композиция по п. 1, отличающаяся тем, что композиция является гелем.4. Способ получения терапевтического средства для применения в лечении нейродегенеративного заболевания или других заболеваний центральной нервной системы интраназальным путем, отличающийся тем, что он включает применение по меньшей мере одной композиции, полученной из по меньшей мере одного содержащего фактор роста компонента крови, где содержащий фактор роста компонент крови является обогащенной факторами роста плазмой.5. Способ по п. 4, отличающийся тем, что композиция ...

СПОСОБ, ПРОБИРКА И УСТРОЙСТВО ДЛЯ ПРИГОТОВЛЕНИЯ КОМПОЗИЦИИ ДЛЯ ЗАЖИВЛЕНИЯ РАН

... 1. Способ приготовления сыворотки с тромбином, включающий следующие стадии:a) забор цельной крови в пробирку, где указанная пробирка выбрана изi) пробирки, содержащей гель для отбора клеток, предпочтительно тиксотропный гель, и которая предпочтительно представляет собой стеклянную пробирку для отбора клеток, содержащую тиксотропный гель на основе полиэфира, илиii) пустой стеклянной пробирки для отбора клеток,где указанная пробирка необязательно дополнительно содержит активатор коагуляции, который предпочтительно представляет собой глюконат кальция,b) центрифугирование указанной пробирки до высвобождения сыворотки с тромбином иc) сбор указанной сыворотки с тромбином, иd) необязательно смешивание сывороткой с тромбином с активатором коагуляции, который предпочтительно представляет собой глюконат кальция,где указанная сыворотка с тромбином предпочтительно является аутологичной.2. Способ по п.1, отличающийся тем, что указанную пробирку подвергают центрифугированию при ускорении от около 1000g ...

Способ лечения острого орхоэпидидимита с использованием тромбоцитарной аутоплазмы

Изобретение относится к медицине, а именно к урологии, к способу лечения острого орхоэпидидимита. Способ включает инфузионную и антибактериальную терапию. Дополнительно производят однократное введение в каждый семенной канатик аутоплазмы, обогащенной тромбоцитами в количестве 2,00-2,25 мл. Изобретение обеспечивает повышение эффективности лечения острого орхоэпидидимита. 1 ил., 3 пр.

Способ хирургического лечения рубцовой стадии субретинальной неоваскулярной мембраны

Изобретение относится к медицине, а именно к офтальмологии, и предназначено для хирургического лечения рубцовой стадии субретинальной неоваскулярной мембраны. Способ включает витрэктомию, удаление задней гиалоидной мембраны стекловидного тела, микроретинотомию и удаление рубцовой субретинальной неоваскулярной мембраны. При этом проводят трехпортовую субтотальную витрэктомию с использованием канюлей 25 и 27 Ga, пилинг внутренней пограничной мембраны перед микроретинотомией и заведение канюлей 38 Ga. В образовавшееся субретинальное пространство вводят 0,1-0,2 мл аутоплазмы, обогащенной тромбоцитами, полученной с использованием пробирки Ycellbio kit (PRP-массы). Затем проводят пневморетинопексию. В раннем послеоперационном периоде пациента на 1-3 суток укладывают лицом вниз. Способ обеспечивает улучшение зрительных функций и анатомо-физиологических показателей пораженного глаза. 2 пр.

СПОСОБ ПОЛУЧЕНИЯ МЕГАКАРИОЦИТОВ И/ИЛИ ТРОМБОЦИТОВ ИЗ ПЛЮРИПОТЕНТНЫХ СТВОЛОВЫХ КЛЕТОК

... 1. Способ получения мегакариоцитов и/или тромбоцитов, включающий культивирование гемопоэтических клеток-предшественников, полученных из плюрипотентных стволовых клеток ex vivo в присутствии соединения, представленного формулой (I), таутомера, пролекарства или фармацевтически приемлемой соли соединения или его сольвата, и дифференцировку гемопоэтических клеток-предшественников в мегакариоциты и/или тромбоциты:,где W представляет собой заместитель, представленный формулой (Ia), или карбоксигруппу:,каждый из R, R, Rи Rнезависимо представляет собой Cалкильную группу, которая может быть замещена одним или более атомами галогена или атомом водорода,n является целым числом 0, 1, 2 или 3,Rпредставляет собой Cарильную группу, которая может быть замещена одним или более заместителями, независимо представленными V, при условии что, когда n равно 2, Rне является незамещенной пиридильной группой,Rпредставляет собой Cалкильную группу, которая можетбыть замещена одним или более атомами галогена или атомом ...

СПОСОБ ПОЛУЧЕНИЯ ФРАКЦИИ ЛИЗАТА ТРОМБОЦИТОВ, ФРАКЦИЯ ЛИЗАТА ТРОМБОЦИТОВ И ЕЕ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ

КОМБИНИРОВАННЫЕ ПРЕПАРАТЫ С АНТАГОНИСТОМ ЦИТОКИНА И КОРТИКОСТЕРОИДОМ

... 1. Фармацевтическая композиция, содержащая кортикостероид вместе с антагонистом цитокина и необязательно фактор роста, причем этот антагонист цитокина состоит из смеси природно-встречающегося IL-1Ra белка и рекомбинантного белка IL-1Ra, в частности, Ортокина или Анакинра, причем эта фармацевтическая композиция пригодна для локального введения.2. Фармацевтическая композиция, содержащая антагонист цитокина и необязательно фактор роста для применения в комбинированной терапии вместе с кортикостероидом, причем этот антагонист цитокина состоит из смеси природно-встречающегося IL-1Ra белка и рекомбинантного белка IL-1Ra, в частности, Ортокина или Анакинра, причем эта фармацевтическая композиция пригодна для локального введения.3. Фармацевтическая композиция по п.2, причем эта фармацевтическая композиция предназначена для одновременного или последовательного введения антагониста цитокина/фактора роста и кортикостероида.4. Фармацевтическая композиция, содержащая кортикостероид для применения в ...

Способ хирургического лечения острого кератоконуса

Изобретение относится к медицине, а именно к офтальмологии, и может быть использовано для хирургического лечения острого кератоконуса. Для этого предварительно проводят забор крови у пациента. Забранную кровь центрифугируют в двойном шприце АСР в течение 5 мин при 1500 оборотов в минуту. Затем надосадочную плазму, богатую тромбоцитами, отбирают во внутренний шприц и выкручивают из основного шприца. Далее формируют парацентез на 12 часах шириной 1,0-1,2 мм. Опорожняют переднюю камеру от внутриглазной жидкости и через сформированный парацентез, с помощью шприца с канюлей, вводят в переднюю камеру 0,2-0,3 мл полученной аутоплазмы. После чего переводят пациента в положение лицом вниз на 1-1,5 ч. Изобретение обеспечивает ускорение резорбции отека, снижение риска воспалительной реакции, а также восстановление прозрачности роговицы и повышение зрительных функций пациента. 1 пр.

Transcription factor mediated programming towards megakaryocytes

Pathogen reduced platelet compositions and related methods

Disclosed are methods for treating platelet compositions (e.g. platelet concentrates and/or platelet lysates) with electron beam radiation, where the compositions are in a frozen state during irradiation with the e-beam radiation. The methods can be conducted using e-beam radiation at doses effective to reduce the pathogen content of the compositions while retaining highly beneficial bioactivities of the compositions. Also disclosed are compositions preparable by the methods, and methods and compositions involving the use of the e-beam treated materials.

Therapeutic preparation and process for preparing said therapeutic preparation

Therapeutic preparation and process for preparing said therapeutic preparation

SEPARATION OF THROMBOZYTEN FROM FULL BLOOD FOR USE AS WUNDHEILMITTEL

PROCEDURE AND DEVICES FOR THE DISTANCE OF PSORALENEN FROM BLOOD PRODUCTS.

COMPOSITIONS AND PROCEDURES FOR THE EXTENSION OF THE DURATION OF SURVIVAL OF BLOOD PANELS

FABRIC IMPLANTS AND PROCEDURES FOR YOUR PRODUCTION AND USE

CAPS FOR THE ADMINISTRATION OF DOTTED MARROW

PREPARATION NUKLEIERTEN ZELLUND/ODER OF THROMBOZYTEN CONCENTRATE FROM A PHYSIOLOGICAL SOLUTION

PROCEDURES FOR THE PRODUCTION OF GEGERBTER THROMBOZYTEN AND THEIR USE

ENRICHED PLASMA DERIVATIVE FOR THE SUPPORT OF WUNDVERSCHLUSS AND WUNDABDECKUNG.

ENRICHED PLASMA DERIVATIVE FOR THE SUPPORT OF WUNDVERSCHLUSS AND CICATRISATION.

PLASMA-FREE MEDIUM TO KEEPING BLOOD PANELS AND PROCEDURE FOR ITS PRODUCTION.

METHOD FOR THE STABILIZATION OF PANELS

IN THE IMMOBILIZED CONDITION DRYING PHARMACEUTICAL COMPATIBLE ONE HUMAN ONE BLOOD PANEL

PROCEDURE FOR THE PRESERVATION OF A PROJECTION PARLIAMENTARY GROUP OF ACTIVATED THROMBOZYTEN

PROCEDURE FOR THE PRODUCTION OF A GEL OF AUTO+LIED BLOOD PANELS

Blood plasma-containing compositions

Provided herein is a composition of matter comprising dried blood plasma substantially free of blood cell components; and a) a resuscitative mixture comprising at least one saccharide, at least one salt, and at least one high molecular weight, non-ionic, hydrophilic polymer, b) platelets or platelet-derived material, or c) both a) and b).

Methods of making platelets comprising modified receptors and uses thereof

Disclosed herein are methods of producing platelets comprising a modified receptor, therapeutic agents, peptides, and/or bioactive molecules. The cells produced by the methods disclosed herein can be used to treat, manage, prevent and diagnosis, for example, lysosomal storage diseases, diabetes and cancer. The cells produced by the methods disclosed herein can be engineered to comprise receptors capable of activating platelets to trigger the release of enzymes, biomolecules or therapeutic agents upon binding to specific drugs and/or binding to tissue specific peptides.

Combination preparations comprising Exosomes and Corticosteroid

The invention relates to pharmaceutical compositions for combination therapy, comprising a corticosteroid and exosomes. Said combination therapy allows diseases such as osteoarthritis, rheumatoid arthritis, and/or degenerative diseases of the spine to be treated.

Freeze-dried polymer compositions for mixing with platelet rich plasma to form implants for tissue repair and/or compositions for therapeutic intra-articular injections

The present application relates to a freeze-dried polymer composition containing chitosan and at least one lyoprotectant, a process for preparing a freeze-dried composition containing chitosan and at least one lyoprotectant and the use of a reconstituted freeze-dried chitosan composition to prepare implants for tissue repair.

Systems, compositions, and methods for transplantation

Systems and methods for purification and concentration of autologous alpha-2-macroglobulin (A2M) from whole blood are provided. Also provided are diagnostic methods for identifying sites in the synovial joints, spine, tendons or ligaments for treatment of pain, degeneration, or inflammation with autologous A2M. Methods for utilizing autologous A2M in combination with other autologous treatments (e.g. platelets and other growth factors) are provided in addition to combinations with exogenous drugs or carriers. Also provided is a method of producing recombinant A2M wild type or variants thereof where the bait region was modified to enhance the inhibition characteristics of A2M and/or to prolong the half life of the protein in joints and spine disc or epidural space.

A poloxamer composition free of long circulating material and methods for production and uses thereof

Provided herein are long circulating material free (LCMF) poloxamer compositions and uses thereof. In particular, provided are LCMF poloxamer 188 compositions and uses thereof. Also provided are supercritical fluid extraction (SFE) methods and high pressure (subcritical) methods for preparing poloxamer compositions, particularly the LCMF poloxamer compositions.

Bovine serum composition and method for culturing cells using said bovine serum composition as additive

Provided is a method for producing an inexpensive bovine serum composition that contains many factors useful for cell growth. The method includes: a step for performing anticoagulant treatment of bovine whole blood by an anticoagulant; a step for acquiring the buffy coat and a fraction having a specific gravity greater than that of the buffy coat from the anticoagulated blood; and a step for promoting the interaction of and activating acquired leukocytes and platelets by taking a certain length of time or longer at a certain temperature, thereby performing recoagulant treatment of the blood components including humoral factors by a recoagulant while causing the humoral factors to be secreted or released from the leukocytes and/or platelets.

RECONSTITUTED PLATELET MEMBRANE VESICLES

Cryopreservation of human adult and fetal pancreatic cells and human platelets

LYOPHILIZED PLATELET RICH PLASMA FOR THE USE IN WOUND HEALING AND BONE OR TISSUE GRAFTS OR REPAIR

This invention relates to an improved lyophilized platelet rich plasma used to make a platelet gel wound healant, and methods of preparation and use thereof for healing wounds are disclosed. the improved wound healant comprises therapeutically effective amounts of activated growth factors, platelet ghost, plasma (know as the plasma back bone), white blood cells with optional none, one or more additional anti-oxidant such as vitamin A and/or c and/or E, and/or none one or more antibiotics and/or GHK-Cu.

COMPOSITION AND METHOD FOR THE REPAIR AND REGENERATION OF CARTILAGE AND OTHER TISSUES

The present invention relates to a new method for repairing human or animal tissues such as cartilage, meniscus, ligament, tendon, bone, skin, cornea, periodontal tissues, abscesses, resected tumors, and ulcers. The method comprises the step of introducing into the tissue a temperature-dependent polymer gel composition such that the composition adhere to the tissue and promote support for cell proliferation for repairing the tissue. Other than a polymer, the composition preferably comprises a blood component such as whole blood, processed blood, venous blood, arterial blood, blood from bone, blood from bone-marrow, bone marrow, umbilical cord blood, placenta blood, erythrocytes, leukocytes, monocytes, platelets, fibrinogen, thrombin and platelet rich plasma. The present invention also relates to a new composition to be used with the method of the present invention.

COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE THEREOF

Methods for producing megakaryocytes and platelets derived from inducible pluripotent stem cells and comprising a therapeutic agent are provided. The present disclosure further provides methods and compositions for loading a platelet or a megakaryocyte with a therapeutic agent and for genetically modifying a platelet or a megakaryocyte to express an agent.

METHODS FOR PREPARING PLATELET RELEASATE

The present invention relates to the use of a quantity of one or more water-soluble calcium salts and a quantity of glass particles for preparing platelet releasate from a sample of a platelet-rich blood composition obtained from a subject, wherein said quantity of glass particles is from 0.010 g to 0.60 g per ml of said sample and said quantity of the one or more water-soluble calcium salts is from 1.0 µmol to 12.0 µmol per ml of said sample. Systems and methods for preparing a platelet releasate are also disclosed, as well as the platelet releasate obtained therefrom and the use thereof in in vitro and in vivo applications.

BLOOD PLASMA-CONTAINING COMPOSITIONS

Provided herein is a composition of matter comprising dried blood plasma substantially free of blood cell components; and a) a resuscitative mixture comprising at least one saccharide, at least one salt, and at least one high molecular weight, non-ionic, hydrophilic polymer, b) platelets or platelet-derived material, or c) both a) and b).

HUMAN PLATELET LYSATE DERIVED EXTRACELLULAR VESICLES FOR USE IN MEDICINE

The present invention is related to human platelet lysate or a fraction that is enriched for human platelet lysate derived extracellular vesicles and their use in medicine, particularly for the prevention and/or treatment of inflammatory driven diseases, neurodegenerative diseases, immune/autoimmune diseases, cardiovascular diseases, dermatologic diseases, orthopedic diseases, tissue regenerative medicine, oncologic diseases, infectious diseases, transplant rejections, stroke, ischemia or Graft-versus-Host Disease. The present invention is further related to a method of manufacture of a pharmaceutical preparation or a diagnostic preparation or a cosmetic preparation comprising the step of adding human platelet lysate or a fraction that is enriched for human platelet lysate derived extracellular vesicles to the pharmaceutical preparation or a diagnostic preparation or a cosmetic preparation.

METHOD FOR IN SITU SOLIDIFICATION OF BLOOD-POLYMER COMPOSITIONS FOR REGENERATIVE MEDICINE AND CARTILAGE REPAIR APPLICATIONS

The present invention relates to a method for repairing or regenerating t issues in a patient such as cartilage, meniscus, ligament, tendon, bone, ski n, cornea, periodontal tissues, abscesses, resected tumors, cardiac tissues and ulcers. The method comprises the step of administering simultaneously or sequentially a pro-coagulant factor and an effective amount of a polymer co mposition comprising a biocompatible polymer and blood or a component thereo f. When the polymer composition is in contact with the pro-coagulant factor it is converted into a non-liquid state such that the polymer composition wi ll adhere to the site in need of repair to effect repair of the tissue and/or regeneration thereof.

METHODS FOR CULTURING AND/OR DIFFERENTIATING HEMATOPOIETIC STEM CELLS INTO PROGENITORS AND USES THEREOF

The present description relates to in vitro methods for culturing hematopoietic stem cells (HSCs) under mild hyperthermia conditions (e.g., between 38°C and 40°C) in the presence of a pyrimidoindole derivative agonist of hematopoietic stem cell expansion. The combined use of mild hyperthermia and the pyrimidoindole derivative act synergistically to promote expansion of CD34+ HSCs and/or differentiation into progenitor cells (e.g., megakaryocytic progenitors). The present description also relates to in vitro expanded cell populations of HSCs and/or progenitors, as well as uses thereof in therapy (e.g., transplantation).

SYSTEM OF MULTIPLE BAGS AND METHOD FOR THE PREPARATION OF HEMOCOMPONENTS

The present invention relates to a biomedical device for the production, storage, traceability and administration of blood components.

FORMULATION OF A BLOOD COMPOSITION THAT IS RICH IN PLATELET AND/OR GROWTH FACTORS AND CONTAINS GELLED PROTEINS, AND A METHOD FOR ITS PREPARATION

Formulation comprising or deriving from an initial blood composition rich in platelets and/or growth factors and proteins originating from the actual initial blood composition, wherein said proteins are in a gel state. Also claimed is a method for the preparation of said formulation, which comprises the steps of heating and subsequently cooling the initial blood composition to specific temperatures and for specific periods of time. Amongst other advantages, the formulation according to the invention is biocompatible and biodegradable, exhibits the desirable biological or medical properties afforded by the presence of platelets or growth factors, and also exhibits a high level of dimensional stability over time.

CROSS-LINKED PLATELET MATERIAL

This document provides methods and materials involved in making and using cross-linked platelet material (e.g., cross-linked lysate material from human platelets such as human platelets obtained from platelet blood collection preparations or platelet apheresis preparations). For example, methods and materials for cross-linking platelet material (e.g., lysate material obtained from human platelets) to form a matrix (e.g. a cell-free tissue scaffold) for wound healing or regenerative medicine or to form conjugates or modified molecules are provided.

METHOD FOR PROMOTING HAIR GROWTH AND PREVENTING HAIR LOSS OF PATIENT, COMPOSITION THEREFOR, AND METHOD FOR PREPARING COMPOSITION

The present invention relates to a method for promoting hair growth and preventing hair loss of a patient, a composition therefor, and a method for preparing the composition. More particularly, the method for promoting hair growth and preventing hair loss of a patient is characterized in that a composition containing an effective amount of an active ingredient comprising bFGF is intradermally or subcutaneously administered into a lesion of a patient suffering from hair loss. The method for promoting hair growth and preventing hair loss of a patient, the composition therefor, and the method for preparing the composition of the present invention have the effects that new blood vessels are generated in a lesion to thereby increase the supply of blood, and growth of fiber tissues and tissue regeneration are promoted to thus thicken the skin tissue of a lesion.

METHOD FOR PROMOTING HAIR GROWTH AND PREVENTING HAIR LOSS OF PATIENT, COMPOSITION THEREFOR, AND METHOD FOR PREPARING COMPOSITION

The present invention relates to a method for promoting hair growth and preventing hair loss of a patient, a composition therefor, and a method for preparing the composition. More particularly, the method for promoting hair growth and preventing hair loss of a patient is characterized in that a composition containing an effective amount of an active ingredient comprising bFGF is intradermally or subcutaneously administered into a lesion of a patient suffering from hair loss. The method for promoting hair growth and preventing hair loss of a patient, the composition therefor, and the method for preparing the composition of the present invention have the effects that new blood vessels are generated in a lesion to thereby increase the supply of blood, and growth of fiber tissues and tissue regeneration are promoted to thus thicken the skin tissue of a lesion.

PLATELET CONCENTRATE FOR INCREASE OF CELL REGENERATION AND CELL GROWTH

The invention refers to a decomposed platelet concentrate containing < 50% intact platelets and optionally > 200pg/ml RANTES and specifically to its use in the prevention or treatment of hair loss and/or for promoting hair growth. The invention further refers to a composition comprising the decomposed platelet concentrate and body fat cells and the use of said composition for reconstructive and aesthetic and curative surgery and pain relief treatment.

COMPOSITIONS, USES, AND PREPARATION OF PLATELET LYSATES

In certain embodiments, this disclosure describes compositions comprising platelet lysates depleted of fibrinogen. In a further embodiment, the composition further comprises a cell culture medium component. This disclosure also provides a method for preparing the composition, comprising the steps of (a) lysing platelets providing a lysate; (b) removing cell debris; and (c) depleting fibrinogen by forming a removable mass by adding a metal salt such as calcium chloride. Furthermore, the disclosure also describes the product produced using said method.

METHOD OF BLOOD POOLING AND STORAGE

The disclosure provides methods of making a cell-containing product having a uniform amount of cells therein. The method comprises pooling red blood cells from a plurality of blood units, and inactivating any pathogen contained therein. A storage solution added to the cellular component results in a cell-containing product that is essentially pathogen and white blood cell free and has an extended shelf life of about 42 to about 100 days. The cell-containing product is further divided into units which comprise a uniform dose of RBCs per unit.

PLATELET MEMBRANE MICROPARTICLES

... 2051659 9012581 PCTABS00002 A heat-treated, viral-inactivated platelet membrane microparticle fraction is provided. The microparticles may be prepared from outdated platelets. The microparticle fraction is substantially free of alloantigens and GP IIb/IIIa complexes and may be used as a pharmaceutical preparation in transfusions.

SELECTIVE CELL PROLIFERATION

This invention provides methods to produce target cell populations which comprise primitive stem cells, progenitor cells, precursor cells, cells at intermediate stages of differentiation and terminally differentiated cells from almost any living cell within a patient such as a human. These target populations can be used in cell transplantation therapy such as bone marrow transplants, peripheral blood transplants, as well as in the recreation or supplementation of any organ or organ system such as the hermatopoietic system. In addition, target cell populations are also useful in gene therapy for the introduction of genes and their expressed products into a patient either systemically or n a targeted fashion.

PLATELET GLUE WOUND SEALANT

A plasma-buffy coat concentrate that comprises plasma, platelets at a concentration of at least 1.0 x 109 cells/ml, and fibrinogen at concentration of at least 5 mg/ml is described. The plasma-buffy coat concentrate can be combined with a fibrinogen activator to form a platelet glue wound sealant. A method for processing blood to produce the plasma-buffy coat concentrate is also provided. The method comprises centrifuging anticoagulated blood to remove red blood cells and produce a plasma-buffy coat mixture. Water is removed from the mixture to produce the plasma-buffy coat concentrate. A fibrinogen activator is mixed with the plasma-buffy coat concentrate to produce a wound sealant, which can then be applied to a wound to facilitate sealing and healing of the wound.

IMPROVED ENRICHED PLATELET WOUND HEALANT

A wound healant composition comprising a therapeutically effective amount of activated growth factors and ascorbic acid and/or at least one retinoid and/or at least one antibiotic, that facilitates the growth of new tissue.

PROCEDURE FOR THE PRODUCTION OF MODIFIED THROMBOZYTEN.

Concentrated growth factor and use thereof.

Le concentré de facteur de croissance est destiné au traitement cosmétique dun sujet nécessitant cela; il comprend des facteurs de croissance décapsulés dérivés de plasma riche en plaquettes sanguines et peut être conservé sur une durée prolongée grâce au procédé de linvention. Linvention concerne également une composition cosmétique antivieillissement comprenant ledit concentré de facteur de croissance, de même quun procédé de rajeunissement de la peau mettant en uvre une telle composition.

Preparation of a platelet concentrate, useful to treat wounds, comprises centrifugation of a total blood sample in the presence of a thixotropic polymeric gel and sodium citrate solution

Preparation of a platelet concentrate, comprises centrifugation of a total blood sample in the presence of a thixotropic polymeric gel and a sodium citrate solution. Independent claims are included for: (1) a device for the implementation of the process comprising a glass centrifuge tube containing the thixotropic polymeric gel solution and sodium citrate solution, having a vacuum for receiving the total blood sample; (2) the use of the process to prepare an enriched plasma to apply on wounds, comprising putting the cells collected from the patient to be treated, the cells from cell bank or culture cells, in suspension in the platelet concentrate; and (3) the use of the preparation to make a semi-solid gel used to fill a cavity, cellular deficit or growth matrix, comprising partial dehydration of the platelet concentrate. ACTIVITY : Vulnerary. MECHANISM OF ACTION : None given.

Use of the content of platelets or platelet rich plasma (obtained by disruption of their membranes) for the preparation of an agent, which is useful for the treatment of bone, cartilage or skin diseases or defects

Use of the content of platelets or platelet rich plasma (I) (obtained by disruption of their membranes) for the preparation of an agent (A) for the treatment of bone, cartilage or skin. An independent claim is also included for a method for preparing (A) comprising subjecting (I) to sonification at 0-37 [deg]C leading to a disruption of the platelet membranes and a release of their content. ACTIVITY : Osteopathic; Dermatological. MECHANISM OF ACTION : None given.

Concentrated growth factor and use thereof.

Le concentré de facteur de croissance est destiné au traitement cosmétique d’un sujet nécessitant cela; il comprend des facteurs de croissance décapsulés dérivés de plasma riche en plaquettes sanguines et peut être conservé sur une durée prolongée grâce au procédé de l’invention. L’invention concerne également une composition cosmétique antivieillissement comprenant ledit concentré de facteur de croissance, de même qu’un procédé de rajeunissement de la peau mettant en œuvre une telle composition.

Dermatological and cosmetic compositions to be administered topically using autologous composition components for.

Topisch zu applizierende Zusammensetzung für dermatologische und kosmetische Präparate unter Verwendung von Eigenblutbestandteilen.

THERAPEUTIC PREPARATION AND METHOD OF ITS PREPARING

METHODS OF EXTRACTING THROMBOCYTES

МНОГОСЛОЙНЫЙ ПРОДУКТ КРОВИ

Продукт крови (10), способ получения продукта крови, продукт крови, получаемый способом, и контейнерное средство получения продукта крови. Продукт крови содержит компоненты из цельной крови, особенно фибрин, тромбоциты и лейкоциты. Продукт крови (10) содержит первый слой (21), второй слой (22) и третий слой (23). Второй слой (22) смежный с первым слоем (21) и третьим слоем (23). Первый слой (21) определяет первую внешнюю поверхность (24) продукта крови (10), а третий слой (23) определяет вторую внешнюю поверхность (25) продукта крови (10). Первый слой (21) содержит большую часть фибрина, второй слой (22) содержит большую часть тромбоцитов, а третий слой (23) содержит большую часть лейкоцитов.

THROMBOCYTES SPOTS, THEIR METHOD OF PREPARATION AND THEIR APPLICATIONS LIKE AGENTS OF DIAGNOSIS

조혈 줄기세포를 전구 세포로 배양 및/또는 분화시키는 방법 및 그의 용도

... 본 발명은 경증 고체온(hyperthemia) 상태(예를 들어, 38℃ 내지 40℃)에서 조혈모세포(hematopoietic stem cell) 증폭의 피리미도인돌(pyrimidoindole) 유도체 작용제(agonist) 존재하에 조혈모세포(HSC)를 시험관내 배양하는 방법에 관한 것이다. 경증 고체온과 피리미도인돌 유도체의 조합 사용은 상승적으로 작용하여 CD34+ HSC의 증폭 및/또는 기원세포(예를 들어, 거핵구 기원세포)로의 분화를 촉진한다. 본 발명은 또한 HSC 및/또는 기원세포의 시험관내 증폭 세포 집단, 및 그의 치료학적 용도(예를 들어, 이식)에 관한 것이다.

혈소판 용해 및 활성화를 위한 디바이스 및 방법

... 환자에게 동시 발생 재주입을 위해 환자 침대 옆에서 변성된 자가 조직의 혈소판 용액의 제조를 위한 디바이스, 시스템 및 방법 실시예가 개시된다. 특정 실시예에서, 혈액 해동, 혈소판 용해, 용액 준비, 및 환자에게로의 재주입을 포함하지만 이에 한정되지 않는 모든 단계들은 환자를 재지정함이 없이 한번의 사무소 또는 병원 방문으로 달성될 수 있다. 따라서, 개시된 장치, 디바이스 및 시스템은 대체로, 혈소판 함유 용액을 수용하고, 혈소판 함유 용액 내의 하나 이상의 혈소판체의 용해를 유도하고, 환자에게 재주입하는데 적절한 방식으로 결과적인 변성 혈소판 용액을 제공하도록 구성된 실질적으로 독립적인 기계, 디바이스 또는 시스템을 포함한다.

COMBINATION PREPARATIONS COMPRISING EXOSOMES AND CORTICOSTEROID

Platelet-rich plasma compositions

METHOD FOR PRODUCING MEGAKARYOCYTES AND/OR PLATELETS FROM PLURIPOTENT STEM CELLS

PLATELET SOLUTION FOR JOINT FLUID

The invention is directed to a method of accelerating healing in a joint comprising administering a platelet composition to the joint.

METHOD FOR PREPARING PLATELET SOLUTION REPLACED WITH ARTIFICIAL PRESERVATION SOLUTION

Disclosed is a novel means for preparing a platelet solution replaced with an artificial preservation solution, said platelet solution having excellent performances of inhibiting platelet activation, recovering platelets and removing plasma. A method of the present invention for preparing a platelet solution replaced with an artificial preservation solution comprises: a filtration step for, under the conditions represented by formula (1), using a separation membrane, said separation membrane having an average pore size of 0.1 μm or more but less than 2.0 μm in the surface to be in contact with a platelet solution, cross-flow filtering the platelet solution at an inlet wall shear rate of 25-1500 s-1 to give a concentrated platelet solution; and a mixing step for mixing the concentrated platelet solution with an artificial preservation solution to give the platelet solution replaced with the artificial preservation solution. Formula (1): 1.0×1011<(A×B)/(γ×μP)≤2.5×1013(platelets/(hr·m2·Pa) ...

METHOD AND COMPOSITION FOR REGENERATING TISSUE WITH THE AID OF STEM OR BONE MARROW CELLS

The invention relates to a novel polymerizable composition, comprising substantially blood or blood plasma, and stem cells or cells of the bone marrow, and to a method for regenerating tissue with the aid of such compositions. Such mixtures can polymerize into viscous gels under the influence of endogenic or exogenic polymerization factors, such as thrombin, calcium ions or cell detritus, said gels being very advantageous for the development and differentiation of the stem or bone marrow cells into tissue-specific cells. Such polymers, comprising particularly also erythropoietin (EPO) or similarly acting growth factors, exhibit excellent properties in the use thereof for tissue regeneration or the regeneration of bone defects.

ONCOLYTIC VIRUS THERAPY

A method of treating a human subject with cancer is disclosed. A pharmaceutical composition is administered to the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution. Alternatively the pharmaceutical composition comprises human leukocytes or platelets infected with an oncolytic virus.

A METHOD AND THERAPEUTIC PLATELETS

A process for preparing a dehydrated biological sample comprising providing a biological sample selected from a mammalian species, loading with a solute the biological sample having an alcohol by fluid phase endocytosis to produce an internally loaded biological sample, and drying the loaded biological sample to produce a dehydrated biological sample.

PYRIDOXAL-5'-PHOSPHATE AS AN IN VITRO ANTICOAGULANT

The use of pyridoxal-5'-phosphate as an in vitro anticoagulant agent which retains the platelet activity of stored whole blood or stored plasma for more than about six hours is disclosed.

METHOD FOR TREATING PATIENTS USING CELLULAR SUSPENSIONS OF EMBRYONIC TISSUES

Cette invention concerne un procédé permettant de soigner des personnes à l'aide de suspensions cellulaires de tissus embryonnaires. Ce procédé consiste à préparer une suspension principale contenant des cellules d'embryon humain qui sont choisies dans le groupe comprenant des cellules hématopoïétiques du foie, des cellules hématopoïétiques de la rate ou un mélange de celles-ci. Cette suspension principale comprend également un excipient liquide acceptable sur le plan pharmaceutique. On prépare également au moins une suspension complémentaire contenant des cellules qui sont choisies dans le groupe comprenant des cellules souches de l'hématopoïèse du foie, des cellules souches de l'hématopoïèse de la rate, des hématocytes, des thymocytes, des cellules épithéliales du canal digestif primaire, des cellules nerveuses de la moelle ou des mélanges d'au moins deux de ces types de cellules. Les deux suspensions sont utilisées de manière combinée afin de traiter des affections internes chez des ...

ACUPOINT INJECTION THERAPY USING AN ENRICHED CELLULAR MIXTURE

A system and method are provided that use the meridian flow defined in traditional Chinese medicine to target specific regions of the body to treat certain health conditions. A cellular mixture is injected into the body via an acupoint on a particular meridian in order to deliver the mixture to an organ or body region associated with the particular meridian. The cellular mixture can be a stem cell/PRP mixture.

COMBINATION PREPARATION INCLUDING A CYTOKINE ANTAGONIST AND CORTICOSTEROID

The present invention relates to pharmaceutical compositions for a combination therapy with a cytokine antagonist and a corticosteroid. By means of the combination therapy diseases such as osteoarthritis, tendon injuries and/or degenerative spinal diseases can be treated.

SURFACE CROSS-LINKED LIPIDIC PARTICLES, METHODS OF PRODUCTION AND USES THEREFOR

A method for producing a composition of lipidic particles coated with a cross-linked surface mesh, the method comprising the steps of: (i) preparing lipidic particles comprising pharmaceutically acceptable lipids, (ii) binding hydrophilic polymer chains to the surface of the lipidic particles, and (iii) cross-linking the hydrophilic polymer chains to form the cross-linked surface mesh. Pharmaceutical compositions comprising surface modified lipidic particles prepared according to this method are also described. The lipidic particles resist fusion with red blood cells and platelets in vitro, and are amenable to further derivatization by targeting molecules for controlled release of component and contents, thus providing a new generation of drug carrier systems.

Medium And Methods For The Storage Of Platelets

Synthetic storage media are disclosed for use in the processing and the storing of platelets. The storage media includes a platelet storage solution and less than 20 percent plasma to preserve platelet function after at least 7 days of storage.

Freeze-dried blood cells, stem cells and platelets, and manufacturing method for the same

The present invention provides a method for manufacturing freeze-dried blood cells, stem cells and platelets comprising the steps of: pre-treating a liquid selected from the group consisting of blood including blood cells, bone marrow fluid (hemopoietic stem cells), and platelets in blood plasma, with a solution containing at least one substance selected from the group consisting of saccharide, biopolymer, acid and acid salt; conducting granulation of the aforementioned pre-treated liquid into a granules of a predetermined size; performing rapid cooling of the granules; and drying the resultant frozen material by sublimation of the water content contained therein.

Composition comprising three platelet lesion inhibitors for platelet storage

This invention provides a method for prolonging the preservation of human blood platelets at reduced temperatures. The method uses an inhibitor system that enables blood platelets to maintain their discoid shape and retain their functional integrity during storage. This is accomplished by interrupting normal platelet function during storage, so as to help keep platelets from activating and losing their shape. Before using the platelets in a transfusion, they are returned to their normal functional level by washing the inhibitor system away from the platelets. In particular, compositions comprising amiloride, adenosine and sodium nitroprusside are disclosed.

Pyridoxal-5'-phosphate as an in vitro anticoagulant for whole blood

The use of pyridoxal-5'-phosphate as an in vitro anticoagulant agent which retains the platelet activity of stored whole blood or stored plasma for more than about six hours is disclosed.

Method for preparing glucose free media for storing blood platelets

Novel methods and storage media for storing platelets in a viable condition for at least five days are disclosed. The disclosed methods comprise the steps of providing a platelet rich suspension of platelets and blood plasma; extracting supernatant plasma from that suspension to leave between about 1 to 15 mls of plasma per unit of blood platelets with those platelets to produce a concentrated platelet button; adding 40 to 70 ml/unit of a glucose free aqueous solution to said concentrated platelet button; agitating the resultant solution to resuspend the platelets to provide a synthetic suspension of those platelets; and storing that synthetic suspension in an oxygen permeable container at about 22 DEG C. until needed for use. Two preferred glucose free aqueous platelet storage media are disclosed which generally comprise sodium citrate, sodium chloride, potassium chloride, and either sodium phosphate or calcium chloride, but not both. The subject media also optionally comprise magnesium ...

Inactivation of extracellular enveloped viruses in blood and blood components by phenthiazin-5-ium dyes plus light

This invention provides methods for inactivating pathogenic contaminants in whole blood, plasma, cellular blood components, or in any combination thereof, by adding a phenthiazin-5-ium dye(s) thereto and irradiating said dye-containing composition for an effective length of time with light of wavelengths from 560 to 800 nm or red light, of an effective intensity, whereby the irradiation in conjunction with the dye(s) inactivate substantially all pathogenic contaminants contained therein. The methods of this invention inactivate pathogenic contaminants, such as viruses, bacteria and parasites, without substantially altering the whole blood, plasma, cellular blood components, or combinations thereof, such that they are suitable for transfusion.

Method for treating a wound using improved placental tissue graft

Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located on top of and within the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high levels of laminin-5, a cell adhesion bio-active factor shown to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.

Spray-Dried Blood Products and Methods of Making Same

The present invention is directed to a method of preparing dehydrated blood products, comprising the steps of: (a) providing a hydrated blood product; (b) spray-drying the hydrated blood product to produce a dehydrated blood product, as well as dehydrated blood products made by the method. The present invention is directed to a method of treating a patient suffering from a blood-related disorder, comprising the steps of: (a) rehydrating a therapeutic amount of the dehydrated blood products to produce a rehydrated therapeutic composition; and (b) administering the rehydrated therapeutic composition to the patient. The present invention is directed to a bandage or surgical aid comprising the dehydrated blood products described above.

Hair growth agent having a platelet dry powder

A hair growth agent having an effective dose of a platelet dry powder and a pharmaceutically acceptable solvent and/or excipient, wherein the effective dose refers to the presence of at least 1,000 platelets in every milligram of the hair growth agent.

Neutrophil-depleted platelet rich plasma formulations for cardiac treatments

Compositions and methods for preparing neutrophil-depleted platelet rich plasma are provided. Generally, these compositions comprise a higher concentration of platelets and depressed concentrations of neutrophils relative to whole blood although white blood cells may be at higher concentrations than whole blood. The concentrations of the platelets and/or the white blood cells may be two to eight times the respective concentrations in whole blood. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue and/or to slow or stop cardiac apoptosis after a heart attack. The neutrophil-depleted platelet rich plasma composition may be delivered in conjunction with reperfusion therapy.

Method of Preconditioning of Cell Suspensions

An apparatus for the preparation of cells for implantation into a living body is disclosed. The apparatus comprises a vessel substantially impermeable to gaseous oxygen; and fluid within said vessel, the fluid having a maximal dissolved oxygen capacity substantially equivalent to normal saline yet having a hypoxic oxygen concentration between about 0% to about 5% of said maximal dissolved oxygen capacity. The bag oxygen concentration level remains low when the apparatus is stored at 22°-25° C. in normal atmospheric conditions for a period of at least 30 days. The present invention simplifies the process of achieving donor cell hypoxic preconditioning for cell implantation, and may be used to bathe said cells to be transplanted for a sufficient time to activate the hypoxic metabolic pathway.

Compositions and methods for platelet enriched fibrin constructs

Compositions and methods are provided for tissue constructs that promote wound healing. The composition comprises a dimensionally stable fibrin construct for local administration to a wound site or region. In one embodiment, the fibrin construct is a wound healing composition, including components that promote wound healing, such as platelets, growth factors, white blood cells and fibrin clots. In another embodiment, the tissue treatment composition includes (i) aggregated fibrin, (ii) blood cells, and (iii) optionally, growth factors and/or other proteins.

Compositions and Methods to Promote Implantation and Engrafment of Stem Cells

Tissue repair in-vivo depends on acute inflammation, but in many clinical situations the other major components of healing such as blood supply, anabolic hormones, growth factors, and stem cells are lacking. This invention includes compositions consisting of an agent which induces an inflammatory healing response combined with an autologous platelet lysate at a specific concentration which may have demonstrated in-vitro abilities to expand autologous tissue repair cells. 1. A composition for facilitating tissue repair in a patient in need thereof comprising a therapeutically effective amount of an autologous platelet lysate in combination with one or more inflammation inducing agent.2. The composition of claim 1 , wherein the inflammation inducing agent is an agent capable of inducing local cell injury claim 1 , in the patient in need thereof.3. The composition of claim 2 , wherein the agent for inducing local cell injury is selected from the group consisting of hypertonic dextrose claim 2 , sodium morrhuate claim 2 , inflammatory cytokines claim 2 , pumice claim 2 , phenol and mixtures thereof.4. The composition of claim 2 , wherein the agent for inducing local cell injury acts through local cell lysis via a hyper or hypo osmolar agent.5. The composition of claim 1 , wherein platelet rich plasma claim 1 , platelet rich fibrin claim 1 , or another whole platelet concentrate is substituted for platelet lysate.6. The composition of claim 1 , wherein cytokines are added to the 5% to 40% platelet lysate to alter the timing of growth factor deganulation off of platelets in the platelet lysate.7. The composition of claim 1 , further comprising one or more essential nutrients wherein the essential nutrients further facilitate tissue repair.8. The composition of claim 7 , wherein the one or more essential nutrient is selected from the group consisting of glycoaminosglycan's claim 7 , collagen claim 7 , amino acids claim 7 , peptides claim 7 , proteins claim 7 , sodium ...

METHOD OF TREATING CANCER USING PLATELET COMPOSITIONS

Platelets are concentrated from the blood of a patient. The platelets are unactivated or are treated by a method such as ultrasound or agitation to obtain platelet releasate. The platelets are formulated into an injectable formulation which is administered to the same patient the platelets were extracted from in order to treat the patient's cancer. 1. A method of treating cancer comprising:preparing a platelet-rich plasma composition from a patient in need of cancer treatment;formulating the platelet-rich plasma composition into an injectable formulation; and injecting the platelet-rich plasma composition into a patient in need of cancer treatment.2. The method of claim 1 , wherein the administering comprises injecting the platelet-rich plasma composition into a tumor of the patient.3. The method of claim 1 , wherein the administering comprises injecting the platelet-rich plasma composition into a cancerous tumor of the patient.4. The method of claim 1 , wherein the patient treated with the formulation is the same patient from which the blood is extracted from claim 1 , and the formulation is buffered to pH 7.4+/−5%.5. The method of claim 1 , wherein the platelet-rich plasma composition comprises:platelets in a concentration of about 500,000/μl to about 7,000,000/μl,monocytes in a concentration of about 400/μl to about 3200/μl, andneutrophils in a concentration of less than about 5000/μl.6. The method of claim 1 , wherein the platelet concentration in the platelet-rich plasma composition is between 2-8 times the platelet concentration in the blood.7. The method of claim 6 , wherein the platelet concentration in the platelet-rich plasma composition is between 4-6 times the platelet concentration in the whole blood.8. The method of claim 1 , wherein the hemoglobin concentration in the platelet-rich plasma composition is less than about 3.5 grams per deciliter.9. The method of claim 1 , wherein the platelet-rich plasma composition comprises white blood cells and ...

Methods of Preventing Platelet Alloimmunization and Alloimmune Platelet Refractoriness and Induction of Tolerance in Transfused Recipients

Methods and compositions for the prevention or reduction of platelet transfusion associated complications are provided. Methods are provided to modify donor whole blood or platelets prior to transfusion to prevent or reduce alloimmune platelet refractoriness.

Bioreactor for Isolation of Rare Cells and Methods of Use

The present invention relates to a bioreactor apparatus, and methods of use, for the isolation of rare blood cells, including hematopoietic stem cells and megakaryocytes. The apparatus includes a soft substrate and an anti-contractility agent, thereby providing a soft microenvironment to cultured cells. The apparatus of the invention is permissive for the survival of non-dividing cells while dividing cells are eliminated. This unique property allows for the simple isolation of rare blood cells without the use of costly equipment and antibodies. 1. An apparatus for the isolation of non-dividing cells from a cell population comprising a substrate layer on at least one surface of the apparatus , wherein the substrate layer includes at least one composition comprising at least one anti-contractility agent for reducing cell contractility when a cell population is in contact with the substrate layer.2. The apparatus of claim 1 , wherein the at least one composition further comprises at least one compound selected from the group consisting of an aryl-hydrocarbon receptor antagonist and a growth factor.3. The apparatus of claim 1 , wherein the non-dividing cells are rare blood cells selected from the group consisting of hematopoietic stem cells claim 1 , polyploid megakaryocytes claim 1 , polyploid non-megakaryocytes claim 1 , granulocyte-macrophage progenitors claim 1 , and erythroid progenitors.4. The apparatus of claim 1 , wherein the substrate layer is a soft substrate having a low stiffness of about 0.3 kPa to 2 kPa.5. The apparatus of claim 1 , wherein the anti-contractility agent inhibits the function of myosin-II.6. The apparatus of claim 1 , wherein the at least one composition is embedded within the substrate layer.7. The apparatus of claim 1 , wherein the surface of the substrate layer is coated with at least one protein selected from the group consisting of collagen claim 1 , fibronectin claim 1 , laminin claim 1 , and vitronectin.8. A bioreactor for the ...

PLATELET-RICH PLASMA COMPOSITIONS

The present invention relates to a method of treating functional disability and/or pain associated with joints, tendons or connective tissue diseases, disorders or injuries comprising oral administration of a composition comprising heterologous platelet-rich plasma. The invention also relates to pharmaceutical compositions and nutritional compositions comprising heterologous platelet-rich plasma and uses thereof. 1. A method of treating functional disability and/or pain associated with joints , tendons or connective tissue diseases , disorders or injuries in a subject in need thereof comprising orally administering to said subject a composition comprising heterologous platelet-rich plasma (PRP) , in an amount effective to treat functional disability and/or pain associated with joints , tendons or connective tissue diseases , disorders or injuries.2. The method according to claim 1 , wherein the joint claim 1 , tendon or connective tissue disease claim 1 , disorder or injury is osteoarthritis.3. The method according to claim 1 , wherein the heterologous platelet-rich plasma is of porcine origin.4. The method according to claim 3 , wherein the composition further comprises growth factors.5. The method according to claim 4 , wherein the growth factors are selected from the group consisting of transforming growth factors (TGF) claim 4 , fibroblast growth factors (FGF) claim 4 , platelet-derived growth factors (PDGF) claim 4 , epidermal growth factors (EGF) claim 4 , vascular endothelial growth factors (VEGF) claim 4 , insulin-like growth factors (IGF) claim 4 , platelet-derived endothelial growth factors (PDEGF) claim 4 , platelet-derived angiogenesis factors (PDAF) claim 4 , platelet factors 4 (PF-4) claim 4 , hepatocyte growth factors (HGF) and mixtures thereof.6. The method according to claim 5 , wherein the growth factors are transforming growth factors (TGF) claim 5 , platelet-derived growth factors (PDGF) claim 5 , fibroblast growth factor (FGF) or mixtures ...

Apparatus and method for separating and concentrating fluids containing multiple components

An apparatus that allows for separating and collecting a fraction of a sample. The apparatus, when used with a centrifuge, allows for the creation of at least three fractions in the apparatus. It also provides for a new method of extracting the buffy coat phase from a whole blood sample. A buoy system that may include a first buoy portion and a second buoy member operably interconnected may be used to form at least three fractions from a sample during a substantially single centrifugation process. Therefore, the separation of various fractions may be substantially quick and efficient.

PLATELET RICH PLASMA FORMULATIONS AND USE THEREOF

Compositions for platelet rich plasma (PRP), depleted in neutrophils, are provided. Generally, these compositions comprise a higher concentration of platelets, lymphocytes and monocytes than whole blood with selective depletion of neutrophils to a concentration of less than about 5000/μl. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue and/or to slow or stop cardiac apoptosis after a heart attack. The PRP composition may be delivered in conjunction with reperfusion therapy.

METHODS AND PRODUCTS FOR TISSUE REPAIR

Methods and devices for the repair of articular tissue using collagen material are provided. Compositions of collagen material and related kits are also provided. 119-. (canceled)20. A composition comprisinga sterile solution of solubilized collagen in a concentration of greater than 5 and less than or equal to 50 mg/ml and having a viscosity of 1,000-200,000 centipoise, hydroxyproline in a concentration of 0.1-5.0 μg/ml, a neutralizing agent wherein the solution has an osmolarity of 280-350 mOs/kg, wherein the composition is free of thrombin.21. The composition of claim 20 , wherein the solution is a liquid or gel.22. The composition of claim 20 , wherein the solubilized collagen is present in a concentration of greater than 15 mg/ml and less than or equal to 40 mg/ml.23. The composition of claim 20 , further comprising a platelet claim 20 , white blood cells claim 20 , an antibiotic claim 20 , an anti-plasmin agent claim 20 , insoluble collagen claim 20 , a plasminogen activator inhibitor claim 20 , a glycosaminoglycan claim 20 , decorin or biglycan.24. The composition of claim 20 , further comprising a buffer claim 20 , wherein the composition has a pH of 6.8-8.0 or a pH of 7.4.25. The composition of claim 20 , wherein the collagen is enzyme solubilized collagen or atelocollagen.26. The composition of claim 20 , wherein the solution is maintained at a temperature of 4° C.27. The composition of claim 20 , wherein the composition is prepared by subjecting a sterile solution of solubilized collagen in a concentration of greater than 5 and less than or equal to 50 mg/ml and having a viscosity of 1 claim 20 ,000-200 claim 20 ,000 centipoises to a temperature of at least 30° C. wherein the sterile solution of solubilized collagen forms a collagen scaffold.28. The composition of claim 27 , wherein the solution is a liquid or gel.29. The composition of claim 27 , wherein the solubilized collagen is present in a concentration of greater than 15 mg/ml.30. The composition ...

Compositions and Methods for Cartilage Repair

Autologous compositions and methods are provided for cartilage repair in patients in need thereof. Some aspects include combinations of platelet-based materials with chondrogenesis inducing agents in the presence or absence of cell-based therapies. 1. A composition for facilitating cartilage repair in a patient in need thereof comprising a therapeutically effective amount of an autologous platelet lysate and one or more chondrogenesis inducing agents.2. The composition of wherein the platelet lysate is from about 5% to about 40% platelet lysate solution.3. The composition of wherein the chondrogenesis inducing agent is one or more growth factors claim 1 , one or more cytokines claim 1 , one or more hormones claim 1 , or one or more essential nutrients.4. The composition of wherein the chondrogenesis inducing agent is a hormone and wherein the hormone is corticosteroid.5. The composition of wherein the chondrogenesis inducing agent is a growth factor and wherein the growth factor is transforming growth factor β claim 3 , fibroblast growth factor or a bone morphogenetic protein.6. The composition of wherein the chondrogenesis inducing agent is a cytokine and wherein the cytokine is IL-1.7. The composition of wherein the chondrogenesis inducing agent is an essential nutrient and wherein the essential nutrient is ascorbic acid claim 3 , collagen claim 3 , amino acids claim 3 , peptides claim 3 , sodium pyruvate claim 3 , glucose claim 3 , glutamine claim 3 , ribonucleosides claim 3 , carbohydrates claim 3 , essential oils or deoxyribonucleosides.8. The composition of further comprising platelet rich plasma claim 1 , platelet rich fibrin claim 1 , whole cell platelets or a mixture thereof.9. The composition of further comprising a gel claim 1 , hydrogel claim 1 , foam claim 1 , or other carrier material.10. A method for facilitating cartilage repair in a patient in need thereof comprising:obtaining platelets from the patient;preparing a 5% to 40% platelet lysate solution ...

Methods And Composition For Treating Heart Failure And Ischemia

Methods and compositions for treating heart failure by administration of beneficial agents to the heart. 1. A method for inhibiting heart failure after myocardial infarction , the method comprising:obtaining platelets from a donor;increasing stromal cell derived factor 1 (SDF-1) content of the donor platelets; andadministering the platelets to the heart of a subject.2. The method of claim 1 , wherein the donor is a mammal.3. The method according to claim 2 , wherein the mammal is a human.4. The method of claim 1 , wherein the SDF-1 content is increased by electroporating the donor platelets in the presence of SDF-1.5. The method of claim 1 , wherein the platelets are administered to the myocardium.6. The method of claim 5 , wherein the myocardium is infarcted.7. The method of claim 1 , wherein the platelets are activated with a cytokine prior to administration.8. The method of claim 7 , wherein the cytokine is thrombopoietin.9. The method according to claim 8 , wherein the cytokine is a soluble kit ligand.10. The method of claim 1 , wherein the platelets are administered to a coronary artery.11. The method of claim 10 , wherein the coronary artery supplies an infarcted myocardium.12. The method of claim 1 , wherein the platelets are administered into the left ventricular chamber claim 1 , or by intra-arterial or intravenous injection.13. The method of claim 12 , wherein the platelets bind to the surfaces of injured arteries within the infarct zone after delivery.14. The method of claim 12 , wherein the methods promote aggregation of platelets to form microvascular obstructions in the infarct zone after delivery.15. The method according to claim 12 , wherein the method promotes stimulation of progenitor cell recruitment and sequestration to replace myocardial cells and promote revascularization of the infarct site.16. A composition comprising:{'b': '1', '(a) modified donor platelets, wherein the modified donor platelets have a greater concentration of stromal cell ...

Cell Preparations For Extemporaneous Use, Useful for Healing and Rejuvenation In Vivo

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell combinasons preparations for use in tissue regeneration and bone regeneration and pain reduction. 2. An implantable device for use in tissue regeneration therapy comprising: i) plasma;', {'sup': '9', 'ii) platelets at a concentration of at least 300×10cells/L;'}, {'sup': '9', 'iii) white blood cells at a concentration of at least 7.0×10cells/L;'}, 'iv) fibrinogen at a concentration of at least 3 mg/L; and', {'sup': 5', '6', '12, "v) a cell extract where cells are selected from dermal cells, keratinocytes, fibroblasts, melanocytes and Langheran's cells; fat cells; bone marrow cells; muscle cells; osteoblasts; chondrocytes; periosteal membrane cells; corneal cells; umbilical cord cells; Schwann cells, tendon cells and pancreas islet cells, wherein cells are at a concentration of about 10to about 10cells/L and wherein the erythrocyte concentration of said cell composition is less than 0.6×10cells/L; and"}], 'a) a permeable core comprising a cell composition comprisingb) an external jacket surrounding said core, said jacket comprising a biocompatible material or a bioresorbable material. This application is a continuation of U.S. Ser. No. 12/438,236, filed Feb. 20, 2009, which is the U.S. national stage application of International Patent Application No. PCT/EP2007/058695, filed Aug. 21, 2007, the disclosures of which are hereby incorporated by reference in their entirety, including all figures, tables and amino acid or nucleic acid sequences.The present invention is related to the field of tissue regeneration, especially skin, cartilage, muscle, ...

AUTOMATED METHODS AND SYSTEMS FOR PROVIDING PLATELET CONCENTRATES WITH REDUCED RESIDUAL PLASMA VOLUMES AND STORAGE MEDIA FOR SUCH PLATELET CONCENTRATES

Automated systems and methods for providing platelet concentrates and synthetic storage media with reduced residual plasma volumes are disclosed. The disclosed systems and methods reduce the residual volume of plasma in platelet concentrate to obtain a platelet product having a volume of plasma that is approximately 5% or less of the total platelet product volume. The disclosed systems and methods also reduce the residual volume of plasma in platelet concentrate to obtain a washed platelet product, wherein the volume of plasma in the washed platelet product is approximately 1% or less of the total washed platelet product volume. Storage media for platelets including less than approximately 10% plasma are also disclosed. 1. A synthetic aqueous solution for the storage of platelets comprising:from about 45 to about 125 mM sodium chloride;from about 5 to about 15 mM sodium citrate;from about 20 to about 40 mM sodium acetate;from about 0.05 to about 12 mM phosphate;from about 0.05 to about 3 mM magnesium ion;from about 0.05 to about 10 mM potassium chloride;from about 5 to about 40 mM sodium bicarbonate; andfrom about 0.5 to about 30 mM glucose.2. The aqueous solution of further comprising from about 0 mM to 3 mM calcium chloride.3. A platelet product claim 1 , comprising: from about 45 to about 120 mM sodium chloride;', 'from about 5 to about 15 mM sodium citrate;', 'from about 20 to about 40 mM sodium acetate;', 'from about 0.05 to about 12 mM sodium phosphate;', 'from about 0.05 to about 3 mM magnesium ion;', 'from about 0.05 to about 10 mM potassium chloride;', 'from about 5 to about 40 mM sodium bicarbonate;', 'from about 0.5 to about 30 mM glucose; and', 'up to about 10% plasma., 'an aqueous solution comprising, 'platelets, and'}4. The platelet product of further comprising from about 0 mM to 3 mM calcium chloride.5. The platelet product of wherein the aqueous solution comprises up to about 5% plasma.6. The platelet product of wherein the aqueous solution ...

Composition with growth factors, to be used in the intranasal treatment of a neurodegenerative disease or other diseases of the central nervous system, and its method of manufacture

The object of the invention is the treatment of neurodegenerative diseases or other applicable diseases by means of the intranasal administration of a composition obtained from at least one growth-factor-containing blood compound, or by means of a therapeutic substance obtained from said composition, in addition to the composition itself. It is guaranteed that the composition reaches the central nervous system in an effective manner in terms of the treatment, and also in a safe manner for the patient.

PRODUCTION OF RED BLOOD CELLS AND PLATELETS FROM STEM CELLS

This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a stem cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and CD235. In some embodiments the number of MEPs produced in the culture increases exponentially. Methods of making a red blood cell (RBC) by culturing a MEP in the presence of an AhR agonist are also provided. Methods of making a megakaryocyte and/or a platelet, comprising culturing a MEP in the presence of an AhR modulator are also provided. In some embodiments the AhR modulator is an AhR antagonist. This disclosure also provides compositions comprising at least 1 million MEPs per ml and compositions in which at least 50% of the cells are MEPs. 1. A method of making a megakaryocyte-erythroid progenitor cell (MEP) , comprising differentiating a pluripotent stem cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) agonist.2. The method of claim 1 , wherein the culture does not comprise serum.3. The method of claim 1 , wherein the culture does not comprise feeder cells.4. The method of claim 1 , wherein the pluripotent stem cell is differentiated into a MEP in the presence of BMP-4 claim 1 , vVEGF claim 1 , WNT3a claim 1 , bFGF claim 1 , hSCF claim 1 , FLT3 claim 1 , TPO claim 1 , and EPO.5. (canceled)6. The method of claim 1 , comprising:a) culturing the pluripotent stem cell in RPMI media supplemented with BMP-4, VEGF, Wnt3a, and knockout serum replacement (KOSR);b) culturing the cell obtained from step a) in RPMI media supplemented with BMP-4, VEGF, bFGF and KOSR;c) culturing the cell obtained from step b) in StemPro 34 media supplemented with BMP-4, VEGF, and bFGF;d) culturing the cell obtained from step c) in StemPro 34 media supplemented with VEGF, and bFGF;e) culturing the cell obtained from step d) in a mixture ...

Viral inactivated platelet extract, use and preparation thereof

The invention relates to a viral-safe platelet extract, to its preparation and use. The extract comprises a mixture of biologically active platelet derived factors. Advantageously, the extract comprises a balanced proportion of the factors and is non-clottable.

DELIVERY OF COMPOUNDS WITH REHYDRATED BLOOD CELLS

Fixed-dried blood cells carrying an active agent are described, along with methods of making the same, methods of using the same, and compositions containing the same. The blood cells are preferably blood platelets. 1. Fixed-dried blood cells having an exogenous active agent coupled thereto , wherein said fixed-dried blood cells comprise fixed-dried blood platelets;wherein said exogenous active agent is selected from the group consisting of diagnostic agents and therapeutic agents;wherein said active agent is coupled covalently to the interior or surface of said cells;wherein said fixed-dried blood platelets are aldehyde fixed-dried blood platelets;and wherein said fixed-dried blood platelets upon reconstitution: adhere to thrombogenic surfaces; undergo shape change upon adhering to a thrombogenic surface; and lead to the formation of a hemostatic plug upon adhering to a thrombogenic surface.2. The fixed-dried blood cells of claim 1 , wherein said fixed-dried blood cells comprise mammalian fixed-dried blood cells.3. The fixed-dried blood cells of claim 1 , wherein said fixed-dried blood cells comprise human fixed-dried blood cells.4. The fixed-dried blood cells of claim 1 , wherein said active agent is contained within said cells.5. The fixed-dried blood cells of claim 1 , wherein said fixed-dried blood cells are fixed-dried blood platelets which upon reconstitution:release their granular contents upon adhering to a thrombogenic surface.6. The fixed-dried blood cells of claim 1 , wherein said active agent comprises an antiviral agent.7. The fixed-dried blood cells of claim 1 , wherein said active agent comprises a blood coagulation protein.8. The fixed-dried blood cells of claim 1 , wherein said active agent comprises a blood anti-coagulation protein.9. The fixed-dried blood cells of claim 1 , wherein said active agent comprises a nucleic acid.10. The fixed-dried blood cells of claim 1 , wherein said exogenous active agent is selected from the group consisting of ...

BLOOD PLASMA BASED HYDROGELS FOR TISSUE REGENERATION AND WOUND HEALING APPLICATIONS

The present disclosure generally relates to tissue engineering and wound healing. More particularly, the present disclosure relates to the modification of plasma with a stability conferring agent to create a hydrogel for use in regenerative medicine and other tissue engineering applications. 1. A composition comprising plasma in which at least a portion of the fibrinogen present in the plasma is co-polymerized with polyethylene glycol.2. The composition of wherein the plasma is from an autologous source.3. The composition of wherein the plasma is platelet free plasma.4. The composition of wherein the plasma is platelet rich plasma.5. The composition of further comprising one or more components chosen from growth factors claim 1 , extracellular matrix proteins claim 1 , therapeutic drugs claim 1 , and antibiotics.6. The composition of further comprising therapeutic cells.7. The composition of further comprising adipose derived stem cells.8. The composition of further comprising a fibrinogen-converting agent.9. The composition of further comprising a fibrinolytic inhibitor.10. The composition of wherein the composition is a hydrogel.11. The composition of wherein the polyethylene glycol is bifunctional.12. The composition of wherein the polyethylene glycol is SG-PEG-SG.13. A method comprising providing a PEGylated plasma and initiating crosslinking of the PEGylated plasma to form a hydrogel.14. The method of claim 13 , wherein the PEGylated plasma is formed by co-polymerizing polyethylene glycol to at least a portion of fibrinogen present in a plasma.15. The method of claim 13 , wherein the initiating crosslinking of the PEGylated plasma comprises introducing a fibrinogen-converting agent to the PEGylated plasma.16. The method of wherein the PEGylated plasma is formed from platelet free plasma.17. The method of wherein the PEGylated plasma is formed from platelet rich plasma.18. The method of wherein the plasma is from an autologous source.19. A method comprising ...

COMBINATION OF BIOELECTRICAL STIMULATOR AND PLATELET-RICH FIBRIN FOR ACCELERATED HEALING AND REGENERATION

Means and methods utilizing a combination of bioelectrical stimulator and platelet-rich fibrin for accelerated tissue or wound healing and regeneration is described. The system bioelectrically stimulates the centrifuge, test tube, and/or subject to produce enhanced levels of, e.g., SDF, PDGF, HGF, VEGF, IGF, Sonic hedgehog, klotho, and/or tropoelastin. The described system produces much higher levels of regenerative proteins delivered over an extended period of time. 1. A method of accelerating tissue healing and tissue regeneration in a subject , the method comprising:administering platelet-rich fibrin (“PRF”), Extended Growth Factor Release platelet-rich fibrin (“ER-PRF”), and/or leucocyte- and platelet-rich fibrin (“L-PRF”) to the subject, andbioelectrically stimulating the subject and/or the PRF, ER-PRF, and/or L-PRF to increase and extend PRF or L-PRF regenerative protein expression,so as to accelerate healing and tissue regeneration in the subject.2. The method according to claim 1 , wherein the PRF or L-PRF regenerative protein is selected from the group consisting of platelet alpha granules claim 1 , platelet-derived growth factor (“PGDF”) claim 1 , transforming growth factors-β (“TGF-β”) claim 1 , vascular endothelial growth factor (“VEGF”) claim 1 , and epidermal growth factor (“EGF”).3. In a method of encouraging tissue healing and regeneration in a subject claim 1 , the improvement comprising:using a combination of bioelectrical stimulation and utilization of platelet-rich fibrin (“PRF”), Extended Growth Factor Release platelet-rich fibrin (“ER-PRF”), and/or leucocyte- and platelet-rich fibrin (“L-PRF”) to increase and extend PRF regenerative protein expression to enhance and/or accelerate tissue healing and regeneration in the subject.4. The method according to claim 3 , wherein the PRF claim 3 , ER-PRF claim 3 , and/or L-PRF regenerative protein is selected from the group consisting of platelet alpha granules claim 3 , platelet-derived growth factor (“ ...

PLATELET RICH PLASMA FORMULATIONS

Compositions for platelet rich plasma (PRP) and neutrophil-depleted PRP are provided. Methods for treating ischemia damaged tissues by delivering a PRP composition, in some embodiments a neutrophil-depleted PRP composition to the damaged tissue are provided. In some variations, the compositions may be useful to treat ischemic heart disease and repair damaged cardiovascular tissue following acute myocardial infarction including congestive heart failure. In some variations, the compositions may be useful to reduce cardiac apoptosis after a heart attack. 131.-. (canceled)32. A method of reducing apoptosis in ischemia damaged tissue , comprising:delivering a platelet rich plasma (PRP) composition to a site of ischemic damage.33. The method of claim 32 , wherein the PRP composition comprises:platelets derived from whole blood at a first concentration of at least about 1.1 times a platelet concentration in the whole blood;white blood cells derived from the whole blood at a second concentration of at least about 1.1 times a white blood cell concentration in the whole blood.34. The method of claim 33 , wherein the white blood cells comprise:neutrophils, wherein the neutrophil concentration is less than the neutrophil concentration in the whole blood;lymphocytes, wherein the lymphocyte concentration is 1.1 times lymphocyte concentration in the whole blood; andmonocytes, wherein the monocyte concentration is 1.1 times monocyte concentration in the whole blood.35. The method of claim 32 , wherein the PRP composition is delivered using a needle or catheter sufficient for injection of the platelet-containing composition.36. The method of claim 32 , further comprising preparing the composition from the whole blood of the patient.37. The method of claim 32 , further comprising testing a platelet rich plasma for conformance to the composition prior to delivering the composition. This application is a continuation of U.S. application Ser. No. 13/636,321, filed Sep. 20, 2012 which is ...

Methods and Devices for Preparation of Enriched Biological Fluids

The present disclosure relates to methods and apparatus for producing platelet rich plasma, bone marrow mononuclear cells, stromal vascular fraction from adipose tissue, and other concentrated or enriched biological fluids. 1. A method of blood fractionation comprising:a) centrifuging whole blood in a first syringe having a top coupling element and a bottom coupling element, wherein the whole blood fractionates into a platelet poor plasma layer, a buffy layer, and an erythrocyte layer within the syringe;b) removing at least a portion of the platelet poor plasma layer from the top coupling element of the first syringe;c) attaching a bottom coupling element of a second syringe or second container to the top coupling element of the first syringe;d) drawing any of the platelet poor plasma layer, the buffy layer, and optionally part of the erythrocyte layer into the second syringe or second container; ande) centrifuging the second syringe or second container wherein the any of the platelet poor plasma layer, the buffy layer, and the erythrocyte layer fractionates into a platelet rich plasma layer and an erythrocyte layer.2. The method of claim 1 , wherein the platelet rich plasma layer is removed and transferred to a container.3. The method of claim 1 , wherein the platelet rich plasma layer comprises about 8×10to about 1×10platelets/μL.4. The method of claim 1 , wherein the platelet rich plasma layer comprises about 0.1×10to about 2×10erythrocytes/μL.5. The method of claim 1 , wherein the platelet rich plasma layer comprises about 500 to about 4000 white blood cells/μL.6. The method of claim 1 , wherein the platelet rich plasma layer comprises about 10 to about 300 neutrophils/μL.7. The method of claim 1 , wherein the centrifuging in step (a) has a relative centrifugal force (RCF) of about 1500×g to about 2000×g.8. The method of claim 1 , wherein the centrifuging in step (e) has a relative centrifugal force (RCF) of about 30×g to about 200×g.9. The method of claim 1 , ...

TECHNIQUES FOR TREATMENT OF ABSCESSES

This document provides devices, system, and methods for treating an abscess cavity. For example, procedures that involve supplementing a biocompatible filler material with a therapeutic agent to promote tissue regeneration and healing are provided. The biocompatible filler materials that are treated with a therapeutic agent are implanted into the abscess cavity. The biocompatible filler material provides a tissue growth scaffold, and the therapeutic agent enhances tissue growth and healing. 1. A method for treating a fistula of a mammal , said method comprising:(a) obtaining a synthetic, bioabsorbable, non-woven material that is configured for implantation into the fistula,(b) soaking the material in a solution comprising adipose-derived stem cells and platelet derivative material for from about 1 hour to about 5 days, wherein the adipose-derived stem cells and platelet derivative material impregnate the material, thereby forming a treated material, and(c) implanting the treated material into the fistula.2. The method of claim 1 , wherein said mammal is a human.35-. (canceled)6. The method of claim 1 , wherein said fistula is an anal fistula.78-. (canceled)9. The method of claim 1 , wherein said soaking step comprises soaking the material in said solution for from about 18 hours to about 5 days.10. The method of claim 1 , wherein said soaking step comprises soaking the material in said solution for from about 1 day to about 5 days.11. The method of claim 1 , wherein said soaking step comprises soaking the material in said solution for from about 3 days to about 5 days. This application is a divisional of U.S. Ser. No. 14/435,778, filed Apr. 15, 2015, which is a National Stage application under 35 U.S.C. § 371 of International Application No. PCT/US2013/065631, having and International Filing Date of Oct. 18, 2013, which a claims the benefit of U.S. Provisional Application Ser. No. 61/715,506, filed Oct. 18, 2012. The disclosures of the prior applications are ...

POLOXAMER COMPOSITION FREE OF LONG CIRCULATING MATERIAL AND METHODS FOR PRODUCTION AND USES THEREOF

Provided herein are long circulating material free (LCMF) poloxamer compositions and uses thereof. In particular, provided are LCMF poloxamer 188 compositions and uses thereof. Also provided are supercritical fluid extraction (SFE) methods and high pressure (subcritical) methods for preparing poloxamer compositions, particularly the LCMF poloxamer compositions. 1. A long circulating material free (LCMF) poloxamer 188 , wherein:{'sub': 2', '2', 'a′', '3', '2', 'b', '2', '2', 'a, 'claim-text': [{'sub': 2', '4, 'each of a and a′ is an integer such that the percentage of the hydrophile (CHO) is between approximately 60% and 90% by weight of the total molecular weight of the copolymer;'}, 'a and a′ are the same or different;', {'sub': 3', '6, 'b is an integer such that the molecular weight of the hydrophobe (CHO) is between approximately 1,300 and 2,300 Daltons;'}, 'no more than 1.5% of the total components in the polymeric distribution of the co-polymer are low molecular weight components having an average molecular weight of less than 4,500 Daltons;', 'no more than 1.5% of the total components in the polymeric distribution of the co-polymer are high molecular weight components having an average molecular weight of greater than 13,000 Daltons;', 'the polydispersity value of the copolymer is less than approximately 1.07 or less than 1.07; and, 'the LCMF poloxamer 188 is a polyoxyethylene/polyoxypropylene copolymer that has the formula HO(CHCHO)—[CH(CH)CHO]—(CHCHO)H, whereinfollowing intravenous administration to a human subject, the circulating plasma half-life of any components not comprising the main peak in the distribution of copolymer is no more than 5.0-fold the circulating half-life of the main component in the distribution of the copolymer.2. The LCMF poloxamer of claim 1 , wherein all components comprising the polymeric distribution of the copolymer have a circulating half-life in the plasma of the subject that is no more than 4.0-fold claim 1 , or 3.0-fold ...

DEVICE AND METHODS FOR PLATELET LYSIS OR ACTIVATION

Device, system and method embodiments are disclosed herein which provide for the production of a modified autologous platelet solution at the patient bedside for contemporaneous reinjection to the patient. In certain embodiments all of the steps including, but not limited to blood draw, platelet lysis, solution preparation and reinjection to a patient may be accomplished in a single office or clinic visit without relocating the patient. Accordingly, the apparatus, devices and systems disclosed herein generally include a substantially stand-alone machine, device or system which is configured to accept a platelet containing solution, induce lysis of one or more platelet bodies within the platelet containing solution and provide the resulting modified platelet solution in a manner suitable for injection into the patient. 1. A device comprising:a housing;an input port into the housing providing for the input of a platelet containing solution;a lysis/activation chamber in fluid communication with the input port and positioned within the housing, wherein one or more platelets within the platelet containing solution input to the device at the input port are caused to undergo lysis or activation in the lysis/activation chamber, thereby creating modified solution; andan outlet port from the housing, in fluid communication with the lysis/activation chamber, providing for the modified solution to be removed through the outlet port.2. The device of further comprising a heating and cooling module in thermal communication with the lysis/activation chamber claim 1 , said heating and cooling module providing for the thermal lysis or activation of one or more platelets of the platelet containing solution within the lysis/activation chamber.3. The device of wherein the lysis/activation chamber comprises a length of disposable sterile tubing.4. The device of wherein the heating and cooling module causes the platelet containing solution to wholly or partially freeze and wholly or ...

Production methods for megakaryocytes and platelets

An object of the present invention is to provide a method of efficiently producing a maturated megakaryocytic cell line from hematopoietic progenitor cells. The present invention provides a method for producing megakaryocytes from hematopoietic progenitor cells, comprising (i) forcibly expressing an apoptosis suppression gene and an oncogene in hematopoietic progenitor cells and culturing the cells, and (ii) arresting forced expression of the apoptosis suppression gene and the oncogene and culturing the hematopoietic progenitor cells.

Compositions and methods for treating bone injury

The disclosure relates to compositions and methods of treating, improving, and accelerating the healing of large segmental bone defects in a subject. The method comprises administering to a patient in need of treatment an effective amount of whole blood, sodium citrate, ecarin and BMP-2.

METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF

Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells. 1. A pharmaceutical preparation that is suitable for use in a human patient comprising at least 10platelets , wherein the preparation is substantially free of leukocytes and wherein substantially all of the platelets are functional.2. The pharmaceutical preparation of that comprises 10-10platelets claim 1 , optionally 10 claim 1 , 10 claim 1 , 10 claim 1 , 10 claim 1 , 10 claim 1 , or 10platelets.3. The pharmaceutical preparation of claim 1 , wherein the platelets have one or more of the following attributes: a mean platelet volume range of 9.7-12.8 fL; a unimodal distribution of size in the preparation; and/or a lognormal platelet volume distribution wherein one standard deviation is less than 2 μm claim 1 , (less than 1.5 μm claim 1 , less than 1 μmor less than 0.5 μm.4. The pharmaceutical preparation of claim 1 , wherein the platelets are positive for at least one of the following markers: CD41a and CD42b.5. The pharmaceutical preparation of claim 1 , wherein the platelets are human platelets.6. The pharmaceutical preparation of claim 1 , wherein at least 50% claim 1 , 60% claim 1 , 70% claim 1 , 80% or 90% of the platelets are functional for at least 2 claim 1 , 3 or 4 days after storage at room temperature.745-. (canceled)46. A method for producing a pharmaceutical preparation comprising:differentiating megakaryocytes positive for CD41a and CD42b expression in a ...

Apparatus for Preconditioning of Cell Suspensions

An apparatus for the preparation of cells for implantation into a living body is disclosed. The apparatus comprises a vessel substantially impermeable to gaseous oxygen; and fluid within said vessel, the fluid having a maximal dissolved oxygen capacity substantially equivalent to normal saline yet having a hypoxic oxygen concentration between about 0% to about 5% of said maximal dissolved oxygen capacity. The bag oxygen concentration level remains low when the apparatus is stored at 22°-25° C. in normal atmospheric conditions for a period of at least 30 days. The present invention simplifies the process of achieving donor cell hypoxic preconditioning for cell implantation, and may be used to bathe said cells to be transplanted for a sufficient time to activate the hypoxic metabolic pathway. 1. A method for the preparation of mammalian cells for implantation into a living body , the method comprising the steps of: i. a first vessel substantially impermeable to gaseous oxygen;', 'ii. hypoxic fluid within said first vessel, the hypoxic fluid having a maximal dissolved oxygen capacity and having an oxygen concentration level of not more than 5% of said maximal dissolved oxygen capacity; and', 'iii. a mammalian cell retaining chamber comprising a filter and mammalian cells having a level of HIF-1α; and, 'a. providing an apparatus comprisingb. contacting said hypoxic fluid with said mammalian cells within said filter.2. The method of wherein said oxygen concentration level is between 0.05% and 1.5% of said maximal dissolved oxygen capacity.3. The method of wherein said hypoxic fluid within said first vessel maintains said oxygen concentration level when said first vessel is stored at 22°-25° C. in normal atmospheric conditions for a period of at least 30 days.4. The method of further comprising storing said first vessel at 22°-25° C. in normal atmospheric conditions for a period of at least 30 days such that said oxygen concentration of not more than 5% of said maximal ...

METHODS AND COLLAGEN PRODUCTS FOR TISSUE REPAIR

Methods and devices for the repair of articular tissue using collagen material are provided. Compositions of collagen material and related kits are also provided. 1. A tissue healing device configured to repair a ligament , comprising:a. a hydrophilic scaffold that is compressible and expandable, the scaffold configured to be positioned between a ruptured end of the ligament and a bone;b. at least one anchor configured to be secured to the bone;c. at least one suture configured to be threaded through or along the scaffold to position the scaffold between to the ruptured end of the ligament and the bone; andd. one or more growth factors configured to be disposed within or on the scaffold.2. The tissue healing device of claim 1 , wherein the scaffold includes collagen.3. The tissue healing device of claim 2 , wherein the collagen is a type I collagen.4. The tissue healing device of claim 3 , wherein a concentration of collagen in the scaffold is at least 15 mg/ml.5. The tissue healing device of claim 1 , wherein the scaffold is configured to carry a repair material.6. The tissue healing device of claim 5 , wherein the repair material includes platelets.7. The tissue healing device of claim 5 , wherein the repair material includes plasma.8. The tissue healing device of claim 5 , wherein the repair material includes white blood cells.9. The tissue healing device of claim 1 , wherein the at least one anchor is a first anchor claim 1 , the at least one suture is a first suture and the bone is a first bone such that the first suture is configured to be secured to the first anchor claim 1 , wherein the device further comprises:a second suture configured to secure the ligament in place relative to the first bone and a second bone; anda second anchor for contact with the second bone such that the second anchor is configured to secure the second suture to the second bone.10. The tissue healing device of claim 9 , wherein the first bone is a femur and the second bone is a tibia ...

APPARATUS AND METHODS FOR SEPARATING BLOOD COMPONENTS

Apparatus and methods for separating blood components are disclosed in which an apparatus for separating blood generally includes a tube defining a channel and configured for receiving a quantity of blood and a float contained within the tube and having a density which is predefined so that the float is maintained at equilibrium between a first layer formed from a first fractional component of the blood and a second layer formed from a second fractional component of the blood. Upon completion of the centrifugation, the first layer may be removed from the tube while the float isolates the second layer from the first layer. 1. An apparatus for separating blood , comprising:a tube defining a channel and configured for receiving a quantity of blood; anda float contained within the tube and having a density which is predefined so that the float is maintained at equilibrium between a first layer formed from a first fractional component of the blood and a second layer formed from a second fractional component of the blood.2. The apparatus of wherein the float defines a shape selected from the group consisting of spherical claim 1 , ellipsoidal claim 1 , and cylindrical shapes.3. The apparatus of wherein the float defines at least one tapered or slanted surface.4. The apparatus of wherein the float defines at least one non-orthogonal surface relative to a normal surface of the float.5. The apparatus of wherein the float has a density of 1.0 to 1.1 gram/ml.6. The apparatus of wherein the float has a density of 1.03 to 1.07 gram/ml.7. The apparatus of wherein the float has a density which is intermediate of the first layer comprised of a RBC layer and the second layer comprised of a PRP layer.8. The apparatus of wherein an outer diameter of the float is between 98 to 101% of the inner surface of the channel.9. The apparatus of wherein the float has a surface configured to retain a layer of red blood cells.10. The apparatus of wherein the float has a surface configured to ...

METHODS OF MAKING PLATELETS COMPRISING MODIFIED RECEPTORS AND USES THEREOF

Disclosed herein are methods of producing platelets comprising a modified receptor, therapeutic agents, peptides, and/or bioactive molecules. The cells produced by the methods disclosed herein can be used to treat, manage, prevent and diagnosis, for example, lysosomal storage diseases, diabetes and cancer. The cells produced by the methods disclosed herein can be engineered to comprise receptors capable of activating platelets to trigger the release of enzymes, biomolecules or therapeutic agents upon binding to specific drugs and/or binding to tissue specific peptides. 1. A nucleic acid construct comprising: a first genetic circuit comprising a tissue-specific promoter operatively linked to a sequence capable of encoding a modified receptor.2. The nucleic acid construct of claim 1 , wherein the tissue-specific promoter is CXCL4 claim 1 , GPIIb claim 1 , or PTPRC.35.-. (canceled)6. The nucleic acid construct of claim 1 , wherein the modified receptor is a modified G-protein coupled receptor (GPCR) or a modified protease-activated receptor (PAR).7. The nucleic acid construct of claim 6 , wherein the modified GPCR is a Gq claim 6 , a Gi claim 6 , a Gs or a G/GGPCR.8. The nucleic acid construct of claim 6 , wherein the modified PAR is PAR1 claim 6 , PAR2 claim 6 , PAR3 or PAR4.9. The nucleic acid construct of claim 1 , further comprising a second genetic circuit claim 1 , wherein the second genetic circuit comprises one or more megakaryocyte differentiation genes.10. The nucleic acid construct of claim 9 , wherein the one or more megakaryocyte differentiation genes are HoxB4 claim 9 , GATA1 claim 9 , c-MYC claim 9 , BMI1 claim 9 , BCL-XL claim 9 , PLK-1 or a combination thereof.1115.-. (canceled)16. The nucleic acid construct of claim 9 , wherein the first genetic circuit or the second genetic circuit further comprises a gene of interest.17. The nucleic acid construct of claim 16 , wherein the gene of interest is a therapeutic agent.18. (canceled)19. (canceled)20. A ...

Pharmaceutical Kits Comprising Mesenchymal Stem Cells

A method of treating a natural soft skeletal tissue injury in a patient the method comprising administering to the patient a composition of mesenchymal stem cells in liquid suspension enriched compared to the natural source of said cells, or tenocytes derived therefrom. The method is particularly suited to the regeneration of tendons in competitive mammals, such as the superficial digital flexor tendon of the horse. 120-. (canceled)21. A composition comprising a liquid suspension of mesenchymal stem cells (MSCs) in a bone marrow supernatant , wherein the composition is enriched for the MSCs compared to a natural source of the MSCs.22. The composition of claim 21 , wherein the composition further comprises a tenocyte.23. The composition of claim 21 , wherein the composition is enriched for the MSCs at least 2-fold claim 21 , at least 3-fold claim 21 , at least 4-fold claim 21 , at least 5-fold claim 21 , at least 10-fold claim 21 , at least 20-fold claim 21 , at least 30-fold claim 21 , at least 40-fold claim 21 , at least 50-fold claim 21 , at least 100-fold claim 21 , at least 1000-fold claim 21 , at least 10-fold claim 21 , or at least 10-fold compared to the natural source of the MSCs.24. The composition of claim 21 , wherein the MSCs comprise at least 10% claim 21 , at least 50% claim 21 , at least 60% claim 21 , at least 70% claim 21 , at least 90% claim 21 , at least 95% claim 21 , or at least 99% of all cells in the liquid suspension.25. The composition of claim 21 , wherein the liquid suspension comprises a gelling agent.26. The composition of claim 21 , further comprising a biological signal to encourage differentiation of the MSCs into a cell type that is useful for regeneration of soft skeletal tissue.27. The composition of claim 26 , wherein the biological signal is selected from a growth factor claim 26 , a differentiation factor claim 26 , a regeneration factor claim 26 , and a cytokine.28. The composition of claim 26 , wherein the biological signal is ...

Compositions and Methods for Cartilage Repair

Autologous compositions and methods are provided for cartilage repair in patients in need thereof. Some aspects include combinations of platelet-based materials with chondrogenesis inducing agents in the presence or absence of cell-based therapies.

Method for Producing Polyploidized Megakaryocyte and Platelets

An object of the present invention is to provide a method of promoting polyploidization of megakaryocytes and thereby producing highly polyploidized megakaryocytes, a method of efficiently producing platelets from polyploidized megakaryocytes, and the like. The present invention provides a method of producing polyploidized megakaryocytes comprising a step of forcing expression of an apoptosis suppressor gene in megakaryocytes before polyploidization and culturing the resulting cells. 119-. (canceled)20. A kit comprisingmegakaryocytes before polyploidization; and (A) an oncogene, and', '(B) at least one gene selected from the group consisting of (i) a gene suppressing expression of a p16 gene or a p19 gene, (ii) a gene suppressing expression of an Ink4a/Arf gene; and (iii) a polycomb gene., 'an expression vector comprising'}21. The kit according to claim 20 , wherein the at least one gene comprises BMI1 gene.22. The kit according to claim 21 , wherein the BMI1 gene comprises a nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 2.23. The kit according to claim 21 , wherein the BMI1 gene comprises the nucleic acid sequence of SEQ ID NO: 2.24. The kit according to claim 20 , wherein the oncogene is a MYC family gene.25. The kit according to claim 24 , wherein the MYC family gene is a c-MYC gene.26. The kit according to claim 24 , wherein the MYC family gene comprises a nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 1.27. The kit according to claim 24 , wherein the MYC family gene comprises the nucleic acid sequence of SEQ ID NO: 1.28. The kit according to claim 20 , wherein the expression vector further induces an apoptosis suppressor gene in the megakaryocytes before polyploidization.29. The kit according to claim 20 , wherein the expression vector further induces BCL-XL gene in the megakaryocytes before polyploidization.30. The kit according to claim 29 , wherein the BCL-XL gene comprises a nucleic acid sequence having ...

DEVICES, COMPOSITIONS AND METHODS FOR TREATING ACUTE AND CHRONIC TISSUE DAMAGE

A device to prepare and deliver a bioactive substance such as stem cells, platelet rich plasma, and/or other bioactive compositions. The device can utilize a hallow interior or cavity to deliver bioactive substances during a surgical procedure or to an area of cartilage defect or cartilage disorder. The treated tissues can include connective tissue, cardiac muscle or tissue, spinal tissue, internal organs, skin tissue, brain tissue, vascular tissue, ocular, ear, nose, throat tissue, and/or other hematologic, endocrine or integumentary tissue. 1. A method of treating an injury , wear or defect in an individual comprising:(a) identifying an area of injury, wear or defect;(b) inserting a device having an awl shaped distal end into the identified area;(c) creating a cavity in the area using the awl shaped distal end of the device;(d) attaching a delivery system to an access port for delivery of a bioactive substance;(e) delivering the bioactive substance through the internal channel and into the identified area;(f) closing the access port on the device;(g) compressing the bioactive substance into the identified area; and(h) removing the device.2. The method of claim 1 , further comprising repeating steps (b) through (h).3. The method of claim 1 , wherein the area of injury claim 1 , wear or defect comprises a tissue selected from the group consisting of connective tissue claim 1 , cardiac muscle or tissue claim 1 , spinal tissue claim 1 , internal organs claim 1 , skin tissue claim 1 , brain tissue claim 1 , vascular tissue claim 1 , ocular claim 1 , ear claim 1 , nose claim 1 , and throat tissue.4. The method of claim 3 , wherein the spinal tissue is selected from the group consisting of nerves claim 3 , spinal cord claim 3 , disc material and vertebral bodies.5. The method of claim 3 , wherein the internal organ is selected from the group consisting of pancreas claim 3 , lungs claim 3 , liver claim 3 , intestines claim 3 , and bladder.6. The method of claim 3 , ...

Methods for production of platelets from pluripotent stem cells and compositions thereof

Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.

PLATELET RICH PLASMA FORMULATIONS

Compositions for platelet rich plasma (PRP) and neutrophil-depleted PRP are provided. Methods for treating ischemia damaged tissues by delivering a PRP composition, in some embodiments a neutrophil-depleted PRP composition to the damaged tissue are provided. In some variations, the compositions may be useful to treat ischemic heart disease and repair damaged cardiovascular tissue following acute myocardial infarction including congestive heart failure. In some variations, the compositions may be useful to reduce cardiac apoptosis after a heart attack. 1. A formulation of platelet rich plasma comprising 1.01 times baseline platelets or more in combination with 1.01 times baseline white blood cells or more.2. The formulation of claim 1 , wherein monocytes and/or lymphocytes are increased in comparison to neutrophils.3. The formulation of claim 1 , wherein neutrophils are depleted to 1% or more of baseline levels.45-. (canceled)6. A method of measuring the value of monocytes and/or lymphocytes to neutrophils which comprises measuring the ratio of monocytes and/or lymphocytes to neutrophils.7. The method of claim 6 , wherein an increased ratio of monocytes and/or lymphocytes to neutrophils indicates that a PRP composition is suitable for use in treating lung disease.8. A composition comprising:platelets derived from whole blood at a first concentration of at least about 1.1 times a platelet concentration in the whole blood; neutrophils at a third concentration, wherein the third concentration is less than the neutrophil concentration in the whole blood;', 'lymphocytes at a fourth concentration of at least 1.1 times a lymphocyte concentration in the whole blood; and', 'monocytes at a fifth concentration of about 1.1 times a monocyte concentration in the whole blood., 'white blood cells derived from the whole blood at a second concentration of at least a white blood cell concentration in the whole blood, wherein the white blood cells comprise9. The composition of claim 8 ...

APPARATUS AND METHOD FOR SEPARATING AND CONCENTRATING FLUIDS CONTAINING MULTIPLE COMPONENTS

An apparatus that allows for separating and collecting a fraction of a sample. The apparatus, when used with a centrifuge, allows for the creation of at least three fractions in the apparatus. It also provides for a new method of extracting the buffy coat phase from a whole blood sample. A buoy system that may include a first buoy portion and a second buoy member operably interconnected may be used to form at least three fractions from a sample during a substantially single centrifugation process. Therefore, the separation of various fractions may be substantially quick and efficient. 132-. (canceled)33. A method of isolating a fraction of nucleated cells , comprising:obtaining a volume of whole blood from a patient;obtaining a volume of bone marrow from a patient;loading the volume of whole blood and the volume of bone marrow into a container configured to be placed in a centrifuge, the container comprising a fraction separator having a selected density operable to physically separate fractions of whole blood based on the density of the fractions, the fractions including a fraction comprising the nucleated cells;centrifuging the container, so as to create a fraction comprising nucleated cells; andcollecting the fraction comprising the nucleated cells.34. The method according to claim 33 , wherein the fraction comprising nucleated cells comprises cells selected from the group consisting of platelets claim 33 , white blood cells claim 33 , stem cells claim 33 , and mixtures thereof.35. The method according to claim 33 , wherein the centrifuging creates at least three distinct fractions comprising a red blood cell fraction claim 33 , a buffy coat fraction claim 33 , and a plasma fraction.36. The method according to claim 33 , wherein the buoy is configured to have a density less than the density of red blood cells and a density greater than the density of the fraction comprising nucleated cells.37. The method according to claim 33 , wherein the separator further ...

CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS

The present disclosure concerns at least methods and compositions for repairing and/or regenerating a disc of an individual in need thereof. In certain embodiments, an individual that is known to have or suspected to have or at risk for having a degenerated disc is provided a therapeutically effective amount of nucleus pulposus cells, one or more components from the nucleus pulposus, conditioned medium generated from nucleus pulposus cells, and additionally may also be provided fibroblasts, platelet rich plasma (PRP), SOX9 (protein or nucleic acid), and/or Tie2+ cells, for example. 1. A method of generating chondrocytes or chondrocyte-like cells for an individual , comprising the step of providing to a degenerated disc of an individual an effective amount of one or more components from the nucleus pulposus (NP) of the same individual or another individual from the same or different species.2. The method of claim 1 , wherein components from the NP comprise notochordal cells claim 1 , notochordal cell conditioned media claim 1 , small chondrocyte-like cells claim 1 , collagen fibrils claim 1 , proteoglycans claim 1 , and/or aggrecan.3. The method of or claim 1 , wherein one or more therapeutic agents are provided to the degenerated disc of the individual.4. The method of claim 1 , claim 1 , or claim 1 , wherein the one or more therapeutic agents comprise nucleic acid claim 1 , peptide claim 1 , protein claim 1 , small molecule claim 1 , or a combination thereof.5. The method of any one of - claim 1 , comprising the step of providing to the individual one or more compositions comprising an effective amount of one or more of the following:a) fibroblasts;b) notochordal cells;c) Tie2+ cells;d) Tie2 gene product;e) platelet-rich plasma (PRP);f) Sox9 gene product;g) transforming growth factor beta-1 (TGFB 1);h) connective tissue growth factor (CTGF);i) WNT1-inducible-signaling pathway protein 1 (WISP1), and/orj) WISP2.6. The method of any one of - claim 1 , wherein cells of ...

METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF

Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells. 1. A pharmaceutical preparation that is suitable for use in a human patient comprising at least 10platelets , wherein the preparation is substantially free of leukocytes and wherein substantially all of the platelets are functional.26.-. (canceled)7. A bioreactor having weakly adherent or non-adherent megakaryocytes that produce functional platelets without feeder cells.8. A composition , a cryopreserved composition , or a bank comprising MLPs.913.-. (canceled)14. A method for producing platelets from megakaryocytes comprising:(a) providing a non-adherent culture of megakaryocytes;(b) contacting the megakaryocytes with (i) TPO or a TPO agonist, (ii) hematopoietic expansion medium and optionally TPO or a TPO agonist, SCF, IL-6 and IL-9, or (iii) hematopoietic expansion medium and optionally TPO or a TPO agonist, SCF, and IL-11 to cause the formation of proplatelets in culture, wherein the proplatelets release platelets; and(c) isolating the platelets.1535.-. (canceled)36. The method of claim 14 , wherein the megakaryocytes are generated by:(a) culturing pluripotent stem cells to form hemogenic endothelial cells (PVE-HE);(b) culturing the hemogenic endothelial cells to form MLPs; and(c) culturing the MLPs to form megakaryocytes.3750.-. (canceled)51. A method of treating a patient in need of platelet transfusion claim 1 , comprising administering to the patient the ...

NEUROMODULATION FOR TREATMENT OF RETINAL, CHOROIDAL AND OPTIC NERVE DISORDERS AND/OR DYSREGULATED REDUCED OCULAR BLOOD FLOW (OBF)

Disclosed are devices, systems and methods for non-invasive neuromodulation system for treating inherited or acquired retinal, choroidal and optic nerve disorders caused by acute or chronic dysregulated reduced ocular blood flow (OBF) and/or energy failure by up regulation of trigemino-vascular system (TVS), trigeminal autonomic brain reflexes (TABRs) and pancreatic trigemino-vagal reflex (TVR) through stimulation of ophthalmic nerve (V1), more specifically but not limited to SP, and CGRP containing unmyelinated C nerve fibers. The invention, in some embodiments thereof, relates to the methods for enhancing SP and CGRP expression in neurovascular tissue of the retina and choroid. The invention, in some embodiments thereof, relates to SP/CGRP mediated pathways, including those involved in vasodilatation, augmentation of OBF, RPE proliferation, prevention of apoptosis, suppressing neuroinflammation, promoting migration and differentiation of vascular endothelial cells as well as mobilization of endogenous mesenchymal stem cells (EMSCs) from the bone marrow to the circulation to accelerate tissue repair. The site of stimulation of V1 nerve includes but not limited to; nasal vestibule nasal bridge, forehead, and upper eyelids. Additionally or alternatively, the subject's sympathetic nervous system (SNS) is down regulated by sympatholytic agents specifically antioxidants. The subject's TVS and autonomic nervous system (ANS) are modulated in a manner that is effective to treat the subject for retinal, choroidal and/or optic nerve disorders. In some embodiments, the devices are handheld, portable with nose supported, having one or more intra-nasal or extra-nasal application heads. The signal can include vibration, chemical, ultrasonic, optical, electrical, hybrid electro-optical or combination of two or more of these types of stimuli. The invention, in some embodiments thereof, relates to a method for decreasing vascular resistance, enhancing vasodilatation in ophthalmic ...

METHODS FOR CULTURING AND/OR DIFFERENTIATING HEMATOPOIETIC STEM CELLS INTO PROGENITORS AND USES THEREOF

The present description relates to in vitro methods for culturing hematopoietic stem cells (HSCs) under mild hyperthermia conditions (e.g., between 38° C. and 40° C.) in the presence of a pyrimidoindole derivative agonist of hematopoietic stem cell expansion. The combined use of mild hyperthermia and the pyrimidoindole derivative act synergistically to promote expansion of CD34+ HSCs and/or differentiation into progenitor cells (e.g., megakaryocytic progenitors). The present description also relates to in vitro expanded cell populations of HSCs and/or progenitors, as well as uses thereof in therapy (e.g., transplantation). 121-. (canceled)23. The method of claim 22 , wherein said pyrimido[4 claim 22 ,5-b] indole derivative is:(1) (1r,4r)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4yl)cyclohexane-1,4-diamine;(2) methyl 4-(3-(piperidin-1-yl)propylamino)-9H-pyrimido[4,5-b]indole-7-carboxylate;(3) methyl 4-(3-(piperidin-1-yl)propylamino)-9H-pyrimido[4,5-b]indole-7-carboxylate hydrochloride;(4) a pharmaceutically acceptable salt, solvate, prodrug, or stereoisomer of any one of (1) to (3); or(5) any combination of (1) to (4).24. The method of claim 22 , wherein said pyrimidoindole derivative agonist of hematopoietic stem cell expansion is: (1r claim 22 ,4r)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4 claim 22 ,5-b]indol-4-yl)cyclohexane-1 claim 22 ,4-diamine; or a pharmaceutically acceptable salt claim 22 , solvate claim 22 , prodrug claim 22 , or stereoisomer thereof.25. The method of claim 22 , wherein said pyrimidoindole derivative agonist of hematopoietic stem cell expansion is: methyl 4-(3-(piperidin-1-yl)propylamino)-9H-pyrimido[4 claim 22 ,5-b]indole-7-carboxylate; methyl 4-(3-(piperidin-1-yl)propylamino)-9H-pyrimido[4 claim 22 ,5-b]indole-7-carboxylate hydrochloride; or a pharmaceutically acceptable salt claim 22 , solvate claim 22 , prodrug claim 22 , or stereoisomer thereof.26. The method of claim 22 , wherein said incubation ...

PLATELET FORMULATIONS AND MEDICAL USES THEREOF

The present invention provides a pharmaceutical composition comprising platelets, calcium chloride, and zinc sulfate, wherein the weight ratio of calcium chloride to zinc sulfate is between about 500:1 and about 10:1. Also provided is a method of treating a wound, chronic pain, neuropathy, orthopedic injury, or musculoskeletal disease, the method comprising: administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising platelets, calcium chloride, and zinc sulfate. 1. A pharmaceutical composition comprising platelets , calcium chloride , and zinc sulfate , wherein the weight ratio of calcium chloride to zinc sulfate is between about 500:1 and about 10:1.2. The pharmaceutical composition according to claim 1 , wherein the platelets are in a concentration of about 100 claim 1 ,000/μl to about 1 claim 1 ,000 claim 1 ,000/μl.3. The pharmaceutical composition according to claim 1 , wherein the weight ratio of calcium chloride to zinc sulfate is between about 350:1 and about 100:1.4. The pharmaceutical composition according to claim 1 , wherein the combined concentration of calcium chloride and zinc sulfate is less than about 500 mg/mL.5. The pharmaceutical composition according to claim 4 , wherein the combined concentration of calcium chloride and zinc sulfate is between about 25 mg/mL and about 300 mg/mL.6. The pharmaceutical composition according to claim 1 , further comprising cytokines claim 1 , chemokines claim 1 , inflammatory mediators claim 1 , and growth factors.7. The pharmaceutical composition according to claim 1 , wherein the composition is formulated as a liquid claim 1 , a solid claim 1 , a semi-solid claim 1 , or a combination thereof.8. A method of treating a wound claim 1 , chronic pain claim 1 , neuropathy claim 1 , orthopedic injury claim 1 , or musculoskeletal disease claim 1 , the method comprising:administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising ...

Incubated platelet concentration module and method for producing platelet preparation using same

The present invention provides a hollow fiber membrane module which makes it possible to concentrate incubated platelets by efficiently removing water from an incubated platelet suspension liquid containing incubated platelets while suppressing deterioration of the function of the incubated platelets. The present invention provides an incubated platelet concentration module in which a plurality of hollow fiber membranes each having pores with an average pore diameter of 2 μm or less on a surface of the hollow fiber membrane are packed in a casing having at least one inlet for supplying an incubated platelet suspension liquid before concentration into the hollow fiber membranes, wherein a value (X/Y1) obtained by dividing a total cross-sectional area (X) of the plurality of hollow fiber membranes by a total cross-sectional area (Y1) of the least one inlet is 4.0 or less.

REAGENTS AND METHODS FOR DETECTING PNH TYPE II WHITE BLOOD CELLS AND THEIR IDENTIFICATION AS RISK FACTORS FOR THROMBOTIC DISORDERS

The disclosure relates to methods for detecting PNH Type II cell populations in biological samples as well as methods for determining whether a patient is at an increased risk for developing thrombocytopenia or thrombosis based on the percentage of PNH Type II cells in the patient's blood. The disclosure also features reagents and conjugates for use in the methods. 1. A method for selecting a therapy for a patient , the method comprising: selecting one or both of an anti-thrombotic therapy and an anti-thrombocytopenic therapy for a patient determined to have a paroxysmal nocturnal hemoglobinuria (PNH) Type II white blood cell population of greater than or equal to 1.2%.2. The method of claim 1 , wherein the anti-thrombotic therapy is an anticoagulant or thrombolytic agent.3. The method claim 1 , wherein the anti-thrombocytopenic therapy is a platelet transfusion.4. The method of claim 1 , wherein a non-lytic variant form of aerolysin protein is used to determine the percentage of PNH Type II white blood cells. This application is a divisional of U.S. patent application Ser. No. 15/591,531, filed May 10, 2017, which is a divisional of U.S. patent application Ser. No. 14/219,218, filed Mar. 19, 2014, which is a divisional of U.S. patent application Ser. No. 13/508,909, filed Oct. 1, 2012, which is a national stage filing under 35 U.S.C. § 371 of International Application No. PCT/US2010/055997, filed on Nov. 9, 2010, which claims the benefit of the filing date under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application Ser. No. 61/280,897, filed Nov. 9, 2009, the entire contents of which are incorporated herein by reference. International Application PCT/US2010/055997 was published under PCT Article 21(2) in English.The instant application contains a Sequence Listing which has been submitted via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Oct. 9, 2018, is named AXJ-150USDV3_SL.txt, and is 23,333 bytes in size.The ...

METHOD FOR PRODUCING ACTIVATED AUTOLOGOUS PLATELET RICH AND PLATELET POOR PLASMA AND METHODS OF USE

A method and kit to produce activated autologous platelet rich and platelet poor plasma (AAPRPP) and methods of use to treat pain. The method to produce AAPRPP generally comprising (1) obtaining whole blood from patient; (2) centrifuging whole blood in a collection tube; (3) extracting platelet rich and platelet poor plasma mixture from collection tube; and (4) transferring platelet rich and platelet poor plasma mixture to an activation tube containing at least one platelet aggregator and at least one platelet activator to obtain a resulting platelet concentration. The method to treat pain generally comprising producing AAPRPP and extracting contents of activation tube into a standard syringe then injecting AAPRPP at or near the nerve group responsible for the affected anatomical area. 1. A method to produce activated autologous platelet rich and platelet poor plasma (AAPRPP) comprising:(1) obtaining whole blood from patient;(2) centrifuging whole blood in a collection tube;(3) extracting platelet rich and platelet poor plasma mixture from collection tube; and(4) transferring platelet rich and platelet poor plasma mixture to an activation tube containing at least one platelet aggregator and at least one platelet activator to obtain a resulting platelet concentration.2. The method according to wherein the platelet aggregator is calcium chloride and the platelet activator is zinc sulfate.3. The method according to wherein the calcium chloride is in a solution at a concentration of at least 30 mg/mL and zinc sulfate is in a solution at a concentration at least 30 mg/mL.4. The method according to wherein the calcium chloride is in a solution at a concentration of about 100 mg/mL.5. The method according to wherein the zinc sulfate is in a solution at a concentration of about 100 mg/mL.6. The method according to wherein the amount of solution of calcium chloride is about 0.5 to about 1.0 mL.7. The method according to wherein the amount of solution of zinc sulfate is about ...

CELL PREPARATIONS FOR EXTEMPORANEOUS USE, USEFUL FOR HEALING AND REJUVENATION IN VIVO

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction. 130-. (canceled)31. A sterilized , vacuum sealed separator tube for preparing a therapeutic platelet concentrate from whole blood comprising:an inlet adapted to introduce whole blood;an anticoagulant composition comprising either: (i) a sodium citrate solution; or (ii) anhydrous sodium citrate; anda thixotropic gel selected from a polyester-based gel or a polymer mixture gel, the thixotropic gel being water insoluble and chemically inert to blood constituents;{'sup': '12', 'wherein the separator tube is adapted to be centrifuged when at least partially filled with the whole blood, at about 1,500 g up to about 2,000 g for about 3 to about 10 minutes in a single centrifugation to separate blood components in the whole blood into at least: (i) the therapeutic platelet concentrate obtained without supernatant removal and containing greater than 300 billion platelets per liter and less than about 0.6×10red blood cells per liter; and (ii) red blood cells.'}32. The separator tube according to claim 31 , wherein the anticoagulant composition comprises a 0.1 M sodium citrate solution.33. The separator tube according to claim 31 , wherein the anticoagulant composition comprises anhydrous sodium citrate.34. The separator tube according to claim 31 , wherein the thixotropic gel is a polyester-based gel.35. The separator tube according to claim 31 , wherein the separator tube is comprised at least of polyethylene terephthalate (PET).36. (canceled)37. ( ...

FORMULATION OF A BLOOD COMPOSITION THAT IS RICH IN PLATELET AND/OR GROWTH FACTORS AND CONTAINS GELLED PROTEINS, AND A METHOD FOR ITS PREPARATION

Formulation comprising, or derived from, an initial blood composition, wherein the formulation is rich in platelets and/or growth factors and proteins originating from the initial blood composition, and wherein the proteins are in a gelled state. The invention also refers to method for preparing the formulation, comprising the steps of heating and then cooling the initial blood composition at certain temperatures and times. Among other advantages, the formulation in accordance with the invention is biocompatible and biodegradable, presents the desirable biological or medical properties provided by the presence of platelets or growth factors, and also presents high dimensional stability over time. 1. Formulation with desirable biological or medical properties , characterized in that it comprises or is derived from an initial blood composition of human or animal origin , said formulation being rich in platelets and/or growth factors and in proteins originating from the initial blood composition , wherein said proteins are in a gelled state.2. Formulation claim 1 , according to claim 1 , characterized in that the proteins are albumin claim 1 , glycoproteins claim 1 , globulins and/or fibrinogen.3. Formulation claim 1 , according to claim 1 , characterized in that the proteins are in a gelled state as a result of a heating and cooling treatment.4. Formulation claim 1 , according to claim 1 , characterized in that the initial blood composition is a platelet-rich blood plasma.5. Formulation according to claim 1 , characterized in that the initial blood composition is a supernatant obtained from a platelet-rich blood plasma.6. Formulation according to claim 1 , characterized in that the initial blood composition is a blood plasma that is rich in released growth factors.7. Formulation according to claim 1 , characterized in that the initial blood composition is a supernatant obtained from a blood plasma that is rich in released growth factors.8. Formulation according to ...

SERUM FRACTION OF PLATELET-RICH FIBRIN

The invention provides for a method of preparing an isolated serum fraction of platelet rich fibrin (PRF), comprising the steps of 1. A pharmaceutical preparation comprising a blood-derived serum product which is an isolated serum fraction of platelet rich fibrin (PRF) said a blood-derived serum product being contained in an application device for administration of the serum fraction to an individual and being obtained by a method comprising the steps ofa. separating and removing the red blood cell fraction from a venous blood sample without the addition of an anticoagulant to provide a plasma having a platelet concentration above baseline;b. clotting said plasma to obtain a coagel of PRF spontaneously by centrifugation carried out at 1000 to 5000 g;c. pressing or squeezing the coagel to separate a serum fraction which comprises an activated platelet releasate from the coagel, thereby obtaining an isolated serum fraction containing the fluid fraction of PRF; andd. providing the serum fraction in a pharmaceutical preparation which is contained in an application device for administration of the serum fraction to an individual, said serum fraction comprising a platelet releasate from activated platelets.2. The pharmaceutical preparation of claim 1 , wherein in said method the centrifugation is carried out for 5 to 10 minutes.3. The pharmaceutical preparation of claim 1 , wherein in said method the centrifugation is carried out at 1600 to 2000 g.4. The pharmaceutical preparation of claim 1 , wherein in said method the centrifugation is carried out within 20 minutes from collecting venous blood.5. The method of claim 1 , wherein the PRF is obtained from venous blood collected from a single donor.6. The pharmaceutical preparation of claim 1 , wherein the blood is collected in a clot tube or syringe.7. The pharmaceutical preparation of claim 1 , wherein the serum fraction is prepared in a period up to 10 hours without adding preservatives.8. The pharmaceutical preparation ...

Cell Preparations For Extemporaneous Use, Useful For Healing And Rejuvenation In Vivo

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction. 1. A method of treating a patient with platelet rich plasma , the method comprising:withdrawing blood from the patient;centrifuging the blood in a centrifugation tube containing a thixotropic gel and an anticoagulant, the thixotropic gel being configured to separate platelet rich plasma, the centrifuging being performed for a length of time such that the thixotropic gel forms a barrier between plasma and erythrocytes;removing the platelet rich plasma from the tube; andadministering the platelet rich plasma to the patient.2. The method of claim 1 , wherein said centrifuging comprises centrifuging the tube at a force between about 1500 g and about 2000 g for about 3 to 10 minutes.3. The method of claim 1 , wherein said centrifuging comprises centrifuging the tube at a force of at least 1500 g for at least 8 minutes.4. The method of claim 1 , further comprising separating the platelet rich plasma by removing approximately half of a supernatant containing platelet poor plasma.5. The method of claim 4 , further comprising re-suspending the platelet rich plasma in the tube claim 4 , wherein said re-suspending follows said separating the platelet rich plasma.6. The method of claim 1 , further comprising admixing the platelet rich plasma with a coagulation activator claim 1 , wherein the coagulation activator comprises at least one of: a thrombin activator claim 1 , a fibrinogen activator claim 1 , a calcium claim 1 , a calcium salt claim 1 , a CaCl ...

METHOD FOR PRODUCING A BLOOD PRODUCT

An object of the invention is to provide a means for accomplishing inactivation of a pathogen in a blood sample containing red blood cells and platelets together, as well as sufficiently reducing the hemolysis rate of the red blood cell product finally obtained. 1. A method for producing a blood product , comprising:irradiating a blood sample with ultraviolet light, said blood sample comprising red blood cells, platelets, a hemolysis inhibitor, and a surfactant having an HLB value of 13 or greater and having a molecular structure comprising a hydrophilic portion wherein the hydrophilic portion comprises a number of oxyethylene groups wherein the number of oxyethylene groups is 20 or greater.2. The method for producing according to claim 1 , wherein the hemolysis inhibitor comprises Vitamin E.3. The method for producing according to claim 1 , wherein the surfactant comprises a polyoxyethylene sorbitan fatty acid ester.4. The method for producing according to claim 3 , wherein the surfactant comprises polyoxyethylene sorbitan monooleate 80).5. The method for producing according to claim 1 , wherein the blood sample is the one from which white blood cells were removed.6. The method for producing according to claim 1 , further comprising:separating the blood sample irradiated with the ultraviolet light into a red blood cell product and a platelet product after the irradiation of the ultraviolet light.7. A blood product comprising red blood cells claim 1 , platelets claim 1 , a hemolysis inhibitor and a surfactant having an HLB value of 13 or greater and having a molecular structure comprising a hydrophilic portion wherein the hydrophilic portion comprises a number of oxyethylene groups wherein the number of oxethylene groups is 20 or greater claim 1 , wherein a pathogen in the blood product is inactivated.8. A storage solution for a blood cell comprising a hemolysis inhibitor and a surfactant having an HLB value of 13 or greater and having a molecular structure ...

THROMBOSOMES AS AN ANTICOAGULANT REVERSAL AGENT

In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent. 1. A method of treating a coagulopathy in a subject , the method comprising administering to the subject in need thereof an effective amount of a composition comprising platelets or platelet derivatives and an incubating agent comprising one or more salts , a buffer , optionally a cryoprotectant , and optionally an organic solvent.2. A method of treating a coagulopathy in a subject , the method comprising administering to the subject in need thereof an effective amount of a composition prepared by a process comprising incubating platelets with an incubating agent comprising one or more salts , a buffer , optionally a cryoprotectant , and optionally an organic solvent , to form the composition.3. A method of restoring normal hemostasis in a subject , the method comprising administering to the subject in need thereof an effective amount of a composition comprising platelets or platelet derivatives and an incubating agent comprising one or more salts , a buffer , optionally a cryoprotectant , and optionally an organic solvent.4. A method of restoring normal hemostasis in a subject , the method comprising administering to the subject in need thereof an effective amount of a composition prepared by a process comprising incubating platelets with an incubating agent comprising one or more salts , a buffer , optionally a cryoprotectant , and optionally an organic solvent , to form the composition.5. A method of preparing a subject for surgery , the method comprising administering to the subject in need thereof an effective amount of a composition comprising platelets or platelet derivatives and an incubating agent ...

THROMBOSOMES AS AN ANTIPLATELET AGENT REVERSAL AGENT

In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent. 1. A method of restoring normal hemostasis in a subject , the method comprising administering to the subject in need thereof an effective amount of a composition comprising platelets or platelet derivatives and an incubating agent comprising one or more salts , a buffer , optionally a cryoprotectant , and optionally an organic solvent , wherein the subject has been treated or is being treated with an antiplatelet agent.2. A method of restoring normal hemostasis in a subject , the method comprising administering to the subject in need thereof an effective amount of a composition prepared by a process comprising incubating platelets with an incubating agent comprising one or more salts , a buffer , optionally a cryoprotectant , and optionally an organic solvent , to form the composition , wherein the subject has been treated or is being treated with an antiplatelet agent.3. A method of treating a coagulopathy in a subject , the method comprising administering to the subject in need thereof an effective amount of a composition comprising platelets or platelet derivatives and an incubating agent comprising one or more salts , a buffer , optionally a cryoprotectant , and optionally an organic solvent , wherein the subject has been treated or is being treated with an antiplatelet agent.4. A method of treating a coagulopathy in a subject , the method comprising administering to the subject in need thereof an effective amount of a composition prepared by a process comprising incubating platelets with an incubating agent comprising one ...

Cell Preparations For Extemporaneous Use, Useful For Healing And Rejuvenation In Vivo

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell combinations preparations for use in tissue regeneration and bone regeneration and pain reduction. 1. A medical separator system for preparation of a platelet concentrate , comprising: a thixotropic gel being adapted to separate blood components in whole blood to provide a platelet concentrate containing less than or equal to 1% hematocrit and a pellet containing more than or equal to 99% hematocrit by forming a barrier between plasma and erythrocytes when said tube is centrifuged; and', 'an anticoagulant being adapted to at least reduce coagulation of said whole blood., 'a tube being adapted to be centrifuged for a length of time and containing two additives, wherein said two additives include2. The medical separator system of claim 1 , wherein said thixotropic gel is adapted to separate said blood components in said whole blood to provide said platelet concentrate containing 2 or more times a normal level of platelets and growth factors compared to said whole blood.3. The medical separator system of claim 2 , wherein said thixotropic gel is adapted to separate said blood components in said whole blood to provide said platelet concentrate with platelet recovery of 95%±5%.4. The medical separator system of claim 3 , wherein no other additives are contained in said tube.5. A kit comprising:{'claim-ref': {'@idref': 'CLM-00003', 'claim 3'}, 'a medical separator system of ; and'}an applicator device for applying said platelet concentrate to a patient for medical, therapeutic, or skincare application.6. The medical separator system of claim 3 , ...

FIBROSIS CAUSING AGENT

A fibrosis-causing agent is highly effective in the fibrosis of tissues. The fibrosis-causing agent contains a fibrosis inducer and a fibrosis promoter. A fibrosis-causing agent dosage form and a method of administering the fibrosis-causing agent is also disclosed. 1. A fibrosis-causing agent comprising a fibrosis inducer and a fibrosis promoter.2. The fibrosis-causing agent according to claim 1 , wherein the fibrosis promoter contains platelets or platelet-rich plasma (PRP).3. The fibrosis-causing agent according to claim 2 , wherein the fibrosis promoter contains platelet-rich plasma (PRP) and a PRP gelling agent.4. The fibrosis-causing agent according to claim 3 , wherein PRP gelling agent contains at least one selected from the group consisting of calcium claim 3 , calcium salt claim 3 , fibrin claim 3 , fibrinogen claim 3 , thrombin claim 3 , vitamin K claim 3 , and factor X.5. The fibrosis-causing agent according to claim 1 , wherein the fibrosis inducer contains at least one polyanion.6. The fibrosis-causing agent according to claim 5 , wherein the polyanion is at least one selected from the group consisting of alginic acid claim 5 , alginate claim 5 , and alginic ester.7. The fibrosis-causing agent according to claim 1 , wherein the fibrosis-causing agent is administered for treatment of pulmonary emphysema.8. A method of causing fibrosis by administering to a patient in thereof claim 1 , a fibrosis causing agent according to .9. A method for causing fibrosis by administering to a subject a fibrosis causing agent.10. The method according to claim 9 , wherein the fibrosis causing agent comprises a fibrosis inducer and a fibrosis promoter.11. The method according to claim 10 , wherein the fibrosis promoter contains platelets or platelet-rich plasma (PRP).12. The method according to claim 11 , wherein the fibrosis promoter contains platelet-rich plasma (PRP) and a PRP gelling agent.13. The method according to claim 12 , wherein PRP gelling agent contains at ...

SYSTEMS, COMPOSITIONS, AND METHODS FOR TRANSPLANTATION

Systems and methods for purification and concentration of autologous alpha-2-macroglobulin (A2M) from whole blood are provided. Also provided are diagnostic methods for identifying sites in the synovial joints, spine, tendons or ligaments for treatment of pain, degeneration, or inflammation with autologous A2M. Methods for utilizing autologous A2M in combination with other autologous treatments (e.g. platelets and other growth factors) are provided in addition to combinations with exogenous drugs or carriers. Also provided is a method of producing recombinant A2M wild type or variants thereof where the bait region was modified to enhance the inhibition characteristics of A2M and/or to prolong the half life of the protein in joints and spine disc or epidural space. 1202.-. (canceled)203. A composition comprising a recombinant A2M polypeptide comprising a non-natural bait region , wherein the non-natural bait region comprises a sequence with at least 6 contiguous amino acid residues of a sequence selected from the group consisting of SEQ ID NOs: 5-9 , 11 , 17 , 27-29 , 34-35 , 37 , 39-42 , 45-47 and 50-66.204. The composition of claim 203 , wherein the non-natural bait region comprises a sequence with at least 80% identity to at least 18 contiguous amino acid residues of a sequence selected from the group consisting of SEQ ID NOs: 47 claim 203 , 52-53 claim 203 , 55 claim 203 , 61-63 and 66.205. The composition of claim 203 , wherein the non-natural bait region comprises a sequence with at least 90% identity to at least 25 contiguous amino acid residues of SEQ ID NO: 47.206. The composition of claim 203 , wherein the non-natural bait region comprises a sequence with at least 24 contiguous amino acid residues of SEQ ID NO: 47.207. The composition of claim 203 , wherein the non-natural bait region comprises two or more protease recognition sequences.208. The composition of claim 203 , wherein the recombinant A2M polypeptide is characterized by an enhanced inhibition of ...

METHODS OF GROWING AND PREPARING STEM CELLS AND METHODS OF USING THE SAME

The present invention relates to methods of improving stem cell delivery to a subject in need thereof and kits designed to assist in such. The methods comprise interchangeably allowing or promoting cell growth in conditions that permit three-dimensional growth, such as with a bioreactor, utilizing allogeneic, autologous or xenogeneic cells, mixing the cells with platelet rich plasma that is autologous, allogeneic or xenogeneic to the subject, and site specific delivery of between about three and ten million activated stem cells per kilogram of the subject receiving the treatment. 1. A method of treating a site specific injury in a subject comprising administration of a suspension of stem cells to a site in need thereof , wherein the suspension comprises about 3-ten million activated stem cells per kilogram of the subject intravenously or about 5 to 10 million cells intra-articularly and further wherein the stem cells are derived from a 3D cell culture.2. The method of claim 1 , wherein the stem cells comprise autologous claim 1 , allogeneic or xenogeneic cells incubated in a bioreactor prior to administration to the subject.3. The method of claim 1 , wherein the suspension further comprises a bio-compatible matrix.4. The method of claim 1 , further comprising mixing the stem cells with autologous platelet rich plasma prior to administration to the subject.5. The method of claim 4 , wherein the autologous PRP is photo bio-stimulated.6. The method of claim 1 , further comprising mixing the suspension with autologous adipose-derived stem cells (ADSCs) isolated from the subject prior to administration.7. The method of claim 6 , wherein the autologous ADSCs are previously activated by PRP and/or photo-biostimulation.8. A method of treating a patient claim 6 , comprising administering a suspension of stem cells grown to the patient claim 6 , wherein the suspension of stem cells are derived from a 3D cell culture and contacted with platelet rich plasma and/or photo bio- ...

INTERNAL MEDICINE DOSING OF STEM CELLS

The present invention relates to methods of improving stem cell delivery to a subject in need thereof and kits designed to assist in such. The methods comprise site specific delivery of between five and fifteen million stem cells at the site and systemic administration of between about three and ten million cells per kilogram of the subject receiving the treatment. 1. A method of treating a site specific injury in a subject comprising administration of a suspension of stem cells to a site in need thereof , wherein the suspension comprises of about between 5 and 15 million cells.2. The method of claim 1 , wherein further cells are administered systemically such that the subject receives between about 3 and 10 million stem cells per kilogram of the subject.3. The method of claim 1 , wherein the stem cells comprise autologous claim 1 , allogeneic or xenogeneic cells incubated in a bioreactor prior to administration to the subject.4. The method of claim 1 , wherein the suspension further comprises a bio-compatible matrix.5. The method of claim 1 , further comprising mixing the stem cells with autologous platelet rich plasma prior to administration to the subject.6. The method of claim 4 , wherein the stem cells are further photo bio-stimulated.7. A method of treating a patient claim 4 , comprising administering a suspension of stem cells to the patient claim 4 , wherein the suspension of stem cells are derived from autologous stem cells derived from the patient and contacted with autologous platelet rich plasma and/or photo bio-stimulated and administered at or near the site in need.8. The method of claim 6 , wherein the stem cells are administered at a count of between about 3 to 10 million cells per kilogram of the patient intravenously or about 5 to 15 million cells intra-articularly at a joint claim 6 , tendon or bone in need thereof.9. A method of using stem cells to treat a bone claim 6 , ligament claim 6 , tendon or cartilage injury in an animal claim 6 , ...

CRYOPRESERVED PLATELET COMPOSITIONS AND METHODS FOR MAKING

This disclosure relates to a composition that, in some embodiments, includes cryopreserved platelets; and a cryoprotectant, wherein the composition comprises less than 6% (v/v) of dimethyl sulfoxide (DMSO). In some embodiments, the composition is substantially free of dimethyl sulfoxide (DMSO). 1. A composition comprising:cryopreserved platelets; anda cryoprotectant;wherein the composition comprises DMSO in the amount of about 0.1% (v/v) to about 5% (v/v).23.-. (canceled)4. The composition of claim 1 , wherein the cryoprotectant is present at about 1 mM to about 1 M.57.-. (canceled)8. The composition of claim 1 , wherein the cryoprotectant comprises a component selected from the group consisting of a saccharide claim 1 , a monosaccharide claim 1 , a disaccharide claim 1 , and combinations thereof.911.-. (canceled)12. The composition of claim 1 , wherein the cryoprotectant comprises a polymer derived from sucrose and epichlorohydrin claim 1 , wherein the polymer is a polysucrose.1316.-. (canceled)17. The composition of claim 1 , wherein the cryoprotectant comprises a high molecular weight polymer claim 1 , wherein the high molecular weight polymer has an average molecular weight of at least about 70 kDa.18. (canceled)19. The composition of claim 1 , wherein the cryoprotectant is selected from the group consisting of serum albumin claim 1 , dextran claim 1 , polyvinyl pyrolidone (PVP) claim 1 , starch claim 1 , hydroxyethyl starch (HES) claim 1 , and combinations thereof.20. The composition of claim 1 , wherein the cryoprotectant comprises a sugar alcohol claim 1 , wherein the sugar alcohol is selected from the group consisting of mannitol claim 1 , sorbitol claim 1 , xylitol claim 1 , maltitol claim 1 , maltitol syrup claim 1 , lactitol claim 1 , erythritol claim 1 , isomalt claim 1 , hydrogenated starch hydrolysates claim 1 , serum albumin claim 1 , dextran claim 1 , polyvinyl pyrolidone (PVP) claim 1 , starch claim 1 , hydroxyethyl starch (HES) claim 1 , and ...

COMPOSITIONS, USES, AND PREPARATION OF PLATELET LYSATES

In certain embodiments, this disclosure describes compositions comprising platelet lysates depleted of fibrinogen. In a further embodiment, the composition further comprises a cell culture medium component. This disclosure also provides a method for preparing the composition, comprising the steps of (a) lysing platelets providing a lysate; (b) removing cell debris; and (c) depleting fibrinogen by forming a removable mass by adding a metal salt such as calcium chloride. Furthermore, the disclosure also describes the product produced using said method. 1. A composition comprising platelet lysate components with reduced amounts of fibrinogen compared to platelet lysates produced by a freeze-thaw process.2. The composition of claim 1 , wherein the composition is substantially depleted of fibrinogen.3. The composition of claim 1 , wherein the platelet lysate components are not substantially depleted of PDGF.4. A composition of claim 1 , wherein the composition is an aqueous solution with a concentration of fibrinogen of less than 50 μg/mL.5. The composition of claim 4 , wherein the concentration of fibrinogen is less than 4 μg/mL.6. The composition of claim 4 , wherein the concentration of PDGF-BB is greater than 15 ng/mL.7. A composition made by the processes of removing water from a composition of .8. A method of culturing cells claim 1 , wherein cells are cultured in a medium of .9. The method of claim 8 , wherein the cells are progenitor cells or stem cells.10. The method of claim 9 , wherein the stem cells are pluripotent stem cells claim 9 , multipotent stem cells claim 9 , somatic stem cells claim 9 , mesenchymal stem cell claim 9 , adipose-derived stem cell claim 9 , endothelial stem cell claim 9 , dental pulp stem cell claim 9 , embryonic stem cells claim 9 , bone marrow or hematopoietic stem cell claim 9 , amniotic stem cells claim 9 , lymphoid or myeloid stem cells11. A method of treating or preventing an ocular disease or condition comprising administering an ...

FREEZE-DRIED POLYMER COMPOSITIONS FOR MIXING WITH PLATELET RICH PLASMA TO FORM IMPLANTS FOR TISSUE REPAIR AND/OR COMPOSITIONS FOR THERAPEUTIC INTRA-ARTICULAR INJECTIONS

The present application relates to a freeze-dried polymer composition containing chitosan and at least one lyoprotectant, a process for preparing a freeze-dried composition containing chitosan and at least one lyoprotectant and the use of a reconstituted freeze-dried chitosan composition to prepare implants for tissue repair. 1. A freeze-dried polymer composition comprising chitosan and at least one lyoprotectant for reconstitution in PRP , blood product and combinations thereof forming an injectable solution which upon injection:i) into tissue solidifies forming an implant for tissue repair; orii) into an articular joint mixing with intra-articular fluids.2. The composition of wherein the at least one lyoprotectant is selected from the group consisting of monosaccharide claim 1 , polyol claim 1 , disaccharide claim 1 , trisaccharide claim 1 , oligosaccharide/polysaccharide claim 1 , high molecular weight excipient claim 1 , amino acid claim 1 , protein and a combination thereof.3. The composition of wherein the chitosan has a molecular weight number from about 20 to about 250 kDa.4. The composition of wherein the chitosan is present from about 0.25% to about 10% w/v.5. The composition of wherein the at least one lyoprotectant is present from about 0.1% to about 30% w/v.6. The composition of further comprising a clot activator.7. The composition of wherein the clot activator is selected from the group consisting of calcium chloride claim 6 , calcium gluconate claim 6 , calcium acetate claim 6 , calcium carbonate claim 6 , calcium glubionate claim 6 , calcium gluceptate claim 6 , calcium lactate claim 6 , calcium lactobionate claim 6 , calcium phosphate and combinations thereof.8. A process for preparing a freeze-dried polymer composition comprising the steps of:a) contacting chitosan with water to form an aqueous mixture,b) contacting the aqueous mixture with at least one lyoprotectant,c) optionally contacting the aqueous mixture with at least one clot activator,d) ...

CLUSTOIDAL MULTILAMELLAR SOY LECITHIN PHOSPHOLIPID STRUCTURES FOR TRANSDERMAL, TRANSMUCOSAL, OR ORAL DELIVERY, IMPROVED INTESTINAL ABSORPTION, AND IMPROVED BIOAVAILABILITY OF NUTRIENTS

Clustoidal multilamellar soy lecithin phospholipid structures are provided. A process enables comprehensive and uniform encapsulation of nutritional and/or pharmaceutical ingredients in multilamellar clustoidal soy lecithin phospholipid (prodosome) capsules facilitating superior absorption of nutritionally and pharmacologically active therapeutic substances that provide benefits following absorption of the energetically enhanced electrolyte-impregnated phospholipids. Methods of use for the soy lecithin phospholipid (SLP) materials are contemplated including delivery of one or more nutrients or nutritional/pharmaceutical compositions as desired through oral and topical administrations. 1. A process for making one or more multilamellar clustoidal phospholipid structures , comprising the steps of:(a) adding a naturally derived ionic mineral composition to water and mixing at high speed vortex to form ionically charged structured water;(b) adding phosphatidylcholine of at least 70% purity to the ion-treated water composition by mixing in a high speed vortex to form a liposomal mixture;(c) adding ethyl alcohol to the liposomal mixture by mixing in a high speed vortex to form the one or more multilamellar clustoidal phospholipid structures in water; and(d) allowing the multilamellar clustoidal phospholipid structures in water to cool to ambient temperature.2. A multilamellar clustoidal phospholipid vehicle for delivery of a cellular , subcellular , nutritional , nutritional , or pharmaceutical ingredient , comprising:a solvent;phosphatidylcholine of at least 70% purity; anda naturally derived ionic mineral composition.3. The multilamellar clustoidal phospholipid vehicle of claim 2 , wherein the solvent is selected from the group consisting of water claim 2 , an alcohol claim 2 , and mixtures thereof.4. The multilamellar clustoidal phospholipid vehicle of claim 2 , wherein the multilamellar clustoidal phospholipid vehicle comprises one or more multilamellar clustoidal ...

Method for Producing Highly Functional Platelets

The present invention provides a highly functional platelet production promoting agent which comprises one or a plurality of aryl hydrocarbon receptor (AhR) antagonists and one or a plurality of Rho-associated coiled-coil forming kinase (ROCK) inhibitors. 1. A highly functional platelet production promoting agent which comprises one or a plurality of aryl hydrocarbon receptor (AhR) antagonists and one or a plurality of Rho-associated coiled-coil forming kinase (ROCK) inhibitors.2. The platelet production promoting agent according to claim 1 , wherein the AhR antagonist is selected from the group consisting of 4-(2-(2-(benzo[b]thiophen-3-yl)-9-isopropyl-9H-purin-6-ylamino)ethyl)phenol (SR-1) claim 1 , 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) claim 1 , N-[2-(3H-indol-3-yl)ethyl]-9-isopropyl-2-(5-methyl-3-pyridyl)purin-6-amine (GNF-351) claim 1 , 6 claim 1 ,2′ claim 1 ,4′-trimethoxyflavone (TMF) and 3′ claim 1 ,4′-dimethoxyflavone (DMF).3. The platelet production promoting agent according to claim 1 , wherein the ROCK inhibitor is selected from the group consisting of Y27632 claim 1 , Y39983 claim 1 , fasudil hydrochloride claim 1 , ripasudil claim 1 , SLX-2119 claim 1 , RKI-1447 claim 1 , azaindole1 claim 1 , SR-3677 claim 1 , Staurosporine and H1152 dihydrochloride.4. The platelet production promoting agent according to claim 1 , wherein the AhR antagonist is SR-1 claim 1 , GNF-351 and/or CH-223191 claim 1 , and the ROCK inhibitor is Y27632 claim 1 , Y39983 claim 1 , fasudil hydrochloride and/or ripasudil.5. A platelet production method claim 1 , which comprises a step for bringing the platelet production promoting agent according to into contact with megakaryocytes or progenitor cells thereof.6. The method according to claim 5 , wherein the contact step is carried out under conditions of not using feeder cells.7. The method according to claim 6 , which is carried out under shake culturing conditions.8. The method ...

SURGICAL WOUND HEALING COMPOSITION AND METHOD OF APPLYING THE SAME

Compositions and methods are disclosed for improving the healing of surgical wounds, and specifically for improving the survival rate, color retention rate, density, and scarring rate of a hair follicular graft following a hair transplantation surgery. The composition may be a suspension for injection proximal to the surgical graft recipient site, with the suspension comprising 0.4-0.5 mL of a suspension of an autologous platelet solution of at least 1 billion platelets at a concentration exceeding 1.5 billion platelets per mL, about 20 mg of granulated extracellular matrix, and about 40 mg of triamcinolone acetonide. 1. A method for facilitating healing of a wound , the method comprising applying proximal to the wound a therapeutically effective amount of a suspension comprising:an autologous platelet solution above basal concentration;granulated extracellular matrix; andtriamcinolone acetonide.2. The method of claim 1 , wherein the concentration of the autologous platelet solution exceeds 1.5 billion platelets per mL.3. The method of claim 1 , wherein the autologous platelet solution is injected proximal to the wound.4. The method of claim 1 , wherein the autologous platelet solution claim 1 , the granulated extracellular matrix claim 1 , and the triamcinolone acetonide are combined in a suspension and injected proximal to the wound.5. The method of claim 4 , wherein the suspension injected proximal to the wound comprises about 1 billion autologous platelets claim 4 , about 20 mg granulated extracellular matrix claim 4 , and about 40 mg triamcinolone acetonide.6. The method of claim 4 , wherein the suspension is injected directly at an opening of the wound.7. The method of claim 1 , wherein the granulated extracellular matrix is autologous.8. The method of claim 1 , wherein the granulated extracellular matrix is non-autologous.9. A composition for facilitating healing of a wound claim 1 , the composition being a suspension comprising:an autologous platelet ...

Systemic and Topical Application of Platelet Microparticles to Treat Bleeding in Trauma Patients

The present disclosure is directed to blood dotting compositions comprising platelet microparticles, method of using said compositions, and methods of preparing the same. 1. A blood clotting composition comprising:isolated platelet microparticles; one or more factors selected from fibrinogen (Factor I), von Willebrand factor, Factor II, Factor V, Factor VII, Factor VIII, Factor IX, Factor X, Factor XI, Factor XII, Protein C (PC), Protein S (PS), antithrombin III (ATIII); and a pharmaceutical carrier;wherein fibrinogen is at about 10-1000 mg/deciliter (dL), Factor V is at about 0.5-2.0 International Unit (IU), Factor VII is at about 0.5-4.0 IU, Factor VIII is at about 0.2-2.0 IU, Factor IX is at about 0.5-3.0 IU, Factor XI is about 0.5-3.0 IU, Factor XII is at about 1.0-7.0 IU, Protein C (PC) is at about 25-300% activity, Protein S (PS) is at about 10-150% activity, antithrombin III (ATIII) is about 25-250% activity.2. The composition of claim 1 , wherein the composition has either prothrombin time that is within a normal reference range or an activated partial thromboplastin time that is within a normal reference range.3. (canceled)4. The composition of claim 1 , wherein the composition has a blood clot initiation time (R-time) of less than three minutes when measured using thromboelastography.5. The composition of claim 1 , wherein the concentration of platelet microparticles in the composition is >10″ microparticles/μl.6. The composition of claim 1 , wherein the composition comprises two or more of the factors or all eight factors.7. (canceled)8. The composition of claim 1 , wherein the composition is formulated for topical administration or systemic administration.9. The composition of claim 8 , wherein the composition is formulated as a spray claim 8 , powder claim 8 , cream claim 8 , gel claim 8 , or ointment.10. (canceled)11. A wound dressing comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the blood clotting composition of and'}a wound dressing ...

METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE

Compositions and methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof. 1. A method for treating a degenerative intervertebral disc in a patient in need thereof comprising:culturing harvested nucleated cells in a culture medium under selective pressure of about 1% to about 10% oxygen for 1-28 days;obtaining viable mesenchymal stem cells capable of growth in the culture medium under selective pressure of about 1% to about 10% oxygen;implanting the viable mesenchymal stem cells in a posterior disc annulus of the degenerative intervertebral disc; andimplanting autologous platelets or platelet lysate in the posterior disc annulus, either separately or in combination with the viable mesenchymal stem cells.2. The method of wherein the selective pressure includes culturing the harvested nucleated cells in from about 3 to about 7% oxygen.3. The method of wherein the selective pressure further includes culturing the harvested nucleated cells in from about 2 to about 10% carbon dioxide.4. The method of wherein the selective pressure further includes culturing the harvested nucleated cells in from about 2 to about 10% carbon dioxide.5. The method of further comprising harvesting autologous platelets from the patient in need thereof.6. The method of claim 1 , wherein the autologous platelets are implanted prior to claim 1 , during or after implanting the viable mesenchymal stem cells.7. The method of wherein the autologous platelets are treated with thrombin and calcium chloride 1-7 days prior to implanting in the posterior disc annulus.8. The method of wherein the amount of thrombin is 28.56 U/ml and the amount of calcium chloride is 2.86 mg/ml.9. The method of wherein the autologous platelets are treated with thrombin claim 5 , calcium chloride or its salts claim 5 , thromboxane A2 claim 5 , adenosine triphosphate and arachidonate.10. The method of further comprising administering one or more compounds selected ...

METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE

Compositions and methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof. 1. A method for treating a degenerative intervertebral disc in a patient in need thereof comprising:co-culturing harvested nucleus pulposis (NP) cells with harvested nucleated cells in a culture medium under selective pressure of about 1% to about 10% oxygen for 1-28 days;obtaining viable mesenchymal stem cells capable of growth in the culture medium under selective pressure of about 1% to about 10% oxygen; andimplanting the viable mesenchymal stem cells in a posterior disc annulus of the degenerative intervertebral disc.2. The method of wherein the selective pressure includes culturing the harvested nucleated cells in from about 3 to about 7% oxygen.3. The method of wherein the selective pressure further includes culturing the harvested nucleated cells in from about 2 to about 10% carbon dioxide.4. The method of wherein the selective pressure further includes culturing the harvested nucleated cells in from about 2 to about 10% carbon dioxide.5. The method of further comprising:harvesting platelets from the patient in need thereof; andimplanting the platelets prior to, during or after implanting the viable mesenchymal stem cells;wherein the implanting of both platelets and viable mesenchymal stem cells is in the posterior disc annulus.6. The method of wherein the platelets are treated with thrombin and calcium chloride 1-7 days prior to implanting in the posterior disc annulus.7. The method of wherein the amount of thrombin is 28.56 U/ml and the amount of calcium chloride is 2.86 mg/ml.8. The method of wherein the platelets are treated with thrombin claim 5 , calcium chloride or its salts claim 5 , thromboxane A2 claim 5 , adenosine triphosphate and arachidonate.9. The method of further comprising administering a compound selected from the group consisting of growth factors claim 1 , cytokines claim 1 , integrins claim 1 , ...

METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE

Compositions and methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof. 1. A method for treating a degenerative intervertebral disc in a patient in need thereof comprising:co-culturing harvested annulus fibrosis (AF) cells with harvested nucleated cells in a culture medium under selective pressure of about 1% to about 10% oxygen for 1-28 days;obtaining viable mesenchymal stem cells capable of growth in the culture medium under selective pressure of about 1% to about 10% oxygen; andimplanting the viable mesenchymal stem cells in a posterior disc annulus of the degenerative intervertebral disc.2. The method of wherein the selective pressure includes culturing the harvested nucleated cells in from about 3 to about 7% oxygen.3. The method of wherein the selective pressure further includes culturing the harvested nucleated cells in from about 2 to about 10% carbon dioxide.4. The method of wherein the selective pressure further includes culturing the harvested nucleated cells in from about 2 to about 10% carbon dioxide.5. The method of further comprising:harvesting platelets from the patient in need thereof; andimplanting the platelets prior to, during or after implanting the viable mesenchymal stem cells;wherein the implanting of both platelets and viable mesenchymal stem cells is in the posterior disc annulus.6. The method of wherein the platelets are treated with thrombin and calcium chloride 1-7 days prior to implanting in the posterior disc annulus.7. The method of wherein the amount of thrombin is 28.56 U/ml and the amount of calcium chloride is 2.86 mg/ml.8. The method of wherein the platelets are treated with thrombin claim 5 , calcium chloride or its salts claim 5 , thromboxane A2 claim 5 , adenosine triphosphate and arachidonate.9. The method of further comprising administering a compound selected from the group consisting of growth factors claim 1 , cytokines claim 1 , integrins claim 1 , ...

METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE

Compositions and methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof. 1. A method for treating an avascular zone in a patient in need thereof comprising:culturing harvested nucleated cells from the patient in need thereof in a culture medium under a selective pressure of about 1% to about 10% oxygen and a pH of about 6.6 to about 7.0;selecting viable, undifferentiated mesenchymal stem cells capable of growth in the culture medium under the selective pressure of about 1% to about 10% oxygen and a pH of about 6.6 to about 7.0; andproviding the selected, viable, undifferentiated mesenchymal stem cells for implantation in the avascular zone.2. The method of claim 1 , wherein the selective pressure is about 3 to about 7% oxygen.3. The method of claim 1 , wherein the selective pressure further includes from about 2 to about 10% carbon dioxide.4. The method of claim 1 , wherein the selective pressure further includes a pH of about 6.7 to about 6.9.5. The method of claim 1 , wherein the culture medium is supplemented with about 10 to about 20% platelet cell lysate.6. The method of claim 1 , further comprising:harvesting platelets from the patient in need thereof; andimplanting the platelets prior to, during, or after implanting the selected, viable, undifferentiated mesenchymal stem cells;wherein the implanting of the platelets and the selected, viable, undifferentiated mesenchymal stem cells is in the avascular zone.7. The method of claim 6 , wherein the platelets are treated with thrombin and calcium chloride 1-7 days prior to implanting.8. The method of claim 7 , wherein the amount of thrombin is about 28.56 U/ml and the amount of calcium chloride is about 2.86 mg/ml.9. The method of claim 6 , wherein the platelets are treated with a composition selected from the group consisting of thrombin claim 6 , calcium chloride or its salts claim 6 , thromboxane A2 claim 6 , adenosine triphosphate claim 6 , ...

METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE

Compositions and methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof. 1. A method for treating a degenerative intervertebral disc in a patient in need thereof comprising:culturing harvested nucleated cells in a culture medium under selective pressure of about 2% to about 10% carbon dioxide for 1-28 days;obtaining viable mesenchymal stem cells capable of growth in the culture medium under selective pressure of about 2% to about 10% carbon dioxide;implanting the viable mesenchymal stem cells in a posterior disc annulus of the degenerative intervertebral disc; andimplanting autologous platelets or platelet lysate in the posterior disc annulus, either separately or in combination with the viable mesenchymal stem cells.2. The method of further comprising harvesting autologous platelets from the patient in need thereof.3. The method of claim 1 , wherein the autologous platelets are implanted prior to claim 1 , during or after implanting the viable mesenchymal stem cells.4. The method of wherein the autologous platelets are treated with thrombin and calcium chloride 1-7 days prior to implanting in the posterior disc annulus.5. The method of wherein the amount of thrombin is 28.56 U/ml and the amount of calcium chloride is 2.86 mg/ml.6. The method of wherein the autologous platelets are treated with thrombin claim 2 , calcium chloride or its salts claim 2 , thromboxane A2 claim 2 , adenosine triphosphate and arachidonate.7. The method of further comprising administering one or more compounds selected from the group consisting of growth factors claim 1 , cytokines claim 1 , integrins claim 1 , cadherins claim 1 , molecules or drugs that promote angiogenesis claim 1 , molecules or drugs that promote vasculogenesis claim 1 , and molecules or drugs that promote arteriogenesis.8. The method of wherein the compound is selected from a group consisting of VEGF-A claim 7 , PIGF claim 7 , VEGF-B claim 7 , VEGF-C ...

METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE

Compositions and methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof. 1. A method for treating a degenerative intervertebral disc in a patient in need thereof comprising:culturing harvested nucleated cells in a culture medium at an osmolarity of about 350 mOsm to about 600 mOsm for 1-28 days;obtaining viable mesenchymal stem cells capable of growth in the culture medium at an osmolarity of about 350 mOsm to about 600 mOsm;implanting the viable mesenchymal stem cells in a posterior disc annulus of the degenerative intervertebral disc; andimplanting autologous platelets or platelet lysate in the posterior disc annulus, either separately or in combination with the viable mesenchymal stem cells.2. The method of further comprising harvesting autologous platelets from the patient in need thereof.3. The method of claim 1 , wherein the autologous platelets are implanted prior to claim 1 , during or after implanting the viable mesenchymal stem cells.4. The method of wherein the autologous platelets are treated with thrombin and calcium chloride 1-7 days prior to implanting in the posterior disc annulus.5. The method of wherein the amount of thrombin is 28.56 U/ml and the amount of calcium chloride is 2.86 mg/ml.6. The method of wherein the autologous platelets are treated with thrombin claim 2 , calcium chloride or its salts claim 2 , thromboxane A2 claim 2 , adenosine triphosphate and arachidonate.7. The method of further comprising administering a compound selected from the group consisting of growth factors claim 1 , cytokines claim 1 , integrins claim 1 , cadherins claim 1 , molecules or drugs that promote angiogenesis claim 1 , molecules or drugs that promote vasculogenesis claim 1 , and molecules or drugs that promote arteriogenesis.8. The method of wherein the compound is selected from a group consisting of VEGF-A claim 7 , PIGF claim 7 , VEGF-B claim 7 , VEGF-C claim 7 , VEGF-D claim 7 , TGF-β claim ...

METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE

Compositions and methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof. 1. A pharmaceutical composition comprising:mesenchymal stem cells cultured under selective pressure of about 1% to about 10% oxygen;a growth factor; anda pharmaceutical carrier or diluent.2. The pharmaceutical composition of wherein the growth factor is selected from the group consisting of TGF-β claim 1 , FGF claim 1 , PDGF claim 1 , IGF claim 1 , VEGF-B claim 1 , and combinations thereof.3. The pharmaceutical composition of wherein the growth factor is PDGF.4. The pharmaceutical composition of wherein the growth factor is FGF.5. The pharmaceutical composition of wherein the growth factor is VEGF-B.6. The pharmaceutical composition of wherein the growth factor is TGF-β.7. The pharmaceutical composition of wherein the mesenchymal stem cells are cultured under selective pressure of about 1% to about 10% and from about 2 to about 10% carbon dioxide.8. The pharmaceutical composition of wherein the mesenchymal stem cells are cultured under selective pressure of about 3% to about 7% oxygen.9. The pharmaceutical composition of wherein the mesenchymal stem cells are cultured under selective pressure of about 3% to about 7% and from about 2 to about 10% carbon dioxide.10. A pharmaceutical composition comprising:mesenchymal stem cells cultured under selective pressure of about 1% to about 10% oxygen;platelets;a growth factor; anda pharmaceutical carrier or diluent.11. The pharmaceutical composition of wherein the platelets are treated with thrombin and calcium chloride for 1-7 days.12. The pharmaceutical composition of wherein the platelets are treated with thrombin claim 10 , calcium chloride or its salts claim 10 , thromboxane A2 claim 10 , adenosine triphosphate and arachidonate.13. The pharmaceutical composition of wherein the growth factor is PDGF.14. The pharmaceutical composition of wherein the growth factor is FGF.15. The ...

METHODS AND COMPOSITIONS TO FACILITATE REPAIR OF AVASCULAR TISSUE

Compositions and methods are provided for repairing damaged avascular zones, including intervertebral disc, in a patient in need thereof. 1. A method for treating an avascular zone in a patient in need thereof , the method comprising:{'claim-text': ['obtaining whole marrow from the patient in need thereof;', 'centrifuging the whole marrow to separate nucleated cells from red blood cells;', 'removing the nucleated cells from the centrifuged whole marrow;', 'washing and counting the nucleated cells;', 'culturing the nucleated cells in a culture medium under a selective pressure of about 1% to about 10% oxygen for 1-28 days;', 'selecting viable mesenchymal stem cells capable of growth in the culture medium under the selective pressure of about 1% to about 10% oxygen;'], '#text': 'an isolation and expansion process consisting of:'}{'claim-text': ['providing the selected, viable, mesenchymal stem cells for implantation in the avascular zone;', 'administering a compound in the avascular zone, wherein the compound is selected from the group consisting of VEGF-A, PIGF, VEGF-B, VEGF-C, VEGF-D, TGF-β, Ang-1, Ang-2, IGF, HGF, FGF, Tie2, PDGF, CCL2, Alpha-V Beta-5, Alpha-5 Beta-1, VE-cadherin, PECAM-1, plasminogen activator, nitrogen oxide synthase, and combinations thereof;', 'wherein the administering the compound in the avascular zone is prior to, during, or after implanting the selected, viable, mesenchymal stem cells.'], '#text': 'an implantation process comprising:'}2. The method of wherein the selective pressure includes culturing the nucleated cells in from about 3 to about 7% oxygen.3. The method of wherein the selective pressure further includes culturing the nucleated cells in from about 2 to about 10% carbon dioxide.4. The method of wherein the selective pressure further includes culturing the nucleated cells in from about 2 to about 10% carbon dioxide.5. The method of claim 1 , wherein the culture medium comprises 10% to 20% human platelet lysate.6. The method of ...

COMPOSITIONS AND METHODS FOR PLATELET ENRICHED FIBRIN CONSTRUCTS

Compositions and methods are provided for tissue constructs that promote wound healing. The composition comprises a dimensionally stable fibrin construct for local administration to a wound site or region. In one embodiment, the fibrin construct is a wound healing composition, including components that promote wound healing, such as platelets, growth factors, white blood cells and fibrin clots. In another embodiment, the tissue treatment composition includes (i) aggregated fibrin, (ii) blood cells, and (iii) optionally, growth factors and/or other proteins. 120-. (canceled)21. A bioimplantable construct , comprising:a fibrin construct derived from whole blood, having a growth factor enriched surface concentrated with blood cells and platelets capable of releasing a growth factor and a growth factor depleted surface, the fibrin construct being dimensionally stable and suturable.22. The construct of claim 21 , wherein the growth factor depleted surface is substantially lacking in blood cells.23. The construct of claim 21 , wherein the growth factor depleted surface is substantially lacking in red blood cells.24. The construct of claim 21 , wherein the growth factor depleted surface includes white blood cells.25. The construct of claim 21 , wherein the fibrin construct has a resiliency that is defined by an elongation at break strength of at least about 200%.26. The construct of claim 21 , wherein the fibrin construct has a strength that is defined by an ultimate strength of at least about 0.15 MPa.2730. The construct of claim 21 , wherein the fibrin construct has a strength that is defined by a compression strength of at least about kPa28. The construct of claim 21 , wherein the fibrin construct is a folded construct that is folded upon itself so that adjacent halves of the growth factor enriched surface contact each other and form an inner portion of the folded construct while the growth factor depleted surface forms an outer portion of the folded construct.29. The ...

Pharmaceutical Composition For Preventing Or Treating Sensorineural Hearing Loss Or Tinnitus Including Platelet-Rich Plasma And Method Using The Same

Provided are a pharmaceutical composition for preventing or treating sensorineural hearing loss or tinnitus including platelet-rich plasma, and a method of preventing or treating sensorineural hearing loss or tinnitus using the same. 1. A pharmaceutical composition for preventing or treating sensorineural hearing loss or tinnitus , the pharmaceutical composition comprising platelet-rich plasma (PRP).2. The pharmaceutical composition of claim 1 , wherein the PRP is PRP immediately after being isolated from blood of a subject claim 1 , PRP incubated at room temperature for about 1 minute to about 40 minutes after being isolated from blood of the subject claim 1 , or a combination thereof.3. The pharmaceutical composition of claim 2 , wherein the PRP immediately after being isolated from blood of the subject and the PRP incubated at room temperature for about 1 minute to about 40 minutes after being isolated from blood of the subject are separate compositions.4. The pharmaceutical composition of claim 1 , wherein the PRP is for autologous blood administration.5. The pharmaceutical composition of claim 1 , further comprising dexamethasone claim 1 , vitamin B1 claim 1 , vitamin B6 claim 1 , vitamin B12 claim 1 , thiamine hydrochloride claim 1 , pyridoxine hydrochloride claim 1 , nicotinamide claim 1 , D-panthenol claim 1 , cyanocobalamin claim 1 , riboflavin claim 1 , biotin claim 1 , Pan-B-Comp injection claim 1 , or a combination thereof.6. The pharmaceutical composition of claim 1 , further comprising a blood clotting accelerant.7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is for administration to the tympanic cavity.8. The pharmaceutical composition of claim 1 , wherein the sensorineural hearing loss is presbycusis; noise-induced hearing loss; sudden hearing loss; Meniere's disease; autoimmune hearing loss; ischaemic hearing loss; head injury-associated hearing loss; ototoxic drug-associated hearing loss; genetic hearing loss; ...

COMBINED AUTOLOGOUS BIOLOGIC AND COLD THERAPY TREATMENT OF SKIN INJURIES

This disclosure describes a combined autologous biologic and cold therapy treatment for treating various skin injuries. The treatment may include applying autologous blood components, including but not limited to platelet rich plasma, to a skin injury in a manner that influences the healing process. A tray assembly for freezing autologous blood components includes a tray body and a plurality of compartments formed in the tray body. Each of the plurality of compartments is configured to receive an individual dose of an autologous blood component. 1. A tray assembly for freezing autologous blood components , comprising:a tray body;a compartment formed in said tray body and configured to receive a dose of an autologous blood component; anda lid connectable to said compartment to cover said dose.2. The tray assembly as recited in claim 1 , wherein said autologous blood component includes platelet rich plasma.3. The tray assembly as recited in claim 1 , comprising an extension that extends from said lid into said compartment.4. The tray assembly as recited in claim 3 , wherein said extension includes a lip.5. The tray assembly as recited in claim 1 , comprising a port formed in said lid and configured to communicate said dose into said compartment.6. The tray assembly as recited in claim 5 , comprising a cap received over said port.7. The tray assembly as recited in claim 5 , comprising an extension in fluid communication with said port.8. The tray assembly as recited in claim 7 , wherein said extension includes a passage adapted to communicate said dose from said port into said compartment.9. The tray assembly as recited in claim 1 , wherein said compartment includes a threaded portion and said lid is attached to said compartment via said threaded portion.10. The tray assembly as recited in claim 1 , wherein said tray body is a plastic component.11. A surgical method claim 1 , comprising:introducing an autologous blood component into a compartment of a tray assembly; ...

TREATMENT OF COLLAGEN DEFECTS USING PROTEIN SOLUTIONS

Methods of stimulating collagen production, including stimulation of chondrocyte production, at the site of a defect. Methods include administering to the site of a defect at least two proteins from the group IL-1ra, sTNF-RI, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-β1, and sIL-1RII. 1. A method for treating a collagen defect in a mammalian subject , comprising administering to the site of the collagen defect a composition comprising interleukin-1 receptor antagonist (IL-1ra) , and soluble interleukin-1 receptor II (sIL-RII) , wherein the concentration of each of IL-1ra and sIL-1RII in the composition is greater than the concentration of the respective protein in normal blood , and wherein the composition stimulates chondrocyte production at the site of the collagen defect.2. The method according to claim 1 , wherein the composition is autologous to the subject.3. The method according to claim 1 , wherein the composition further comprisesat least about 1,000 pg/ml hepatocyte growth factor and.4. A method for treating a collagen defect in a mammalian subject comprisingstimulating chondrocyte production at the site of the collagen defect, wherein the stimulating inhibits enlargement of the collagen defect.5. The method according to claim 4 , wherein the stimulating includes administering to the site of the collagen defect a composition comprising at least about 15 claim 4 ,000 pg/ml soluble interleukin-1 receptor II.6. The method according to claim 4 , wherein the stimulating includes administering to the site of the collagen defect a composition comprising at least about 1 claim 4 ,000 pg/ml to hepatocyte growth factor.7. The method according to claim 6 , wherein the the composition further comprises at least about 10.000 pg/ml interleukin-1 receptor antagonist.8. The method according to claim 6 , wherein the composition further comprises platelet-derived growth factor-AB claim 6 , platelet-derived growth factor BB claim 6 , insulin-like growth factor ...

Megakaryocytic particles and microparticles for cell therapy & fate modification of stem and progenitor cells

Applications in transfusion medicine requiring platelets, and hematopoietic stem-cell transplantations require either platelets or enhancement of in vivo platelet biogenesis. Gene therapy applications of hematopoietic stem and progenitor cells (HSPCs) require effective and specific modification of HSPCs by DNA, RNA or other biological molecules. Here we disclose methods for the generation, and modification of megakaryocytic microparticles (MkMPs) or microvesicles, that can be used in the aforementioned transfusion and transplantation medicine applications and in gene therapy applications involving hematopoietic stem cells. The biological effects of modified or unmodified MkMPs have never been previously disclosed and thus, this invention claims all biological applications of MkMPs in in vivo therapeutic applications or ex vivo applications to produce various cells and cell parts, modify various target cells or deliver molecules including drugs to HSPCs and related cells. 1. A method to generate particles for platelet function comprising the steps of:a. culturing cells selected from the group of megakaryocytes and immature megakaryocyte cells;b. providing said cultured cells to an exposure of biomechanical stress.wherein providing of said cultured cells to said exposure of biomechanical stress increases DNA synthesis, cell ploidy and generation of particles selected from the group consisting of megakaryocyte microparticles, proplatelets, preplatelets, platelet-like particles and megakaryocyte microvesicles.2. The method of claim 1 , wherein said exposure of biomechanical stress is selected from the group consisting of shear stress claim 1 , normal stress claim 1 , laminar flow stress and turbulent flow stress3. The method of claim 1 , wherein said biomechanical stress is up to about 400 dyn/cm.4. The method of claim 1 , wherein said biomechanical stress is up to about 100 dyn/cm.5. The method of claim 1 , wherein said biomechanical stress is ranges from about 1.0 dyn ...

POLOXAMER COMPOSITION FREE OF LONG CIRCULATING MATERIAL AND METHODS FOR PRODUCTION AND USES THEREOF

Provided herein are long circulating material free (LCMF) poloxamer compositions and uses thereof. In particular, provided are LCMF poloxamer 188 compositions and uses thereof. Also provided are supercritical fluid extraction (SFE) methods and high pressure (subcritical) methods for preparing poloxamer compositions, particularly the LCMF poloxamer compositions. 1. A long circulating material free (LCMF) poloxamer 188 , wherein:{'sub': 2', '2', 'a′', '3', '2', 'b', '2', '2', 'a, 'claim-text': [{'sub': 2', '4, 'each of a and a′ is an integer such that the percentage of the hydrophile (CHO) is between approximately 60% and 90% by weight of the total molecular weight of the copolymer;'}, 'a and a′ are the same or different;', {'sub': 3', '6, 'b is an integer such that the molecular weight of the hydrophobe (CHO) is between approximately 1,300 and 2,300 Daltons;'}, 'no more than 1.5% of the total components in the polymeric distribution of the co-polymer are low molecular weight components having an average molecular weight of less than 4,500 Daltons;', 'no more than 1.5% of the total components in the polymeric distribution of the co-polymer are high molecular weight components having an average molecular weight of greater than 13,000 Daltons;', 'the polydispersity value of the copolymer is less than approximately 1.07 or less than 1.07; and, 'the LCMF poloxamer 188 is a polyoxyethylene/polyoxypropylene copolymer that has the formula HO(CHCHO)—[CH(CH)CHO]—(CHCHO)H, whereinfollowing intravenous administration to a human subject, the circulating plasma half-life of any components not comprising the main peak in the distribution of copolymer is no more than 5.0-fold the circulating half-life of the main component in the distribution of the copolymer.2. The LCMF poloxamer of claim 1 , wherein all components comprising the polymeric distribution of the copolymer have a circulating half-life in the plasma of the subject that is no more than 4.0-fold claim 1 , or 3.0-fold ...

BIOACTIVE COMPOSITIONS DERIVABLE FROM PLATELET CONCENTRATES, AND METHODS FOR PREPARING AND USING SAME

The present disclosure provides a composition comprising a bioactive fraction derived from a platelet concentrate, methods of making the bioactive fraction, and culture medium supplemented with the bioactive fraction. Preferred bioactive fractions have relatively low fibrinogen concentrations while retaining native growth factors in beneficial amounts and ratios. 1. A composition comprising:a bioactive fraction of a human blood-derived platelet concentrate, the platelet concentrate containing human platelets and human plasma, the bioactive fraction comprising native components of the platelet concentrate including fibrinogen, albumin, globulin, and at least one of TGF-β1, EGF, FGF-basic, PDGF-AA, PDGF-BB, SDF-1α, and VEGF.2. The composition of claim 1 , wherein the fibrinogen is present at a level of less than 20 claim 1 ,000 ng/mL.3. The composition of claim 1 , which comprises each of said TGF-β1 claim 1 , EGF claim 1 , FGF-basic claim 1 , PDGF-AA claim 1 , PDGF-BB claim 1 , SDF-1α claim 1 , and VEGF4. The composition of claim 1 , wherein the composition is essentially free from heparin.5. The composition of claim 1 , wherein the bioactive fraction also includes at least one of claim 1 , and preferably each of claim 1 , IL-1b claim 1 , IL-6 claim 1 , IL-8 claim 1 , IL-10 claim 1 , IL-13 claim 1 , IL-17 claim 1 , IFN-gamma claim 1 , and TNF-alpha native to the platelet concentrate.6. The composition of claim 1 , wherein the bioactive fraction is a liquid bioactive fraction claim 1 , and wherein the composition includes:about 0.5 to 2.5 g/dL globulins, preferably about 1 to 2 g/dL globulins;about 2 to 5 g/dL albumin, preferably about 3 to 4 g/dL albumin;about 100 to 200 mmol/L sodium, preferably about 120 to about 160 mmol/L sodium;about 50 to 120 mg/dL triglycerides, preferably about 60 to 110 mg/dL triglycerides; and/orabout 150 to 300 mg/dL glucose, preferably about 150 to 250 mg/dL glucose.7. The composition of claim 1 , which is free from detergent residues.8. ...

ISOLATION AND USE OF AUTOGENOUS PLATELET DERIVED EXOSOMES

Disclosed are compositions and methods for the isolation of platelet derived exosomes. In some aspects the exosomes may be used to treat chronic orthopedic conditions without causing inflammation, may include extracting platelet-rich plasma (PRP) from whole blood; isolating platelets from the PRP; activating the platelets to induce the release of the exosomes; and isolating the exosomes by differential centrifugation. 2. The method of isolating platelet derived exosomes of claim 1 , wherein the PRP is extracted by density gradient centrifugation claim 1 , differential centrifugation claim 1 , or elutriation.3. The method of isolating platelet derived exosomes of claim 1 , wherein to extract the PRP from the whole blood claim 1 , the whole blood is centrifuged at 250×g for 15 min at least one time.4. The method of isolating platelet derived exosomes of claim 1 , wherein the extracted platelet rich plasma comprises at least 2×10 claim 1 , 3×10 claim 1 , 4×10 claim 1 , 5×10 claim 1 , 6×10 claim 1 , 7×10 claim 1 , 8×10 claim 1 , 9×10 claim 1 , 1×10 claim 1 , 1.1×10 claim 1 , 1.2×10 claim 1 , 1.3×10 claim 1 , 1.4×10 claim 1 , 1.5×10 claim 1 , 1.6×10 claim 1 , 1.7×10 claim 1 , 1.8×10 claim 1 , 1.9×10 claim 1 , or 2×10platelets per microliter.5. The method of isolating platelet derived exosomes of claim 1 , wherein the platelets are isolated from the PRP by applying the PRP to a centrifuge at 250×g for 15 min at least one time.6. The method of isolating platelet derived exosomes of claim 1 , wherein the isolated platelets are activated by contacting the isolated platelets with CaCl claim 1 , thrombin claim 1 , collagen claim 1 , lipopolysaccharide claim 1 , and/or Ca ionophores.7. The method of isolating platelet derived exosomes of claim 1 , wherein the released exosomes are separated from the platelets by filtration prior to isolating the exosomes.8. The method of isolating platelet derived exosomes of claim 1 , wherein the exosomes are isolated by centrifugation with a ...

THERAPEUTIC PREPARATION AND PROCESS FOR PREPARING SIAD THERAPEUTIC PREPARATION

Provided is a therapeutic preparation including a substance including ozone and a proteic substance. Also provided are methods of treating a disorder in a bovid, including administering to a subject in need thereof, a therapeutically effective amount of the therapeutic preparation. 1. A therapeutic preparation comprising: a substance comprising ozone and a proteic substance.2. The therapeutic preparation as claimed in claim 1 , wherein said proteic substance is a combination of one or more growth factors.3. The therapeutic preparation as claimed in claim 2 , wherein said proteic substance is a platelet concentrate.4. The therapeutic preparation as claimed in claim 2 , wherein said proteic substance is a medium conditioned by stem cells.5. The therapeutic preparation as claimed in claim 1 , wherein said substance comprising ozone is ozone in solution in a fluid.6. The therapeutic preparation as claimed in claim 5 , wherein said fluid is an oil.7. The therapeutic preparation as claimed in claim 1 , wherein said substance comprising ozone is ozonised oil.8. The therapeutic preparation as claimed in claim 3 ,wherein said substance comprising ozone is ozone in solution in an oil, andwherein said platelet concentrate and said ozone in solution in an oil are present in said therapeutic preparation in a ratio of from about 2 to 4:1.9. The therapeutic preparation as claimed in claim 1 , for the treatment of bovine mastitis.10. A process for preparing a therapeutic preparation for the treatment of bovidae claim 1 , comprising:mixing together a substance comprising ozone and a proteic substance, to produce a mixture.11. The process according to claim 10 , further comprising cooling the mixture to a temperature substantially equal to −80° C.12. The process according to claim 10 , further comprising freezing the mixture with liquid nitrogen.13. The therapeutic preparation as claimed in claim 8 , wherein said ozone in solution in an oil is ozonised oil.14. The therapeutic ...

COMPOSITIONS AND METHODS FOR PROLONGED CELL STORAGE

Provided in some aspects are methods and compositions for preserving platelets or other cells. In some embodiments, a platelet storage media or cell storage media may comprise a low molecular weight polyethylene glycol (e.g. PEG-400) to allow for extended storage and/or refrigeration of the platelets or cells. 1. A method for preserving cells , comprising:(a) admixing cells with a cell media comprising a polyethylene glycol having an average molecular weight of from 200 g/mol to less than 1000 g/mol in a concentration of from about 0.1% (wt/v) to less than 5.6% (wt/v); and(b1) wherein if the cells are platelets, then the method comprises storing the cell media comprising the platelets at a temperature of from about 0.1° C. to about 25° C.;(b2) wherein if the cells are stem cells, apheresis derived hematopoietic cells, sperm cells, hematopoietic stem cells, stem cells from cord blood, pluripotent cells, multipotent cells, embryonic stem cells, or induced pluripotent cells, then the method comprises storing the cell media comprising the platelets at a temperature of from about −157° C. to about 15° C.;wherein the cells are platelets, stem cells, apheresis derived hematopoietic cells, sperm cells, hematopoietic stem cells, stem cells from cord blood, pluripotent cells, multipotent cells, embryonic stem cells, or induced pluripotent stem cells.2. The method of claim 1 , wherein the concentration of the polyethylene glycol is from about 1% to about 5%.3. The method of claim 1 , wherein the concentration of the polyethylene glycol is from about 1.1% to about 2.5%.4. The method of any one of - claim 1 , wherein the cells are platelets claim 1 , and wherein the method allows for storage of the platelets for more than 5 days without irreversible aggregation of the platelets.5. The method of claim 4 , wherein the method allows for storage of the platelets for at least 5-30 days without irreversible aggregation.6. The method of any one of - claim 4 , wherein the temperature is ...

Personalized Immunotherapies for Reduction of Brain Inflammation and Suicide Prevention

Disclosed are means, methods and compositions of matter useful for reduction of brain inflammation and prevention of suicidal ideations and suicidal attempts. In one embodiment the invention provides utilization of autologous platelet rich plasma, alone, or admixed with regenerative/anti-inflammatory adjuvants, for reduction of neural inflammation. In one embodiment autologous PRP is admixed with oxytocin and administered intranasally in a patient at risk of suicidal ideation. In another embodiment, PRP is admixed with fortified and non-fortified nigella sativa oil and administered intranasally. Other embodiments include utilization of autologous stromal vascular fraction cells alone and/or admixed with regenerative/anti-inflammatory adjuvants. 1711-. (canceled)712. A method of reducing suicidal ideations/suicidal attempts comprising the steps of:a) obtaining a patient with a propensity for suicidal ideation/suicidal attempts; b) assessing one or more markers associated with said suicidal ideations/suicidal attempts; c) administering to said patient platelet rich plasma and/or cord blood plasma alone or in combination with an anti-inflammatory/regenerative adjuvant; d) assessing levels of said one or more markers associated with said suicidal ideations/suicidal attempts; and e) adjusting dosage/frequency of administration of said platelet rich plasma alone or in combination with an antiinflammatory/regenerative adjuvant.713. The method of claim 712 , wherein propensity for suicidal ideation/suicidal attempts is associated with augmentation of inflammatory cytokines and/or mediators in a biological fluid as compared to an age matched control.714. The method of claim 713 , wherein said inflammatory cytokines are selected from a group consisting of: a) IL-1 beta; b) IL-6; c) TNF-alpha; d) IL-18; e) IL-17; f) IL-33 and g) interferon gamma.715. The method of claim 712 , wherein said anti-inflammatory/regenerative adjuvant is human chorionic gonadotropin.716. The method ...

PHARMACEUTICAL COMPOSITION USING ENDOGENOUS CELLS FOR PREVENTING OR TREATING MUSCULOSKELETAL DISORDERS

The present disclosure relates to a pharmaceutical composition for preventing or treating musculoskeletal disease, which has the effect of proliferating endogenous cells in bone marrow. More specifically, the pharmaceutical composition of the present disclosure can be used for the treatment of musculoskeletal disease since it proliferates endogenous cells in bone marrow and enhances the functions thereof. 1. A pharmaceutical composition for preventing or treating a musculoskeletal disease , comprising platelet-rich plasma (PRP) , batroxobin , calcium and tranexamic acid as active ingredients.2. The pharmaceutical composition for preventing or treating a musculoskeletal disease according to claim 1 , wherein a mixing weight ratio of the platelet-rich plasma (PRP) claim 1 , the batroxobin claim 1 , the calcium and the tranexamic acid is 10-20:1-4:1:1-3.3. The pharmaceutical composition for preventing or treating a musculoskeletal disease according to claim 1 , wherein the platelet-rich plasma (PRP) is autologous or allogeneic.4. The pharmaceutical composition for preventing or treating a musculoskeletal disease according to claim 1 , wherein the concentration of the platelet-rich plasma (PRP) is 200-5 claim 1 ,000×10platelets/microL.5. The pharmaceutical composition for preventing or treating a musculoskeletal disease according to claim 1 , wherein the pharmaceutical composition is a gel-type injection injected to an affected part.6. The pharmaceutical composition for preventing or treating a musculoskeletal disease according to claim 5 , wherein the affected part is a bone-tendon junction or a bone-ligament junction.7. The pharmaceutical composition for preventing or treating a musculoskeletal disease according to claim 5 , wherein the affected part is an intraosseous passage formed through multiple channeling.8. The pharmaceutical composition for preventing or treating a musculoskeletal disease according to claim 1 , wherein the musculoskeletal disease is one or ...

Mesoderm Induction Method Having High Blood Cell Differentiation Capacity

Provided is a method for inducing mesoderm, comprising a step of bringing pluripotent stem cells into contact with bone morphogenetic protein 4 (BMP4) or CHIR for at least 3 days. 1. A method for inducing mesoderm , comprising a step of bringing pluripotent stem cells into contact with bone morphogenetic protein 4 (BMP4) or CHIR for at least 3 days.2. The method according to claim 1 , wherein the pluripotent stem cells are also brought into contact with Activin A.3. The method according to claim 1 , wherein the mesoderm comprises cells that are both CD56-positive and APJ-positive.4. The method according to claim 1 , further comprising a step of bringing the CD56-positive claim 1 , APJ-positive cells into contact with VEGF claim 1 , bFGF and a TGFβ inhibitor.5. The method according to claim 1 , wherein the contact step is performed under serum-free and/or feeder-free conditions6. A method for producing a culture containing megakaryocytes and megakaryocyte precursor cells claim 1 , comprising a step of inducing differentiation of megakaryocyte cells from mesoderm induced by a method according to .7. A method for producing platelets from megakaryocytes produced by the method according to .8. A platelet preparation containing platelets produced by the method according to .9. A method for transplanting or transfusing platelets produced by the method according to into a test subject. The present invention relates to a novel mesoderm induction method, and relates in particular to a method for inducing mesoderm with high blood cell differentiation ability from human pluripotent stem cells, and to a method for producing megakaryocytes and platelets using the same.A supply of blood cells for treatment is considered necessary when performing surgical treatment or treatment for blood-related diseases. There is especially strong demand for platelets and proplatelets, which are essential for blood coagulation (hemostasis), and also for megakaryocytes because they produce ...

MULTILAYERED BLOOD PRODUCT

A blood product (), a method for preparing the blood product, a blood product obtainable by the method and a blood product preparing container means. The blood product comprises components from whole blood, especially fibrin, thrombocytes and leukocytes. The blood product () comprises a first layer (), a second layer () and a third layer (). The second layer () is adjacent to the first layer () and the third layer (). The first layer () defines a first outer surface () of the blood product () and the third layer () defining a second outer surface () of the blood product (). The first layer () comprises a majority of fibrin, the second layer () comprises a majority of thrombocytes and the third layer () comprises a majority of leukocytes. 1105. A method for preparing a blood product () from a volume of whole blood () , the method comprising the following steps:{'b': 5', '1', '1', '3', '5, 'a) placing the volume of whole blood () in a container means (), the container means () comprising a first material defining an inner surface () in which the whole blood () is in contact with,'}{'b': '5', 'b) activating coagulation of the whole blood (),'}{'b': 5', '11', '9', '10', '6', '5', '1', '10', '11', '10', '9', '11', '10', '9', '10', '6', '6', '10, 'c) separating the whole blood () into erythrocytes (), serum () and blood product () by a centrifugal force () acting on the whole blood () placed in the container means (), whereby the whole blood () separates into layers comprising erythrocytes (), blood product () and serum () due to the differences in densities between the erythrocytes (), blood product () and serum (), the blood product () comprising fibrin, leukocytes and thrombocytes, the applied centrifugal force () being at least 1000 times greater than the gravity force, e.g. g, acting on the whole blood, the applied centrifugal force () being of such a value and time that the components in the blood are separated into a 3 layers blood product (), and'}{'b': 10', '1, ' ...

SEPARATION SUBSTRATE, CELL SEPARATION FILTER, AND METHOD FOR PRODUCING PLATELET

An object of the present invention is to provide a separation substrate having a high megakaryocyte blocking rate and a high platelet permeation rate, and a cell separation filter and a method for producing a platelet which use the same. The separation substrate of the present invention is a separation substrate including a porous membrane for separating a platelet from a cell suspension containing a megakaryocyte and the platelet, in which an average pore diameter of the separation substrate is 2.0 μm to 12.0 μm, and the separation substrate is formed of at least one resin selected from the group consisting of a polysulfone resin and a polyvinylidene fluoride resin. 1. A separation substrate comprising:a porous membrane for separating a platelet from a cell suspension containing a megakaryocyte and the platelet,wherein an average pore diameter of the separation substrate is 2.0 μm to 12.0 μm, andthe separation substrate is formed of at least one resin selected from the group consisting of a polysulfone resin and a polyvinylidene fluoride resin.2. The separation substrate according to claim 1 , wherein the separation substrate has a pore diameter distribution in which a pore diameter decreases continuously or discontinuously from a surface in a central thickness direction.3. The separation substrate according to claim 1 , wherein a surface of the separation substrate is modified with a hydrophilic polymer or a hydrophilic group.4. A cell separation filter comprising:a container in which a first liquid inlet and a second liquid inlet are disposed; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a filtering medium filled between the first liquid inlet and the second liquid inlet, wherein the filtering medium is the separation substrate according to .'}5. A cell separation filter comprising:a container in which a first liquid inlet and a second liquid inlet are disposed; anda filtering medium filled between the first liquid inlet and the second liquid inlet,{' ...

ANGIOGENESIS INITIATION AND GROWTH

Methods for promoting angiogenesis comprising administering platelet-rich plasma to a site and stimulating the site with an electromagnetic field. Platelets include platelet-rich plasma and compositions can further include stem cells such as adipose stromal cells and cells derived from bone marrow aspirate. Methods also comprise isolating platelets from a patient's blood, forming a composition including the platelets, delivering the composition to a site in need of treatment, and electrically stimulating the site. 112-. (canceled)13. A method for promoting angiogenesis at a site on a patient , the method comprising:obtaining blood compatible with the patient;isolating platelet-rich plasma;administering said platelet-rich plasma to the site; andstimulating the site with an electromagnetic field following administration of said platelet-rich plasma to the site; therebypromoting angiogenesis at the site upon application of said electromagnetic field and said platelet-rich plasma to the site.14. The method for promoting angiogenesis at a site on a patient as set forth in claim 13 , wherein the isolating of the platelet-rich plasma comprises density fractionation of said blood claim 13 , and the stimulating of the site with an electromagnetic field comprises generating in the tissue a capacitively-coupled time-varying electromagnetic field claim 13 , or generating a pulsed electromagnetic field.15. The method for promoting angiogenesis at a site on a patient as set forth in claim 13 , wherein the density fractionation comprises centrifugation claim 13 , and the stimulating of the site with the electromagnetic field comprises generating in the tissue a capacitively-coupled time-varying electromagnetic field having a peak amplitude of from about 0.1 to about 100 millivolts per centimeter claim 13 , and having a frequency from about 1 kHz to about 200 kHz.16. The method for promoting angiogenesis at the site on a patient as set forth in claim 13 , wherein the density ...

SYSTEMS AND METHODS FOR LOCAL MODULATION OF WNT SIGNALING

A system is provided including a promoter of Wnt signaling and an autologous body material (ABM) or its functional equivalent. The promoter of Wnt signaling can be an agent that inhibits the activity or bioavailability of DKK1 protein, e.g., an anti-DKK1 antibody (DKAB). The promoter of Wnt signaling can also be an agent that initiates, promotes, or potentiates Wnt signaling by means other than inhibition of DKK1. The ABM in some embodiments are prepared to remove DKK1 or an antagonist of Wnt signaling. A process of locally administering the system is also provided to enhance the intended or ancillary effects of the ABM. The system is useful in promoting the growth of new bone or the augmentation, reconstitution, regeneration, fusion, fixation, repair, or healing of damaged, injured or otherwise deficient bone in therapeutically or esthetically desirable locations, or for promoting hair growth or wound healing. 1. A composition comprising:a promoter of Wnt signaling; andan autologous body material, an allogeneic body material, a xenogeneic body material or a functional equivalent thereof.2. The composition of claim 1 , wherein the promoter of Wnt signaling comprises an anti-Dickkopf-related protein 1 (DKK1) antibody (DKAB) or other inhibitor of Dickkopf-related protein 1 (DKK1); scFv-DKK1c or other Wnt receptor heterodimerizing agent; a sclerostin antibody or other inhibitor of sclerostin; Wnt3a claim 1 , liposomal Wnt3a or other recombinant Wnts that promote Wnt signaling; R-Spondin; lithium; WAY316606; LY2090314; promoters of LRP5 claim 1 , LRP6 or frizzled receptor signaling; an inhibitor of Kremen function; an inhibitor of Wnt inhibitory factor-1 (WIF-1); an inhibitor of Wise/SOSTDC; or an inhibitor of secreted frizzled-related proteins (sFRPs).3. The composition of claim 1 , wherein the autologous body material comprises platelet-rich plasma (PRP) claim 1 , platelet-rich fibrin (PRF) claim 1 , bone autograft claim 1 , surgical bone claim 1 , surgical blood ...

CANINE BLOOD PLATELET PREPARATIONS

The present disclosure provides dry and liquid compositions that include canine platelets and/or canine platelet-derived substances in dried form or rehydrated form from a dried form of canine platelets and/or canine platelet-derived substances, as well as processes for preparing such compositions. The disclosure also provides processes for making the compositions and methods of using the compositions for therapeutic, prophylactic, diagnostic, and research purposes, and kits comprising the compositions. 1. A hemostatic composition derived from canine platelets , wherein the composition does not comprise DMSO and does not comprise platelets that are chemically cross-linked by way of platelet proteins or carbohydrates found on platelet membranes.2. The hemostatic composition of claim 1 , which is in dry form claim 1 , having less than ten percent moisture content.3. The hemostatic composition of claim 2 , having less than two percent moisture content.4. The hemostatic composition of claim 1 , which comprises canine platelets claim 1 , particles of canine platelets claim 1 , or a combination of the two.5. The hemostatic composition of claim 1 , wherein the composition comprises one or more additional blood components.6. The hemostatic composition of claim 5 , wherein the composition has less than two Endotoxin Units per milliliter.7. The hemostatic composition of or claim 5 , wherein the pH of the composition is greater than 5.0.8. The hemostatic composition of claim 7 , wherein the pH of the composition is above 5.5.9. The hemostatic composition of claim 8 , wherein the pH of the composition is in a range of 6.4 to 7.4.10. The hemostatic composition of claim 1 , wherein the composition does not show observable reactivity to a human clone of an antibody that binds to CD42b when assayed by fluorescence.11. The hemostatic composition of claim 1 , wherein the composition shows observable reactivity to a human antibody that binds to CD41 claim 1 , a human antibody that ...

Systems And Methods For Deriving And Collecting Platelet Products

Systems and methods are provided for deriving a platelet product from a plurality of buffy coats. A plurality of buffy coats are separately collected, for example, using a conventional floor centrifuge. Plasma and/or a platelet additive solution may be added to the buffy coats. The buffy coats are pooled into a container and conveyed into a centrifuge or are sequentially conveyed into the centrifuge without being pooled, where they are continuously processed to separate platelets from the other cellular blood components. The separated platelets are conveyed out of the centrifuge as a platelet product, which may be passed through a leukocyte removal filter to reduce the white blood cell content of the platelet product. By continuously separating the buffy coats, fewer buffy coats are required to produce a single-dose platelet product, while also allowing for the derivation and collection of a plurality of single-dose platelet products. 1. A method of deriving a platelet product from a plurality of buffy coats comprising:conveying a plurality of buffy coats into a centrifuge;continuously separating platelets from other cellular blood components of the plurality of buffy coats in the centrifuge; andcollecting the separated platelets as a platelet product.2. The method of claim 1 , further comprising adding plasma or platelet additive solution to said plurality of buffy coats before conveying said plurality of buffy coats into the centrifuge.3. The method of claim 1 , further comprising conveying said separated platelets through a leukocyte removal filter before collecting the separated platelets as a platelet product.4. The method of claim 1 , whereinsaid conveying said plurality of buffy coats into the centrifuge includes conveying said plurality of buffy coats into a rigid separation chamber.5. The method of claim 1 , wherein said conveying said plurality of buffy coats into the centrifuge includes conveying said plurality buffy coats into a flexible separation ...

COMPOSITIONS CONTAINING PLATELET CONTENTS

This document provides methods and materials relating to platelet lysates. For example, methods and materials for using platelet lysate compositions to grow adult stem cells, to differentiate adult stem cells, to grow primary cell cultures, to grow tumor stem cells, and to identify effective growth factors are provided. 1. A platelet lysate composition comprising a filtrate from a lysed platelet preparation passed through a 0.45 um or smaller filter and comprises greater than 200 pg of VEGF polypeptide per ml.2. The platelet lysate composition of claim 1 , wherein said filtrate is from said lysed platelet preparation being passed through a 0.45 μm filter and a 0.2 um filter.3. The platelet lysate composition of claim 1 , wherein culturing 1.4×106 mesenchymal stem cells with media containing about five percent of said platelet lysate composition results in greater than 1.4×10 7 cells after three days.4. A method for making a platelet lysate composition claim 1 , wherein said method comprises:(a) lysing platelets via one or more freeze/thaw cycles to obtain lysed platelets,(b) centrifuging said lysed platelets to obtain a supernatant, and(c) filtering said supernatant through a 0.45 μm or smaller filter to obtain a filtrate, wherein said filtrate is said platelet lysate composition.5. The method of claim 4 , wherein said lysing step comprises at least two freeze/thaw cycles.6. The method of claim 4 , wherein said centrifuging step comprises using a force between 2000×g and 4000×g for between 15 and 45 minutes.7. The method of claim 4 , wherein said filtering step comprising filtering said supernatant through a 0.45 μm filter and a 0.2 μm filter.8. A method for expanding a cell population comprising culturing a first population of cells in the presence of medium comprising a platelet lysate composition under conditions wherein said first population of cells is expanded to a second population of cells having more cells than said first population claim 4 , wherein said ...

Cell Preparations For Extemporaneous Use, Useful for Healing and Rejuvenation In Vivo

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell combinations preparations for use in tissue regeneration and bone regeneration and pain reduction. 1. A separator system for the preparation of a platelet rich plasma , comprising:a tube;a thixotropic gel disposed in the tube, the thixotropic gel being adapted for separating platelet rich plasma and including a polymer mixture; andan anticoagulant disposed in the tube, the anticoagulant including a buffered sodium citrate solution at 0.1 M;the tube being adapted to be centrifuged for a sufficient length of time to form a barrier with the thixotropic gel between plasma and erythrocytes.2. A platelet rich plasma produced by centrifuging whole blood in the separator system of .3. The platelet rich plasma of claim 2 , wherein centrifugation is performed at a force between about 1000 g and about 2000 g.4. The platelet rich plasma of claim 2 , wherein a cell extract is mixed with the platelet rich plasma.5. A method of treating a patient with platelet rich plasma claim 2 , comprising:withdrawing blood from the patient;centrifuging the blood in a glass tube containing a thixotropic gel and an anticoagulant, the centrifuging being performed for a sufficient length of time to form a barrier between plasma and erythrocytes;removing the platelet rich plasma from the tube; andadministering the platelet rich plasma to the patient.6. The method of claim 5 , wherein the treating comprises tissue healing or regeneration treatments claim 5 , traumatic or surgical wound treatments claim 5 , vasculitis treatments claim 5 , ulcer or decubitus sore treatments ...

PRODUCTION OF MEGAKARYOCYTES OR PLATELETS FROM MONOCYTES

We disclose a method, comprising extracting cells from a tissue of a donor, wherein the tissue is selected from the group consisting of blood and bone marrow; isolating CD14 monocytes from the extracted cells; culturing the isolated CD14 monocytes; differentiating the cultured CD14 monocytes into megakaryocytes; and administering, to a patient suffering from a platelet deficiency, at least one cell type selected from the group consisting of the differentiated megakaryocytes and platelets produced by the differentiated megakaryocytes. We also disclose a kit comprising at least one material usable in a method; and instructions to perform a method. 1. A method , comprising:extracting cells from a tissue of a donor, wherein the tissue is selected from the group consisting of blood and bone marrow;{'sup': '+', '#text': 'isolating CD14 monocytes from the extracted cells;'}{'sup': '+', '#text': 'culturing the isolated CD14 monocytes;'}{'sup': '+', '#text': 'differentiating the cultured CD14 monocytes into megakaryocytes; and'}administering, to a patient suffering from a platelet deficiency, at least one cell type selected from the group consisting of the differentiated megakaryocytes and platelets produced by the differentiated megakaryocytes.2. The method of claim 1 , wherein the isolated CD14 monocytes further exhibit a CD34 phenotype.3. The method of claim 1 , wherein one individual is both the donor and the patient.4. The method of claim 3 , wherein the cell type administered to the patient is the megakaryocytes.5. The method of claim 1 , wherein the donor is a first individual and the patient is a second individual.6. The method of claim 5 , wherein the cell type administered to the patient is the platelets produced by the differentiated megakaryocytes.7. The method of claim 1 , further comprising:cryopreserving the extracted cells prior to the isolating.8. The method of claim 7 , wherein the cryopreserving is at about −80° C. for up to about 48 hr.9. The method of ...

PIC1 VARIANTS WITH IMPROVED SOLUBILITY AND METHODS OF USING THE SAME

A method of improving the lifespan of transfused platelets is described. The method may be useful for patients with alloimmunozation who are refractory to transfused platelets. A method of treating delayed hemolytic transfusion reaction is also described. Also described are PIC1 peptide variants with improved solubility and activity. 1. A method for inhibiting an immune response to transfused platelets in a subject , said method comprising the steps of:a) administering a classical complement pathway inhibitor to a subject in need thereof; andb) transfusing platelets to the subject.2. A method for inhibiting refractoriness to platelets in an alloimmunized subject , comprising the steps of:a) treating platelets with a classical complement pathway inhibitor; andb) transfusing the treated platelets to the subject.3. A method of preventing platelet refractoriness in a subject receiving platelets from an antigenically mismatched donor , the method comprising administering a classical complement pathway inhibitor to the subject before the platelets are transfused to the subject.4. A method of preventing platelet refractoriness in a subject receiving platelets from an antigenically mismatched donor , the method comprising the steps of:a) treating platelets with a classical complement pathway inhibitor; andb) transfusing the treated platelets to the subject.5. The method of claim 1 , wherein the method is effective to increase survival of the transfused platelets in the subject.6. The method of claim 1 , wherein the method is effective to reduce complement-mediated attack of the transfused platelets in the subject.7. The method of claim 1 , wherein the method is effective to increase survival of the transfused platelets in the subject.8. The method of claim 1 , wherein the subject is human.9. The method of claim 1 , wherein the complement mediated inhibitor is a PIC1 peptide.10. The method of claim 9 , wherein the PIC1 peptide comprises an amino acid sequence at least 85% ...